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1.1. General Introduction. 
The use of targeted drug delivery systems has become a real need in the 
clinic and ‘Nanomedicine’ has already demonstrated its key role in this 
field (Ferrari, 2005). Nanomedicine presents advantages to target cancer 
at late stages as its nanometric scale facilitates the pass through different 
biological barriers and could attain specifically the damaged cell more 
efficiently. More than 40 nanomedicines are in routine clinical use since 
the 90’s including liposomal formulations (i.e. with doxorubicin (Dox)) 
Doxil® (Barenholz, 2012), nanocrystals or polymer therapeutics (i.e. 
PEGylated proteins) (Duncan and Gaspar, 2011).  
Polymer therapeutics has emerged as the first generation of polymeric 
nanomedicines (Duncan, 2003). The term polymer therapeutics includes 
(1) water-soluble polymers with inherent activity known as polymeric 
drugs; (2) polymer-drug and (3) polymer-protein conjugates; (4) 
polymeric-micelles that contain covalently bound drugs and (5) 
multicomponent polyplexes used as non-viral vectors for gene delivery. 
Thirteen polymer therapeutics are already in routine clinical use (mostly 
PEGylated proteins) and many are in advanced clinical research (Duncan 
and Vicent, 2013).  
Polymer anticancer drug conjugates are nano-sized, multi-component 
constructs, used both as single agents and as elements of combinations. 
They have the potential to improve pharmacological therapy of a variety 
of solid tumours mainly due to two mechanisms: (i) polymer-drug 
conjugation that promotes passive tumour targeting by the enhanced 
permeability and retention (EPR) effect and (ii) allows for lysosomotropic 
drug delivery following endocytic capture (Duncan, 2006, Vicent and 
Duncan, 2006) (see chapter 1.4.2 for more detailed explanation). 
In the early 1980’s, Duncan and collaborators designed the first polymer 
anticancer drug conjugate to enter clinical trials, N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer-Dox (HPMA-Dox, PK1, 
FCE28068) (Vasey et al., 1999; Seymour et al., 2009). After PK1, an 
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exponential growing number of polymer conjugates have been transferred 
into the clinics bearing different anticancer agents (such as Paclitaxel 
(PTX) or campthotecin (CPT)) and different polymeric carriers (HPMA), 
polyethylenglycol (PEG) or poly-L-glutamic acid (PGA)) (Canal et al, 
2011; Sanchis et al., 2010; Knop et al., 2010). Many of them have shown 
even more promising results mainly in combination with other therapy 
(Herzog et al., 2005) and for example, the most advance, Opaxio®, a 
PGA-PTX conjugate in Phase III has been designated as orphan drug for 
the treatment of glioblastoma when combined with radiotherapy (Duncan 
and Vicent, 2013). These facts have opened the field to a second 
generation of polymer drug conjugates based on combinations and to the 
term coined as polymer-based combination therapy (Greco and Vicent, 
2009; Deladriere et al., 2010).  
Breast cancer is the most common cause of cancer death in women 
worldwide, estimated to be responsible for around 458 500 female death 
in 2008 or nearly one in seven (around 14%) of all cancer deaths in 
women being higher after 40 years old, age of menopause (figure 1.1.) 
(http://www.cancer.org; http://www.cancerresearchuk.org / cancer- info / 
cancerstats /types / breast/ mortality/). 
 
2010 new cancer cases 
  all cancers 6 234 
Prostate 832 
Breast 575 
Brain 405 
Skin 333 
Lung  318 
 
 
Figure 1.1. Representative cancer statistics in 2010. Panel (a) shows 
worldwide cancer statistics and panel (b) shows the percentage of breast 
cancer incidence depending on age (http://www.cancer.org; 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/mortality/). 
(a) (b) 
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Moreover based on TNM classification (annexe II), breast cancer stage 
(annexe III) could be determined having a direct correlation with survival 
(figure 1.2.) in collaboration with receptor status, patient menopausal 
status and age. 
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Figure 1.2. Representation of the percentage of survival at 5 years depending 
on disease stage (described in annexe II) (Maughan et al., 2010).  
Good prognostic is achieved in the earliest stages of breast cancer thanks 
to the widespread use of mammographic screening, precise diagnosis and 
increased numbers of women receiving the adequate treatment for their 
conditions. However in the latter stage (III and IV) the survival is still 
really low and an efficient treatment is still required. 
 Due to the molecular complexity of cancer, the use of polymer-
drug conjugates in combination therapy represents an important 
opportunity to enhance tumour response rates as the polymeric carrier 
provides an ideal platform for the simultaneous delivery of drug cocktails 
(Greco and Vicent, 2009; Deladriere et al., 2010). In the treatment of 
hormone-dependent breast cancer, it has been demonstrated that the 
combination of endocrine therapy with a chemotherapeutic agent may 
bring significant advantages (Vicent et al., 2005; Greco et al., 2007; 
Greco et al., 2005). This novel approach includes drug synergism and 
patience compliance. In this study, the conjugate containing both drugs 
(HPMA copolymer-AGM-Dox) showed markedly enhanced cytotoxicity 
compared with HPMA copolymer-Dox (Greco et al., 2005; Vicent et al., 
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2005; Greco et al., 2007), which has already shown clinical activity in 
anthracycline-resistant breast cancer patients (Duncan et al., 1992).  
HPMA copolymer-AGM-Dox combination conjugate is the starting point 
of this project and has been used as model system. The final aim of this 
study is to develop a new family of clinically relevant polymer-based 
combination conjugates for the treatment of advanced hormonal 
dependent breast cancer, using endocrine therapy in combination with 
chemotherapy. Multivalent polymeric carrier, passive tumour targeting 
and drug cocktail release at the same target site are advantages of the 
conjugate design including also lesser side effects and better patience 
compliance.  
To accomplish this goal it was considered of importance, first, to achieve 
in vivo proof of concept of the already reported system (HPMA 
copolymer-AGM-Dox conjugate (Vicent et al., 2005; Greco et al., 2007). 
At the same time it was taken into account that the understanding of the 
molecular basis for synergism could provide guidance in conjugate 
design. As a second step, due to the fact that HPMA copolymer could 
present limitations in its use for chronic diseases as a result of its non 
biodegradability, we aim to synthesise the same combination conjugate 
but using a biodegradable carrier, such as PGA (Singer et al., 2003) also 
in advanced clinical trials. The same drug combination (AGM-Dox) was 
used in order to understand the carrier effect resulted from its evaluation 
of antitumor properties in in vitro and in vivo breast cancer models. 
Finally, taking into account that AGM is a first generation aromatase 
inhibitor not used anymore in the clinic, a High Throughput Screening 
(HTPS) including other endocrine therapies and cytotoxic drugs, was 
implemented in order to identify novel drug combinations for future 
design of PGA-based combination conjugates.  
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1.2. Hormone dependent breast cancer. 
    1.2.1. Breast organ development and oestrogen involvement. 
Breast organ is made up mostly of fat and breast tissue, along with 
nerves, veins, arteries and connectives tissue. Breast tissue is a complex 
network of lobules (milk production) and ducts (canals that carry milk 
from lobules to the nipple). Breast development is well controlled by 
different hormones according to the different women stage. 
 
 
Figure 1.3. Breast organ. Panel (a) shows the breast representation 
(http://www.cancertreatment-wecareindia.com/breast_cancer.html). Panel (b) 
shows breast evolution steps and its hormones involved, adapted from 
(Schulz, 2005).  
As described above, breast cancer is a multifactorial cancer. In this 
context, life style such as a late menopause, the age of the first periods, a 
belated pregnancy or even a fat diet can be involved in breast cancer 
(a) 
(b) 
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development (Dolle et al., 2009; Phipps et al., 2011; McNamara et al., 
2012). Indeed, those life styles induce an extended exposure to oestrogens 
and a higher number of cell cycles that implicates a greater proportional 
mutation risk and longer carcinogenic cell proliferation stimulation 
(Schulz, 2005). On the contrary, during pregnancy, strong signals 
reinforce differentiation of breast ductal cell and extensive apoptosis of 
alveolar and ductal cells after weaning. All those cycle modifications 
induce an elimination of abnormal mutations and reduce breast cancer 
risk (Schulz, 2005; Barnes et al., 2012). Spontaneous mutation is not the 
only explanation for breast cancer; oxide chemical structure of oestrogen 
metabolites could also affect, in particular diphenolic compounds that can 
be partially oxidised to semiquinones and then interact with DNA 
triggering mutations. Semiquinones could initiate a process named 
quinone redox cycling that produces highly reactive oxygen species 
(ROS). In consequence, the cancer risk in breasts with high oestrogen 
concentrations may strongly depend on the individual ability to 
metabolise oestrogens and deals with quinone adducts to DNA and redox 
cycling (Samuni et al., 2003; Schulz, 2005).  
 
Figure.1.4. ROS species formation from oestrogen metabolite. Adapted from 
(Samuni et al., 2003).  
Another western life style feature that could induce breast cancer is diet 
with high fat content. Indeed in post-menopausal women the adipose 
tissue is the major source of oestrogens; therefore the accumulation of 
this tissue could induce oestrogen overproduction (Schulz, 2005). 
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    1.2.2. Post-menopausal hormone dependent breast cancer. 
Different types of breast cancer are described depending on there stage 
based on TNM nomenclature (Tumour, Lymph node and metastasis 
state), and regarding the localisation in early stage (ductal or lobular in 
situ). Nevertheless the classification is more complicated and depended 
also on tumour cell characteristics and its cell proliferation pathways: (i) 
hormone dependent with oestrogen (ER) and progesterone receptor (PR) 
positives, named Luminal A (ER +, PR + / - , HER 2 –, low Ki67), and 
Lumina B (ER+, PR + / - , HER 2 +) (ii) growth factor sensitive with only 
HER2 receptor positive, ( ER - , PR - , HER2+) and (iii) the triple 
negative or basal-like without any of the above-mentioned receptors ( ER 
- , PR - , HER 2-, cytokeratine 5/6+) (Lewis-Wambi and Jordan, 2009; 
Schmitt, 2009; Oakman et al, 2010).  
It has been described that hormone receptor positive tumours tend to 
respond better to chemotherapy, which is the treatment of choice for stage 
III and IV (Maughan et al., 2010). Therefore in this project, we develop 
new polymer drug conjugate treatment for luminal A breast tumours in 
stage III and IV mainly based on chemotherapy, (Tkaczuk, 2009) and 
endocrine therapy (Cheung, 2007).  
In the clinics, radiotherapy and endocrine therapy are mostly used to 
reduce tumour size. But, so far, chemotherapy is the most efficient 
treatment together with surgery to significantly control breast cancer 
progression. However, chemotherapy related non-specific toxicity is still 
its major limitation (Rahman et al., 2007). In consequence, administered 
dose and frequency have to be well controlled in order to achieve an 
adequate antitumor effect with controlled side toxicities in healthy 
tissues. To overcome these drawbacks, the development of systems able 
to specifically delivery and release a bioactive drug in a control manner at 
the site of action is seek. The use of nanomedicine as drug delivery 
systems has been sought, (i) to alter drug pharmacokinetics, (ii) to 
increase the tumour specificity of the drugs after conjugation or 
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encapsulation and, consequently, (iii) to reduce side toxicities and 
improve therapeutic efficiency (Greco and Vicent, 2008).  
 
    1.2.3. Signalling pathways involved in proliferation and cell 
death. 
As described above, oestradiol (E2) plays a key role in breast 
development but also in hormone dependent breast cancer (ER+) 
proliferation. The E2 fixation to the ER triggers protein cascades involved 
in cell proliferation. 
There are three different pathways involved in the complex oestradiol-
oestrogen receptor (E2-ER) described as (i) classic genomic (figure 1.5.), 
(ii) non-classical genomic (figure 1.6.) and (iii) non-genomic pathways 
(figure 1.7.). 
(i) The classic genomic pathway takes place in the nucleus. In its 
inactive form, ER has to be dimerised into the nucleus. In order to 
achieve the translocation from the non-active ER in the cytosol to the 
active dimerised ER complex in the nucleus, oestradiol (E2) has to 
recognise the ER. The complexation of E2-ER induced the translocation 
and consequently the dimerization occurs. The complex is stabilised by 
the binding of a co-activator then is capable to recognise the oestrogen 
response element (ERE) inducing gene transcription directly involved in 
cell proliferation and ER expression. The down regulation also exists and 
occurs mediated by the repression of the dimer ER through a co-
repressor.  
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Figure 1.5. Description of the classic genomic pathway, activation via ERE. 
(ii) The Non-classical genomic pathway does not require the E2-ER 
binding to ERE element. The first step of the mechanism is the same as 
described above. However, once the ER translocation occurs and it is 
stabilised with the co-activator, the complex does not recognise ERE 
anymore, but binds to AP1 through the Jun and Fos proteins to induce 
gene transcription of proliferation proteins such as cycline D1 and 
insulin-like growth factor I receptor (IGFR1). 
 
Figure 1.6. Description of the non-classical genomic pathway, activation via 
AP-1.  
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(iii) Non-genomic pathway (Platet et al., 2004; Zilli et al., 2009). 
 
Figure 1.7. Description of the non-genomic pathway, activation via AP1 
without oestrogen pathway. 
The last pathway involved in cell proliferation is the growth factor 
pathway. The interaction with its receptor induces the activation of 
proteins involved in the MAPK kinase cascade and consequently the 
transcription of proteins involved in cell proliferation. 
To control cell proliferation in a hormone dependent breast cancer ER+, 
oestrogen levels should be reduced. Consequently, in post-menopausal 
stage two options are available, (i) to block the oestrogen fixation on ER 
by selective oestrogen receptor modulators (SERM’s) or (ii) to block the 
oestrogen production, inhibiting the enzyme involved in the 
transformation of androstenedione, to oestradiol: P450 aromatase enzyme 
(Jordan and Brodie, 2007). On the other hand, by means of a different 
pharmacological approach and in order to gain effective tumour cell 
death, the best option is the use of a chemotherapeutic agents acting on 
DNA stability or microtubule formation. The different possible targets to 
use are represented in figure 1.8. 
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Figure 1.8. Summary of different targets for breast cancer therapy in where 
 is oestrogen receptor,  is Receptor Tyrosine Kinase (RTK). Adapted 
from (Tkaczuk, 2009). 
1.3. Current treatments for breast cancer.  
Nowadays, there is a well-defined armoury of drugs for the treatment of 
breast cancer. Nevertheless the most efficient approach is tumour ablation 
or breast ablation in the worst scenarios. In some cases, chemotherapy 
and/or radiotherapy and/or hormone therapy pre-treatment are required as 
neoadjuvants in order to decrease tumour volume and simplify surgery. 
Moreover, in order to diminish the risk of tumour recurrence and death, 
adjuvant therapy is also administered. In hormone dependent cancers, 
endocrine therapy is prescribed during the 5 first years after surgery 
controlling the hypothetic tumour recovery and the spread of breast 
cancer cells (Nicholson and Gee, 2000; Dodwell et al., 2006). In tumours 
with high risk of recurrence or in presence of metastasis, longer cycles of 
chemotherapy are required. A milder or palliative treatment alternatives 
are seek for old patients as enhancing quality of life it is in this case more 
important.  
    1.3.1. Chemotherapy. 
Anthracyclines and Taxanes are the most common options in breast 
cancer treatment. Both are still really important and efficient as first line 
breast cancer therapy. 
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      1.3.1.a. Anthracyclines. 
Dox, epirubicin (Epi) and daunorubicin (Dau) are part of the most widely 
used drugs in the clinics (figure 1.9.). Their exact mechanisms of action is 
still poorly understood (Gewirtz, 1999) and several cellular processes 
have been described: (i) inhibition of DNA and RNA synthesis through 
intercalation in nucleic acids (Goodman et al., 1974; Momparler et al., 
1976); (ii) generation of reactive free radicals after Dox-redox cycling 
(Davies and Doroshow, 1986; Fornari et al., 1994); (iii) interference with 
DNA helicases (Bachur et al, 1993); (iv) induction of DNA strand breaks 
through type II topoisomerase inhibition (Davies and Doroshow, 1986; 
D’arpa and Liu, 1989; Fornari et al. 1994); (v) induction of cell death 
apoptosis pathway, through tumour suppresor p53 protein dependent or 
independent (Skladanowski and Konopa, 1993; Kaufmann and Earnshaw, 
2000) or (vi) cell growth arrest (Ling et al., 1996). For this reason and 
even though anthracyclines can be considered extremely potent drugs, a 
number of important side toxicities have been reported, including acute 
and chronic cardiotoxicity and liver, kidneys and peripheral nervous 
system damage (Rahman et al., 2007; Carvalho et al., 2009). 
Consequently, the identification of a maximum tolerated dose (MTD) and 
an adequate dosage schedule are key issues to be considered. Dox MTD 
has been set at 80 mg/m
2
 in patients (Singal and Iliskovis, 1998; Duncan, 
2007; Roca-Alonso et al., 2012).  
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Figure 1.9. Examples of anthracycline chemical structures (Bachur et al, 
1993). 
Besides, it is interesting to note that patients which have any of the 
following conditions should not be treated with Dox: (i) baseline 
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neutrophil count < 1500 cells/mm
3
; (ii) severe hepatic impairment; (iii) 
recent myocardial infarction; (iv) severe myocardial insufficiency; (v) 
severe arrhythmias; (vi) previous treatment with complete cumulative 
doses of Dox, Dau and/or other anthracyclines and anthracenediones; or 
(vii) hypersensitivity to Dox, any of its excipients, or other anthracyclines 
or anthracenediones. 
      1.3.1.b. Taxanes.  
Paclitaxel (PTX) (Taxol) and Docetaxel (DTX) can be considered the 
most used taxanes for breast cancer treatment. They are known to 
interfere with microtubules and block the microtubule flexibility 
necessary for cell division (mitosis) (Whelan, 2002). As a consequence, 
the mitosis cannot be properly achieved and death signalling pathways 
trigger tumour cell death.  
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Figure 1.10. Examples of taxanes chemical structure. 
      1.3.1.c. Chemotherapy-based Combination Therapy. 
Due to the molecular complexity of cancer, combination therapy 
is becoming increasingly important for a better long-term prognosis and 
to decrease side effects. Combination therapy refers to either 
simultaneous administration of two or more pharmacologically active 
agents but also to the combination of different therapies (such as 
chemotherapy and radiotherapy). The advantage of the multi-agent 
therapy is the possibility to modulate different signalling pathways in 
tumour cells, maximising the therapeutic effect and, possibly, overcoming 
mechanisms of resistance (Broxterman and Georgopapadakou, 2005). 
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The use of combination therapy for cancer treatment is well established 
(Gee et al., 2005). Whereas chemotherapeutic drugs are normally 
associated with severe side effects, administration of agents hitting 
different targets and decreasing different toxicity profiles can improve the 
therapeutic index. Even if the MTD of Dox is 80 mg/m
2
, (Duncan, 2007) 
in combination therapy the administered dose is much lower due to the 
combination with other toxic drug. Presently, some well-known 
combinations are used for cancer treatment. For example, Dox (60 
mg/m
2
) in combination with cyclophosphamide (600 mg/m
2
) is 
administrated i.v. (intravenously) each 21 d (day) (AC), (Fisher et al., 
1997), also the cocktail cyclophosphamide (500 mg/m
2
, i.v. d 1), 5-
fluorouracyl (500 mg/m
2
, i.v., d 1) and Dox ( 50 mg/m
2
, i.v., d 1) each 21 
d (CAF) is commonly used (Stewart et al., 1997; Hortobagyi, 2002). In 
the last few years, new combinations of anthracyclines plus taxanes are 
being tested with promising results. Firstly, PTX was added to existing 
combinations such as ACT. ACT is known as AC (Dox 60 mg/m
2
 i.v. d 1 
+ cyclophosphamide 600 mg/m
2
 i.v. d 1 each 21 days 4 times) regime 
followed by PTX (175 mg/m
2
) during 3h d 1 each 21 days 4 times 
(Parnes et al., 2003). Combination of Dox and taxanes has been also 
reported, such as, Dox (50 mg/m
2
 i.v 15 min. D 1) and DTX (75 mg/m
2
 
i.v. 1 h d 1) each 21 d or Dox (50 mg/m
2
 i.v. d 1) followed by PTX (200 
mg/m
2
 i.v. 3 h d 2) 24 h after each 21 d (Jassem et al., 2001). In the 
1980’s, the combination of chemotherapeutic agent with an endocrine 
agent was firstly reported for hormone-dependent breast and prostate 
cancer (Pearson et al., 1989). More recently, the use of endocrine therapy 
with adjuvant bisphosphonate therapy (zoledronic acid) has been shown 
to be effective in breast cancer preventing bone loss in postmenopausal 
women with breast cancer (Greco and Vicent, 2009). Combination 
therapy seems, therefore, to be a good opportunity to achieve a more 
effective treatment with better patience compliance. 
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    1.3.2. Endocrine therapy. 
For hormone dependent breast cancer, endocrine therapy has 
been described as an indispensable tool to modulate cell proliferation. 
Two options are used, the blockage of the ER by SERM’s or the decrease 
in the oestrogen production by aromatase enzyme inhibition (important in 
postmenopausal population) (Jordan, 2003; Jordan and Brodie, 2007). 
      1.3.2.a. SERM’s therapy. 
The selective oestrogen receptor modulators (SERM’s) are competitive 
antagonists of oestrogens. They bind to the ER preventing its activation 
and consequently cell growth. Representative examples of SERM’s are 
shown in figure 1.11. 
The most widely used in breast cancer therapy is tamoxifen discovered by 
ICI Pharmaceuticals in the early 1970’s (Jordan, 2006). The food and 
drug administration (FDA) approved the use of tamoxifen in June 1990 
for a major additional use to help prevent the recurrence of cancer in 
“node negative” patients. It is administrated orally and daily. Liver 
metabolisation leads to the active compound: 4-OH-Tamoxifen , which 
shows a ten-folds more interaction with the ER than Tamoxifen (Jordan, 
2003; Cheung, 2007). The treatment is used for women pre- o post-
menopausal for a maximum of 5 years. Another interesting SERM is 
Fulvestrant known as Falsodex. It received the FDA approval in April 
2002 for hormone receptor positive metastatic breast cancer in 
postmenopausal women whose disease has progressed after receiving 
anti-oestrogen therapy such as Tamoxifen. Instead of blocking ER, this 
compound targets and degrades the ER present in breast cancer blocking 
ER transcription. The Falsodex therapy is given as a once-a-month 
intramuscular injection (Tang et al., 2008; http://www.fda.gov). 
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Figure 1.11. SERM’s chemical structures (Jordan, 2003).  
. 
      1.3.2.b. Aromatase inhibitors. 
The other strategy followed to limit the oestrogen-induced cell 
proliferation is to diminish the oestrogen flow. The oestrogen 
biosynthesis is involved in the last step of cholesterol degradation, the 
aromatisation of the androstenedione steroid A-ring. Once 
androstenedione fixes the aromatase enzyme (cytochrome P450) through 
its haeme centre, serial reactions occur involving NADPH, NADP 
mechanisms to achieve the A ring aromatisation (figure 1.12.) (Jordan, 
2007). 
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Figure 1.12. Last step of oestrogen biosynthesis adapted from (Jordan and 
Brodie, 2007). 
Aromatase inhibitors act on the haeme nucleus arresting the oestrogen 
production. This treatment is orally available but it could be only 
administered for post-menopausal women due to the oestrogen need in 
pre-menopausal women. Aminoglutethimide (AGM), marketed under the 
name ORIMETEN
®
 was the first aromatase inhibitor used clinically in 
the treatment of postmenopausal breast cancer for 20 years with a modest 
response rate. AGM is a non-steroidal, nonspecific, reversible and 
competitive aromatase inhibitor with very low potency (Lombardi, 2002). 
For example, it was observed that women treated with AGM could 
develop osteoporosis, thereof cortisol had to be administrated as adjuvant 
therapy (Kelloff et al., 1998). Since AGM, research has devoted to 
develop new aromatase inhibitors with better pharmacological profile. 
Currently two families of inhibitors are indexed, (i) Irreversible Inhibitors 
and (ii) Reversible inhibitors (figure 1.13.) (Cheung, 2007; Jordan, 2007). 
Aromatase inhibitors, such as AGM, Fadrozole, Letrozole and 
Anastrozole act by reversibly binding to the enzyme and by interfering 
with the haeme-iron group of the cytochrome P-450 moiety of the 
enzyme (Lombardi, 2002). A variety of pathways involve cytochrome P-
450, therefore, a carefully design of the aromatase inhibitor have to be 
done. Furthermore, due to their reversibility, the oestrogen deprivation 
highly depends on the presence of the drug, thus posing potential toxicity 
issues. 
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Figure 1.13. Representative example of aromatase inhibitors (Jordan, 2003). 
The irreversible inhibitors also known as suicide inactivators, such as 
Formestane and Exemestane interact with the substrate-binding site of the 
enzyme. They must have an androstenedione-like structure to be 
transformed by the normal catalytic action of the target enzyme. A 
covalent bond formation then occurs with its nucleophilic site, leading to 
the irreversible inactivation of the aromatase enzyme (Lombardi, 1995). 
Due to its irreversibility, the biosynthesis of new aromatase enzymes is 
required to achieve oestrogen production (Miller, 1996). 
Regarding clinical trials in postmenopausal women with hormone 
dependent breast cancer (ATACC trial), letrozole and anastrozole were 
more effective than tamoxifen with lesser side effects, as consequence 
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these aromatase inhibitors are considered first line treatment in 
postmenopausal patients (Goss and Strasser, 2002; Howell et al., 2005).  
    1.3.3. Tyrosine Kinase Inhibitors. 
As described above, growth factor pathways are also involved in cell 
proliferation and thereof could be an interesting target. The downstream 
signalling pathway begins with the interaction between growth factors 
and their receptors situated on the plasma membrane. The receptor 
triggered by the ligand, activates kinase cascade, including the receptor’s 
intrinsic tyrosine kinase activity and the mitogen-activated protein (MAP) 
cascade involved in cell proliferation (Dancey and Sausville, 2003). 
However, in normal cells a balance between activation and inhibition of 
these pathways is highly regulated and well-balanced. In the development 
of cancer pathology, those pathways could be altered in several ways. For 
example, growth factor receptors such as epidermal growth factor (EGF) 
receptor (EGFR) and/or insulin-like growth factor (IGF) receptor (IGFR) 
can be overexpressed. Consequently, the blockage of the growth factors 
downstream signalling pathways at any level should theoretically be 
beneficial in several types of cancer. 
Some studies have shown that the EGF and oestrogen signalling are 
strictly connected (Nicholson et al., 2001). In fact, not only are EGFRs 
over-expressed in cells previously treated with anti-hormonal drugs, but 
there is an active crosstalk between oestrogen and growth factor 
signalling pathways (Nicholson and Gee, 2000). The crosstalk can be 
summarised as follows (Nicholson and Gee, 2000). Growth factors like 
EGF, Transforming growth factor (TGF-α) and IGF are able to 
phosphorylate the serine 118 residue of ER and activate the receptor 
without previous oestrogen fixation. 
- Oestrogens are able to trigger positive elements involved in 
growth factors signalling cascade. 
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- The ER enhances the activity of nuclear transcription factors 
induced by growth factors. 
In addition, oestrogen deprivation has been correlated with up-regulation 
of growth factor receptors such as EGFR. The tyrosine kinase inhibitor 
(TKI) drug most used clinically is Trastuzumab (Herceptin
®
) for HER-
2/neu receptor (Gschwind et al., 2004; Nielsen et al., 2009; Normanno et 
al., 2009). The standard clinical administration is Trastuzumab 4 mg/kg 
i.v. d 1, then 2 mg/kg i.v. per week followed by PTX (175 mg/m
2
) during 
3 h i.v d 1 each 21 d. 
    1.3.4. Surgery. 
Breast conservation is currently the most popular treatment as most 
carcinomas have a restricted size and large primary tumours could be 
reduced in size by primary chemotherapy. In most breast-cancer centres, 
conservative surgery represents 75–80 % of all operations. However, 
surgeons are advised to undertake mastectomies in the same operative 
sessions as reconstruction of the breast. Moreover the resection of the 
axillaries nodes closely depends on the results of the sentinel lymph-node 
biopsy (Veronesi et al., 2005
a
; Veronesi et al., 2005
b
).  
    1.3.5. Radiotherapy. 
As described above, in most developed countries the current standard of 
care for patients with early-stage breast cancer consists of breast 
conserving surgery, followed by 5-6 weeks postoperative radiotherapy. 
Three different approaches are described, whole breast irradiation, partial 
breast irradiation and intraoperative radiotherapy. 
In daily practice, radiotherapy is used on the whole breast. Probabilities 
of adequate local control rates are high with this conventional 
fractionation. Some data support the effectiveness of an additional dose 
applied to the tumour bed (i.e. boost irradiation). The traditional schedule 
is 42,5 Gy in 16 fractions for 22 days in patients with negative lymph 
node. For patients younger than 48 years who received an intraoperative 
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boost dose of 12 Gy, a rapid course of external radiotherapy is used (13 
fractions of 2,85 Gy each). 
In parallel, the rationale for the use of partial breast irradiation instead of 
the conventional approach is based on the finding that most recurrences 
arise near the primary tumour location. And concerning intraoperative 
radiotherapy, it corresponds to the application of a high dose of radiation 
during surgical intervention after removal of the tumour. ELIOT 
(Electron Intra Operative Therapy) is currently used in early stage breast 
cancer as the only treatment at the European Institute of Oncology and 
prospective randomised trial is ongoing (Veronesi et al., 2005
a
; Leonardi 
et al., 2012).  
1.4. Polymer Therapeutics.  
It could be said that the beginning of polymer therapeutics was 
established in the 70’s when the concept of polymer-drug conjugates 
(Duncan, 2003) and the first PEGylated proteins (Davis, 2002) were 
developed to achieve in 1994 the first anticancer PEG-protein conjugate, 
PEG-L-Asparaginase (Oncaspar
®
) approved by FDA. However, it was 20 
years ago when the known term ‘Polymer Therapeutics’ was coined by 
Prof. Ruth Duncan to define a family of new chemical entities (NCEs) 
considered the first polymeric nanomedicines (Duncan, 2003; Duncan 
and Gaspar, 2011). After the 70’s, the field has been in permanent 
evolution. The term ‘Polymer Therapeutics’ includes different complex 
macromolecular systems, in which a water-soluble polymeric carrier 
(with or without inherent activity) and the bioactive molecule(s) are 
covalently bond (figure 1.14.). Drug conjugation to a polymer not only 
enhances its aqueous solubility but also changes drug pharmacokinetics at 
the whole organism and even subcellular level with the possibility to 
clearly enhance drug therapeutic value (Duncan, 2006; Vicent and 
Duncan, 2006). This family can be subdivided in five general categories 
(figure 1.14.): polymeric drugs, polymer-protein conjugates, polyplexes, 
polymeric micelles and polymer-drug conjugates (Duncan, 2003; Duncan, 
2006).  
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In our purpose, we focus on polymer-drug conjugates. With 16 
conjugates already transferred to clinical trials (Table 1.1.) (Vicent et al., 
2009; Duncan and Vicent, 2013), the new research trends in this field are 
focused on four main strategies: 1) design of innovative polymer 
conjugates targeted to new molecular targets, 2) the search for better 
physico-chemical characterisation methods paying special attention to 
conformational issues in solution, 3) the synthesis of new polymeric 
carriers with defined architecture and, 4) the use of polymer conjugates as 
a platform for the simultaneous administration of more than one drug, 
strategy known as polymer-based combination therapy. 
 
Figure 1.14. Polymer Therapeutics family adapted from (Duncan, 2003). 
    1.4.1. Polymer-drug conjugates. 
With the vision of Ringsdorf and De Duve the concept of polymer 
anticancer drug conjugates (1975) was born (Ringsdorf, 1975). The first 
polymer-drug conjugate, an HPMA copolymer-anticancer drug conjugate 
(HPMA copolymer–Dox conjugate, FCE28068 known as PK1) was 
transferred to clinical trials in the 90’s (Duncan et al., 1998). Currently, 
the most advanced is the PGA paclitaxel conjugate known as Opaxio
®
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(previously Xyotax
TM
 or PPX (paclitaxel polyglumex)) from Cell 
Therapeutics Inc. (CTI, Seattle (USA)) (Singer et al., 2003; Singer, 2005; 
Singer et al., 2005) in phase III trials for several cancers (ovarian, 
prostate, stomach, etc.) alone or in combination. In fact, last September 
Opaxio in combination with radiotherapy was designated by the FDA as 
Orphan drug for the treatment of glioblastoma (figure 1.15.).  
 
Figure 1.15. From polymer chemistry to Polymer Therapeutics (Duncan, 
2006). 
What is a polymer-drug conjugate? 
A polymer-drug conjugate is a new “chemical” entity in which a drug is 
covalently bound to a polymer through a bioresponsive linker. Each part 
(polymer, drug and linker) has to fulfil exigencies related to the molecular 
target, way of administration, pharmacokinetics, etc... Therefore, the use 
of a biological rational is key prior to the design of an efficient polymer 
anticancer drug conjugate. 
The polymer backbone has to be non-toxic, non immunogenic and 
water-soluble to allow i.v. administration. In order to achieve a better 
pharmacological profile, the use of biodegradable carriers allows us to 
always use a polymer size with safe renal excretion. However, in the case 
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of non-biodegradable polymers, a maximum weight of 40 kDa should be 
used to allow renal clearance. The most widespread polymers in the last 
20 years were the non-biodegradable HPMA, PEG and the biodegradable 
PGA (Singer et al., 2003; Vicent and Duncan, 2006) nevertheless new 
polymers are currently appearing (Tong et al., 2010).  
The drug is chosen according to the target, but it has also to fulfil some 
prerequisites. Apart from bearing adequate functionalities and a high 
potency, our drug has to be stable under lysosomal conditions in order to 
preserve its therapeutic activity as once the polymer drug conjugate reach 
the tumour, the conjugate is internalised generally by endocytosis. 
The linker is a bioresponsive spacer used to attach drugs to the polymer 
backbone. This spacer has to be design in order to be degraded under 
specific conditions to release the cargo, which usually remains inactive 
when attached to the polymer backbone. Intracellularly, release should be 
triggered within the lysosomes to achieve a lysosomotropic drug delivery 
(Duncan, 1992). Consequently, the linker should be responsive in 
presence of lysosomal enzymes such as cathepsin B and/or hydrolytically 
labile at acidic pH. Two strategies are generally developed, a peptidic 
substrate as linker or a pH labile linker. It should be noted the importance 
of enzyme levels in patients receiving this type of treatments. For 
example, during clinical studies with Opaxio
®
 it was demonstrated that 
patient cathepsin B levels were directly correlated with the oestrogen 
levels and since then oestrogen levels are considered as biomarker to 
indicate the possible effectiveness of this treatment. Concerning the 
treatment of a hormone dependent breast cancer in post-menopausal 
women, cathepsin B levels could represent a limitation in the use of 
nanomedicines bearing PGA as carrier or linkers based on peptides 
substrate for cathepsin B (Devetzi et al., 2009). 
A target moiety is an optional part of the nanoconjugate. It is used to 
actively target and to directly and specifically deliver the drug to the 
targeted cell or tissue. Nevertheless, of the conjugates transferred to 
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clinical trials only one bears a targeting group. This is the HPMA 
copolymer-Dox-galactosamine conjugate (also known as FCE28069 or 
PK2) and was designed to achieve liver targeting by selective binding to 
the asialoglycoprotein receptor in the hepatocytes and therefore, to be 
used as treatment for hepatocellular carcinoma (Seymour et al., 2002). 
It could be summarised that, the main benefits of polymer-drug 
conjugates compared to the parent free drug are: (a) passive tumour 
targeting by the enhanced permeability and retention (EPR) effect, which 
can be utilised for tumour targeting and polymer-drug conjugate 
accumulation (Maeda, 1994), (b) a decrease of toxicity (Vasey et al., 
1999), (c) an increase of solubility in biological fluids (Meerum et al., 
2001), (d) an ability to overpass some mechanisms of drug resistance 
(Minko et al., 1998) and (e) an ability to elicit immunostimulatory effects 
(Rihova et al., 2003; Sirova et al., 2007). 
Table 1.1. Polymer-drug conjugates in clinal trials (Duncan and Vicent., 
2013; Sanchis et al., 2010). 
conjugate Name  Trial Phase   
HPMA copolymer-Dox PK1 II 
HPMA copolymer-Dox-galactosamine PK2 I 
OxDetran-Dox AD-70 I/disc. 
PGA-CPT CT-2106 I/II 
Cyclodextrin-CPT IT-101 I 
Polyacetal-CPT XMT-1001 I 
HPMA copolymer-CPT MAG-CPT I 
PEG-CPT pegamotecan II/disc. 
Carboxymethyl-dextran-exatecan DE-310 I 
PEG-irinotecan NKTR-102 II 
HPMA copolymer-PTX PNU166945 I/disc. 
PGA-PTX CT-2103 (Opaxio) III 
PEG-docetaxel NKTR-105 I 
HPMA copolymer-malonato-platinate AP5280 I 
HPMA copolymer-DACH-platinate AP5346 (Prolindac
TM
) II 
PEG-naloxone NKTR-118 III 
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    1.4.2. Enhance-permeability and retention (EPR) effect 
represents an indispensable tool to target solid tumours. 
The EPR effect offers a passive targeting to solid tumour tissues after i.v. 
administration of a macromolecular conjugate. The cancerous cells are 
rapidly growing and creating its own vessels to support its significant 
growth. This process is known as angiogenesis, a biological mechanism 
regulated by many different growth factors (Folkman and Shing, 1992; 
Segal and Satchi-Fainaro, 2009). The new vessels created by the 
cancerous mass, possess its own characteristics (e.g. lack of smooth 
muscle layer cells, looser endothelial cell-cell junctions, incomplete 
basement membrane). This leads to an enhanced permeability of the 
cancerous capillaries for macromolecules (Duncan et al., 1987; Maeda et 
al., 2001). Moreover, solid tumours lack effective lymphatic drainage, 
leading to lower clearance ability from the tumours, and consequently an 
enhanced retention of the macromolecular drug within the tumour. The 
EPR effect allows a discrimination of healthy tissues. This passive and 
selective targeting present in tumour tissues allows an increased 
accumulation of the macromolecular constructs. Due to the different 
pharmacokinetics of macromolecular anticancer drugs, chemotherapy 
side effects can be minimised. It was reported that the ideal size for take 
profit of EPR effect is a molecular size larger than 40 kDa (Maeda, 2001; 
Maeda, 2010). However some other characteristics and limitation have to 
be taking into account (Maeda et al., 2012). The macromolecule cannot 
interact with blood components or blood vessels, the total surface charges 
have to be weakly negative to near neutral and ideal time required to 
achieve the EPR have to be larger than several hours in systemic 
circulation in mice (Maeda et al., 2012).  
It is extremely important to note that, EPR effect is heterogeneous and 
highly depends on the tumour type and cancer stage. Recent studies 
demonstrate that it is possible to enhance the EPR effect by using 
molecules such as brakylin, NO and prostaglandins to facilitate 
extravasation. In addition combination of small drug, such as Angiotine II 
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and angiotensin converting enzyme (ACE), induce hypertension and 
consequently increase tumour blood flow (Maeda et al., 2012).  
 
 
Figure 1.16. Enhance permeability and retention (EPR) effect adapted from 
(Duncan, 2006; Peer et al., 2007) where  is Dox,  is AGM,  is the 
conjugate,        is an angiogenic vessel and  is an epithelial cell. 
Once present in the tumour interstitium, polymer-drug conjugates can be 
act either extracellularly or after being uptaken by the cells via 
endocytosis (Duncan, 2003). It has been demonstrated that cellular uptake 
of macromolecules is limited to endocytosis, and this process would lead 
to a “lysosomotropic” drug delivery (De Duve et al., 1974). Endocytosis 
involves cell membrane invagination for the capture and vesicular 
internalisation of extracellular molecules. Once internalised, 
macromolecules are transferred via endosomes (pH 6,0–6,5) to lysosomal 
compartments, which contain hydrolytic enzymes and a lower pH (pH 
5,0-5,5) (Duncan, 2003; Duncan, 2006). Conjugation of therapeutic 
agents to macromolecules through a linker that only degrades when 
exposed to these specific lysosomal conditions would allow intracellular 
release of the drug, which would then passively diffuse through the 
Tumour 
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lysosomal membrane to reach its pharmacological target in the cell 
(figure 1.16.). 
1.5. Polymer-based combination therapy. 
The term “polymer-drug conjugates for combination therapy” is a general 
phrase that comprises at least four families of systems (figure 1.17.). 
1) Family I: polymer-drug conjugate plus free drugs. This concept was 
developed based on the combination of a polymer-drug conjugate 
carrying a single drug administered with a low molecular weight drug or 
a different type of therapy (e.g. radiotherapy). 
2) Family II: polymer-drug conjugate plus polymer-drug conjugate. In 
this approach the strategy developed is the combination of two different 
polymer-drug conjugates each containing a single therapeutic agent. 
3) Family III: single polymeric carrier carrying a combination of drugs. In 
contrast to the other families, this approach involves only one polymer 
mainchain in which two or more single drugs are conjugated. 
4) Family IV: polymer-directed enzyme prodrug therapy (PDEPT) and 
polymer enzyme liposome therapy (PELT). PDEPT relies on the 
combination of polymer drug conjugate with a polymer-enzyme 
conjugate capable of the selective release of the drug at the tumour site. 
PELT is a comparable strategy where a polymer enzyme conjugate is 
administered in combination with the liposome to induce its degradation 
allowing the release of the encapsulated drug. 
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Figure 1.17. Schematic representation of the different types of polymer-based combination therapy with representative examples and 
their target sites. Family I: PGA-PTX+radiotherapy; Family II: HPMA-Dox + HPMA-Me6; Family III: HPMA-AGM-Dox; Family 
IV: PDEPT approach, HPMA-Dox + HPMA-Cathepsin B (Deladriere et al., 2010). 
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    1.5.1. Challenges and Opportunities associated with the use of 
polymer-based combination therapy. 
Due to the intra-tumour heterogeneity of the tumour tissue and the 
complex molecular mechanism of tumour progression, the presence of two or 
more therapeutic agents on a single polymeric chain opens new therapeutic 
possibilities, but also new challenges to be overcome. Therefore, several issues 
should be considered in order to develop polymer-drug conjugates for 
combination therapy. 
      1.5.1.a. Identification of appropriate drug combinations and drug ratios.  
Most drug combinations are based on the assumption that by targeting 
different cellular pathways there is an enhancement in the therapeutic benefit 
and a decrease in toxicity. Several studies confirmed this statement while others 
did not reach their expectative (Jones, 2009). Indeed, two important and not 
trivial points have to be considered, firstly the identification of the drugs to be 
combined that will be subsequently released together, and secondly, the 
determination of the optimal drug ratio. 
In order to achieve the maximum clinical benefit in patients, clinicians usually 
combine drugs that do not have overlapping toxicities at their individual 
maximum tolerated dose (MTD). However, this assumption is not correct in 
many cases as a different ratio of the selected drugs may be synergistic (greater 
effect than the sum of the individual drugs), additive (equal activity to the sum 
of the individual drugs) or antagonistic (less anti-cancer effect than the sum of 
the individual drugs). In order to evaluate the possible synergism of both drugs a 
Combination index (CI) have to be determined using the method described by 
Chou (2006). 
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CI = D1   +    D2 
         (Dm)1    (Dm)2 
 
D1 and D2 are the corresponding concentrations determined to achieve 50% of 
cell death (IC 50) when drug 1 and 2 are tested in combination. Dm is the IC50 
of drug 1 and 2 when they are tested as single drug.  
When CI < 1, this indicates synergism,  
When CI = 1, this indicates an additive effect  
When CI > 1 this indicates an antagonism  
Moreover drug ratios can play a critical role when combining drugs. The results 
of multiple in vitro and preclinical studies have demonstrated that the molar 
ratios of drugs used can have a significant impact on the overall efficacy and 
safety of combination chemotherapy (Mayer and Janoff, 2007). The full 
understanding of this concept has been the key of the successful technology 
developed by the Canadian company Celator Technologies Inc. 
(www.celator.ca, 01 November 2010). Ideally, it is hoped that a similar 
approach will be applied to the development of polymer-drug combination 
conjugates. In this context, further studies investigating the impact of different 
drug ratios on biological activity of polymer-drug conjugate should be carried 
out. 
      1.5.1.b. Kinetics of drug release. 
This is another important parameter to control when developing 
polymer-drug combination conjugates that confers clear benefits to this platform 
technology when compared to other nanopharmaceuticals. The presence of 
bioresponsive polymer-drug(s) linker(s) offers the possibility of finely tuning 
drug release ratio(s) that could be directly translating in an enhancement of the 
therapeutic output. However, achieving a successful drug(s) release rate is not a 
trivial issue.  
It is well established that the drug release rate from the polymer to the target site 
is an essential requirement for polymer-drug conjugates to reach its activity. 
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Therefore, the ideal linker has to be stable in blood but readily cleaved at the 
target site. Meticulous research carried out in the 1980s comparing peptidyl 
linkers for selective cleavage in the lysosomal compartment led to the 
development and clinical assessment of HPMA copolymer-GFLG-Dox (Gly-
Phe-Leu-Gly) conjugate (Duncan, 2005). These early studies showed that the 
different peptidyl linkers displayed a different release rate. It was also observed 
that the biodegradability of the linker also depended on the conjugated drug. 
Indeed, the linker –GlyGly- is non-biodegradable when it is designed in the 
conjugate HPMA copolymer-GlyGly-Dox. However, when it is used in the 
conjugate HPMA copolymer-GlyGly-melphalan, the drug release is achieved 
(Duncan et al., 1991). In addition, when more than one drug is linked to the 
carrier, drug release can be clearly affected by the presence of the second 
bioactive agent, mainly due to changes in hydrophobicity, pH or conjugate 
conformation in solution. Also, for conjugates combining more than one agent, 
relative drug release rate (which drug is released faster) and sequential drug 
release (which drug is released first) can further increase the complexity of the 
system and become key factors for activity (Vicent et al., 2005; Greco et al., 
2007). 
      1.5.1.c. Loading capacity.  
In order to design polymer-based combinations a multifunctional carrier should 
be used. Ideally with a loading capacity adequate to ensure delivery of sufficient 
amount of drugs to the tumour site, very important if multi-agent therapy is 
used. For instance, cyclodextrins (Davis, 2009), polyacetals (Yurkovetskiy and 
Fram, 2009) or PGA can theoretically carry one drug molecule per monomer 
and indeed, conjugates based on these platforms have a high drug loading (10 
w% Cyclodextrin-CPT (Davis, 2009), 10 wt% poly (1-hydroxymethylene 
hydroxymethyl formal) (Fleximer®)-CPT (XMT-1001) (Yurkovetskiy and 
Fram, 2009) or 37 wt % PGA-PTX. It is important to note that, to achieve an 
efficient polymer combination system it is required to get the best drug ratio that 
will provide an optimal therapeutic output, whilst maintaining water solubility 
(Bhatt et al., 2003; Duncan, 2005; Singer et al., 2005; www.celator.ca, 01 
November 2010). In addition to linear polymers, novel branched polymeric 
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architectures that display a good carrying capacity together with other 
interesting characteristics are also being explored (Duncan and Izzo, 2005; 
Vicent et al., 2008). 
    1.5.2. Correlation of in vitro studies with behaviour in vivo.  
The main limitation here is the lack of preclinical models for combination 
therapy neither in vitro (i.e. screening cell models to examine combinations) nor 
in vivo models standardised for use with targeted combinations.  
Preliminary screening of the anticancer activity of newly synthesised polymer-
drug conjugates is normally carried out in vitro against cancer cells using 
standard cell viability assays. The usefulness of such in vitro screening is 
debatable as, polymer-drug conjugates relay on accumulation in the tumour 
tissue via the EPR effect, which can be observed only in vivo. In addition, and 
due to the different cell trafficking mechanisms, the free drug is normally more 
active in vitro than the conjugated drug but in vivo studies show opposite trends 
(Duncan, 2005). Based on these considerations, the significance of in vitro tests 
and their relevance to predict in vivo behaviour are difficult issues. Ethical 
considerations and cost are obvious reasons in favour of in vitro pre-screening 
but there are additional advantages, particularly in the case of polymer based 
combination therapy. First, in vitro testing allows a comparison of the relative 
activity of different polymer-drug conjugates, possible benefits of combining 
two agents within a single drug carrier can be highlighted at this early stage. 
Second, an extensive evaluation of different drug ratios can be carried out, 
which would not be feasible at a later stage. Finally, specific experiments can be 
designed to elucidate the mechanism of action of these systems including drug 
release mechanisms and their ability to trigger or block specific cell processes.  
    1.5.3. Clinical Development. 
Transfer of these combination products into the clinic is extremely challenging, 
since it calls for additional measures to unequivocally prove their clinical 
benefit. In particular, there is the need to demonstrate that clinical benefits are 
due to the advanced drug delivery strategy rather than simply the 
additive/synergistic effects of the parent compounds administered as separate 
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therapeutic entities. In other words, there is the need to demonstrate that the 
combination of two or more agents within a single delivery system provides 
advantages over the simple administration of the free drugs. Due to the 
complexity in designing such clinical trials and the consequent ethical issues, it 
is envisaged that the development costs for such combination products might be 
significantly more than the development of current pharmaceutical preparations. 
However, if the therapeutic output of the developed combination is clinically 
valuable, it would be always possible to accelerate this process asking FDA to 
recognise the combination compound as a single entity, this is the case for 
Combiplex® technology  (www.celator.ca, 01 November 2010). 
Representative examples of each family system are described and classified 
below following their clinical status. It is important to note that the combination 
therapy based on polymer-drug conjugate plus free drug (family I) is already in 
clinical trials, and families II, III and IV are mainly in preclinical status and few 
of them are still under early in vitro evaluation (Table 1.2.).  
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Table 1.2. Summary of polymer–drug conjugates based on combination therapy classified by its clinical status. 
 
 Name Family Carrier Drugs Drug types Ref 
In Vitro 
CPT–PEG-LHRH + CPT –PEG-BH3 
II 
PEG 
CPT Chemotherapeutic 
(Khandare et 
al., 2006) 
  LHRH Targeting residue  
  BH3 Proapoptotic protein  
 
HPMA copolymer-Dox-DEX 
III HPMA copolymer Dox Chemotherapeutic 
(Krakovicova et 
al., 2009) 
   DEX Antiinflammatory  
 HPMA copolymer-AGM-Dox III HPMA copolymer 
AGM 
Dox 
Endocrine therapy 
Chemotherapeutic 
(Vicent et al., 
2005; Greco et 
al., 2007) 
 
PEG-poly(aspartate hydrazide) block 
copolymer-Dox-WOR 
III 
PEG-poly(aspartate 
hydrazide) 
Dox 
WOR 
Chemotherapeutic 
Phosphotidylinositol-3kinase 
inhibitor 
(Bae et al., 
2007) 
Preclinical 
HPMA copolymer-Dox + HPMA 
copolymer Mscl e6 
II HPMA copolymer 
Dox 
Mscl e6 
Chemotherapeutic 
Phototherapy 
(Krinick et al., 
1994; Shiah et 
al., 2001) 
 
PEG-(ZnPP) + PEG-(DAO) 
II 
PEG 
ZnPP Hemeoxigenase inhibitor enzyme 
(Fang et al., 
2004) 
  DAO oxidative chemotherapeutic type  
 
HPMA copolymer-TNP-470-ALN 
III 
HPMA copolymer 
ALN 
Bone targeting - antiangiogenic 
agent 
(Satchi-Fainaro 
et al., 2004; 
  TNP 470 Anti angiogenic agent 
Satchi-Fainaro 
et al., 2005) 
 
HPMA copolymer-PTX-ALN 
III 
HPMA copolymer 
PTX Chemotherapeutic 
(Miller et al., 
2009) 
  ALN 
Bone targeting – 
antiangiogenic agent 
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Preclinical  
HPMA copolymer-Gem-Dox 
III 
HPMA copolymer 
Gem Chemotherapeutic 
(Lammers et al., 
2009) 
  Dox Chemotherapeutic  
 
PEG-NO-EPI 
III 
PEG 
NO signalling molecule 
(Santucci et al., 
2006) 
  EPI Chemotherapeutic 
(Santucci et al., 
2007) 
 
CPT-PEG-LHRH-BH3 
III 
PEG branched 
CPT Chemotherapeutic 
(Khandare et 
al., 2006) 
  LHRH Targeting residue 
Chandna et al., 
2007) 
  BH3 Proapoptotic protein  
 
HPMA copolymer-Dox + HPMA 
copolymer-cathepsin B 
IV HPMA copolymer 
Dox 
Cathepsin B 
Chemotherapeutic 
Proteolytic enzyme 
(Satchi-Fainaro 
et al., 2003) 
 
HPMA copolymer-Dox + HPMA 
copolymer-β-lactamase 
IV HPMA copolymer 
Dox 
-lactamase 
Chemotherapeutic 
Proteolytic enzyme 
(Satchi-Fainaro 
et al., 2002) 
 
Clinical 
PGA-PTX + cisplatium 
I 
PGA 
PTX Chemotherapeutic 
(Verschraegen 
et al., 2009) 
Phase I  Cisplatium Chemotherapeutic  
Phase I PGA-PTX + radiotherapy 
 
I 
PGA 
PTX Chemotherapeutic 
(Dipetrillo et 
al., 2006) 
 Radiotherapy Radiotherapy 
(Orphan drug 
for 
Glioblastoma) 
Phase III 
PGA-PTX + carboplatinum 
I 
PGA 
PTX Chemotherapeutic 
(Langer et al., 
2008) 
 Carboplatinum Chemotherapeutic  
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    1.5.4. HPMA copolymer-AGM-Dox conjugate: First described 
combination conjugate for the treatment of breast cancer. 
The use of polymer-drug conjugates has been traditionally limited to the 
delivery of a single therapeutic agent. However, the multivalency of polymeric 
carriers allows their use to deliver cocktails of different drugs. This is a huge 
therapeutic opportunity as it is becoming increasingly clear that multi-agent 
therapy as opposed to single agent therapy is warranted for diseases such as 
cancer. At present, only few groups have suggested the use of a polymeric 
carrier for delivery of drug combinations. Dr Vicent in collaboration with Prof 
Duncan and Dr Greco (Vicent et al., 2005) developed the first conjugate that 
combined endocrine therapy and chemotherapy on a single polymeric chain; an 
HPMA copolymer carrying the aromatase inhibitor AGM and the 
chemotherapeutic agent Dox. The observations that HPMA copolymer-Dox 
(FCE28068, PK1) showed activity in chemotherapy refractory breast cancer 
patients in Phase I clinical trials (Vasey et al., 1999), and that aromatase 
inhibitors can act synergistically with chemotherapy (Johnston and Dowsett, 
2003), led them to synthesise HPMA copolymer-AGM-Dox as a novel 
particular combination conjugate (figure 1.18.) (Vicent et al., 2005).  
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Figure 1.18. Structure of HPMA copolymer-AGM-Dox combination conjugate. 
This combination conjugate showed markedly enhanced cytotoxicity in MCF7 
breast cancer cells compared to HPMA copolymer-Dox whose activity has been 
proven clinically (Vasey et al., 1999) and to any other combination of single 
agents (namely, AGM + Dox or HPMA copolymer-AGM conjugate + HPMA 
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copolymer-Dox conjugate or HPMA copolymer-Dox conjugate + AGM) (Vicent 
et al., 2005; Greco et al., 2007) (figure 1.19.).  
 
 
Figure 1.19. Comparison of the cytotoxicity HPMA copolymer-AGM-Dox and 
conjugate mixture in MCF7 and MCF7 Ca cells. Panel (a) shows cytotoxicity in 
MCF7; panel (b) shows cytotoxicity in MCF7 Ca (Greco et al., 2007). 
Furthermore, experiments studying a library of HPMA copolymer conjugates 
containing AGM alone (the first conjugates to contain endocrine therapy), 
confirmed aromatase inhibition in vitro, and also that AGM liberation was a 
requirement for activity (Greco et al., 2005). To further investigate the 
mechanism of enhanced cytotoxicity of HPMA copolymer-AGM-Dox, 
particularly in comparison with HPMA copolymer-Dox, the possible different 
mechanisms or rates of endocytic uptake, the differences in the rate of release of 
the bioactive drug(s) and the differences in the molecular mechanisms of cell 
death were studied. Flow cytometry and live-cell imaging were used to evaluate 
cell binding (4 °C) and endocytic uptake (37 °C). In addition, studies in the 
presence of methyl-β-cyclodextrin (MßCD) (inhibits clathrin-mediated and 
clathrin- and caveolin-independent endocytosis), chlorpromazine (inhibits 
clathrin-mediated endocytosis) and cytochalasin B (inhibits macropinocytosis) 
were undertaken to proof the mechanism of endocytic internalisation. The rate 
of Dox and AGM release from the conjugates was measured in vitro in the 
presence of rat liver lysosomal enzymes (tritosomes).  
HPMA copolymer-AGM-Dox and HPMA copolymer-Dox conjugate showed a 
similar pattern of cell binding and endocytic uptake (via cholesterol dependent 
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pathway). However, marked differences on drug release profile were found. Dox 
was released with time from HPMA copolymer-Dox showing a linear trend 
whereas the release of Dox from HPMA copolymer-AGM-Dox did not (figure 
1.20.). 
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Figure 1.20. Drug release from HPMA copolymer conjugates. Panel (a) shows the 
release of Dox from the conjugates in presence of tritosomes. Panel (b) shows the 
release of AGM from conjugate in presence and absence of tritosomes and the panel 
(c) shows the release of Dox and AGM from HPMA copolymer-AGM-Dox 
conjugate (Vicent et al., 2005). 
Finally, immunocytochemistry was used to assess the effect of both conjugates 
on the proliferation marker ki67 and the anti-apoptotic protein B-cell lymphoma 
2 (Bcl-2). The preliminary immunocytochemical studies showed decreased 
expression of ki67 following incubation of MCF7 and MCF7 Ca cells with 
HPMA copolymer-Dox and HPMA copolymer-AGM-Dox. This effect was 
higher for the combination polymer. As ki67 is a well-described marker for the 
proliferating fraction of a cell population this was consistent with the higher 
cytotoxicity obtained with the combination polymer. More importantly, HPMA 
copolymer-Dox had no effect on Bcl-2 protein expression whereas a marked 
Bcl-2 down-regulation was induced after MCF7 treatment with the combination 
conjugate, suggesting that combined AGM and Dox leads to a synergistic effect 
which induces a different cell death mechanism, hence the increased activity of 
the combination polymer. 
As a conclusion it is possible to say that these early studies highlighted that the 
conjugate conformation in solution and the drug release rates are key parameters 
for the activity (Greco et al., 2007). However, further studies are still needed to 
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investigate these effects and define both therapeutic potential of HPMA 
copolymer-AGM-Dox conjugate and to establish the exact mechanism of action. 
It is clear that this approach offers a new opportunity for the treatment of 
chemoresistant metastatic breast cancer. Apart from enhancing the cytotoxic 
activity, this technological platform is intravenously administered (adequate for 
a systemic treatment of metastasis with enhanced angiogenesis) and its cellular 
internalisation mechanism is different, avoiding mechanism of resistance such as 
the overexpression of p-glycoprotein in cell membrane. 
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2.1. Aims and objectives. 
Based on the in vitro evaluation of HPMA copolymer-AGM-Dox conjugate, it 
seems that the combination of the AGM with Dox in the same polymeric 
backbone induces a synergistic effect against human breast cancer cells. 
However in vitro tests are not taken into account the in vivo complexity, 
therefore, the first aim of this PhD thesis is to achieve in vivo proof of concept 
for HPMA copolymer-AGM-Dox conjugate synergism followed by a fully 
understanding of the molecular mechanism of action for our combination 
conjugate, HPMA copolymer-AGM-Dox conjugate.  
Additionally, HPMA copolymer is known as a non-biodegradable polymer, 
which induces an unfavourable pharmacological profile for long-term treatment 
(Duncan et al., 2010). Therefore in order to improve the structure and also to 
know if the carrier chosen could influence drug synergism, a new family of PGA 
conjugates will be developed. The design of an effective PGA-AGM-Dox 
conjugate family and its comparison with the model conjugate will be the main 
objective in order to understand the basis for synergism that would allow us a 
better design of a future combination therapy.  
The therapeutic potential of polyglutamates as drug delivery systems is based on 
the successful development of Xyotax
TM
 now named as Opaxio® (Singer et al., 
2005) (from Cell Therapeutics Inc.) the first polymer-drug conjugate that is 
expected to come to market as anticancer treatment alone and in combination 
with radiotherapy. Moreover, Dr Vicent’s group, in collaboration with Dr Pérez-
Payá and Dr Messeguer, has developed the first antiapoptotic medicine, PGA-
peptoid conjugate, currently in preclinical development (Vicent and Perez-Paya, 
2006; Vicent, 2007; Mondragon et al., 2008).  
Although it is important to keep the same combination of drugs in order to 
evaluate the influence of the carrier, AGM is a first generation aromatase 
inhibitor already removed from the market. Therefore, new drug cocktails 
should be identified. In this sense, as a final chapter in this thesis, a high 
throughput screening (HTPS) has been developed with 4 chemotherapeutic 
agents and 3 endocrine agents looking for new efficient combinations including 
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current drugs in the market with better therapeutic profile, such as second 
generation of aromatase inhibitors (i.e. Exemestane, Formestane). 
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3.1. Equipment. 
Gel Permeation Chromatography (GPC) analysis was carried out with Two 
Waters pumps mixer using Two TSK-gel columns in series G25000PWXL 
(200-12000) and G3000 PWXL (1000-250000). The detection was performed 
with a quadruple detector Viscotek TDA
TM
; Ultraviolet (UV), Light Scattering 
(LS), Refractive Index (RI) and Viscosimetry. 
Mass Spectrometry was used for metabolite identification with a MALDI-ToF 
bruker for weight higher than 500 kDa and Waters HPLC-MS quadruple system 
for the weight lesser than 500 kDa. 
NMR: The NMR was performed with a 300 MHz Bruker equipment. 
High Performance Liquid Chromatography (HPLC) analysis was performed 
with three Waters pumps mixer 515 using RP18 column (125x4mm). The 717 
autosampler was from Waters and the HPLC was provided of two detectors, a 
diode array (2996 Waters) and a multi wavelength detector (2475 Waters). The 
chromatograms were recorded and analysed by Empower Software. 
Size Exclusion Chromatography (SEC) was carrying out with Sephadex G25 for 
waters soluble sample and with Sephadex LH20 for organic soluble sample.  
Thin Layer chromatography (TLC) was performed on Merck silica gel plates 
(TLC silica gel 60 F254) and on Merck C18 gel plates (TLC silica gel 60 RP-18 
F254 S) 
Ultraviolet (UV-Vis) spectra were measured by a Jasco V630 spectrophotometer. 
Small Angle Neutron Scattering (SANS) experiments were carried out in ILL 
Grenoble (France) in collaboration with Dr Paul (Cardiff Univ., UK). 
 
    3.1.1. Cell Culture and equipment for biological tests. 
Cell experiments were performed in Laminar flow hood. Cell cultures were 
grown in tissue culture sterile plates (P100, 55cm
2
) from Falcon (353003) and 
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maintained in incubator at 37°C with or without 5% of CO2 depending of the 
cell line culture conditions. For cell experiments, tissue culture sterile plates (96 
wells and P60, 21cm
2
) from costar (3596) were used. For cell passaging, alive 
cell number was counted in a Neubauer camera following previous trypan blue 
staining. Sterile pipette were from costar. Centrifuge tubes were from ependorf 
(5702).  
Microtome. Histological slides were performed/prepared with MICROM 
international model HM 340E. 
Ultraturrax. The animal samples were processed by means of IKA T 25 digital 
ultraturrax. 
IVIS Spectrum Optical Imaging System. Pre-clinical In Vivo Imaging System 
(Perkin Elmer). 
3.2. Materials. 
    3.2.1. Chemical reagents. 
Dimethylformamide (DMF), Hydroxybenzotriazole (HOBt), N,N’-
diclyclohexylcarbodiimide (DCC), N,N’-Diisopropylcarbodiimide (DIC), 4-
Dimethyl amino pyridine (DMAP), Aminoglutethimide (AGM), Diisopropyl 
ethyl amide (DIEA), 5-fluorouracil (5 FU), Oestradiol, Daunorubicin, Fluorenyl 
methyl chloride (Fmoc-cl), 4-OH-Tamoxifen (4 OH-T), tert-butyl oxy carbonyl 
Leucine-Glycine (Boc-Leu-Gly), Carbobenzyloxy Glycine Phenylalanine (Z-
Gly-Phe), Glycine Glycine (GlyGly), camptothecin were provided by Sigma 
(ES). Methanol (MeOH), acetonitrile (ACN), Acetone, O-phosphoric acid, Ethyl 
acetate (EtAc) were supplied from VWR (SP). Carbobenzyloxy Glycine Glycine 
(Z-GlyGly), Carbobenzyloxy Glycine (Z-Gly) were bought in Bachem (Sp). 
Fluorenyl methyl Glycine (Fmoc-Gly) was from Iris Biotech Gmb (DE). 
Paclitaxel (P) was from Shaanxi sciphar (China). Doxorubicin (Dox) and 
exemestane (E) were from Sinoapex pharm (CN). 
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    3.2.2. Polymeric carriers. 
N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer precursors, carrying 
either a Gly-Gly-p-nitrophenol ester (ONp) (5 mol%; Mw~30.000 g/mol and 
Mw/Mn = 1,3-1,5) or Gly-Phe-Leu-Gly-ONp (either 5 or 10 mol%; Mw~30.000 
g/mol and Mw/Mn = 1,3-1,5) were from Polymer Laboratories Ltd, Shropshire, 
U.K. The bound ONp content of polymeric precursors was calculated using ε274 
nm = 9500 L.mol-1.cm-1 (in DMSO). Poly-L-Glutamic acid (PGA) were 
provided by Cell Therapeutics Europe s.r.l. or synthesised as reported elsewhere 
(Conejos-Sánchez et al., 2013). 
    3.2.3. Chemical reagents for biological analysis. 
Dimethylsufoxyde (DMSO), Charcoal A, Dextran, Bradford reagent, Sodium 
Dodecilsulfate (SDS), Tris, borate acid and phenazine methosulfate (PMS) were 
supplied by Sigma (Sp). Dulbecco’s Modified Eagle’s Medium (DMEM), 
Leibovitz, Phosphate buffer saline (PBS), Foetal bovine serum (FBS) and 
Trypsin, were provided from Gibco. Penicillin/ Streptomycin (P/S) and Bovine 
Serum Albumin (BSA) were from Invitrogen. (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) was 
supplied by Promega (Sp). Ammonium Persulfate, Tetramethylethylenediamine 
(TEMED) and tween 20 were provided by VWR. 
The acrylamide/bis was supplied by BioRad (Sp) and non-fat dry milk was 
bought in Carrefour. For histological analysis, eosine, hematoxyline and sodium 
azide were from Sigma, SuperFrost Plus slide from Menzel-Glaser, Thermo 
Fisher Scientific Inc. UK, formaldehyde and Eukitt were bought in Panreac (Sp) 
and paraffin was purchased from ParaPlast Plus, Tyco Healthcare (UK). 
For in vivo models, sevofluorane, buprex and morfine were provided by the 
animal house keeping office. The androstenedione and Evans blue were 
purchased from sigma. Matrigel was bought in BD (Sp). 
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3.3. Experimental Methods. 
    3.3.1. Synthesis of conjugates and derivatised linker drugs. 
3.3.1.a. Synthesis of linker-drugs. 
 G-AGM: Fluorenylmethyloxycarbonyl glycine (Fmoc-G) (0,65 mmol, 
193,24 mg) was dissolved in DMF anhydrous (5 mL), DIC (0,975 mmol, 153 
µL) activation was done during 5 min then 1-hydroxybenzotriazole (HOBt) 
(0,975 mmol, 132 mg) was added. After 10min, AGM (0,65 mmol, 147 mg) was 
finally added. The pH was controlled and adjusted with DIEA to pH8. The 
reaction was left to react for 36 h at room temperature (RT). The DMF was 
evaporated by high vacuum and Fmoc-G-AGM was purified by liq/liq 
extraction. Fmoc-G-AGM was dissolved in AcOEt (10 mL) and extracted with 
sat NaHCO3 (3 x 10 mL). Synthesis and characterisation of Fmoc-G-AGM was 
performed by NMR. 
1
H NMR (300MHz,DMSO) 10, (s, 1H, NH Gly), 11,(s, 1H, 
NH AGM), 7,85 (d9d3, 1H, arom. Fmoc), 7,65(d9d3, 1H, arom. Fmoc), 7,53 
(t7, 1H, arom. Fmoc), 7,5 (d9, 1H, arom. AGM), 7,37 (t9d3, 1H, arom. Fmoc), 
7,18 (d9, 1H, arom. AGM). 4,2 (m, 2H, CH, CH2 Fmoc), 3,7 (d7, 2H, CH2 
Gly), 2-2,3 (m, 2H, CH AGM), 1,8 (q7, 2H, CH2 AGM) and 0,7 (t7, 3H, CH3 
AGM).
13
C NMR 300 MHz, 176 (1C, C=O AGM), 173 (1V, C=O Gly), 168 (1C, 
C=O AGM), 157 (2C, C=O Fmoc), 144 (2C, Cq Arom. Fmoc), 141 (2C, Cq 
Arom. Fmoc), 139 (1C, Cq Arom. AGM), 136 (1C, Cq Arom. AGM), 128 (2C, 
CH Arom. Fmoc), 127 (2C, CH Arom. Fmoc), CH Arom. AGM), 125 (125 (2C, 
CH Arom. Fmoc), 120 (2C, CH Arom. Fmoc), 119 (2C, CH Arom. AGM), 70 
(1C, CH2, Fmoc) 50 (1C, Cq AGM), 47 (1C, CH, Fmoc), 32 (1C, CH2, AGM), 
29 (2C, CH2, AGM), 26 (2C, CH2, AGM), 10 (1C, CH3, AGM). 
Then the organic phase was washed with acid chloride (HCl) 1M (3 x 10 mL), 
dried on sodium sulphate (Na2(SO4)) and evaporated to yield 90% of a white 
product. Afterwards, a deprotection step was performed using piperidine 20% in 
AcOEt during 1 h. Product purification was carried out by RP-chromatography 
with a C18 Porous resin. The starting chromatographic conditions were water 
(H2O)/acetonitrile (ACN) (30:70). After 30 mL of elution, further ACN (10 mL) 
was also poured. The purification was monitored by TLC (G-AGM Rf:0, Fmoc 
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Rf: 0,83 with Hexane:AcOEt 1:4). A double detection protocol was used: UV 
and Nihindrin staining. The reaction yield was 70% (0,46 mmol, 125 mg). 
Characterisation of G-AGM was performed by NMR. 
1
H NMR (300 MHz, 
DMSO)): 7,6 (d9, 2H, Arom. AGM), 7,22 (d9, 2H, Arom. AGM), 3 (t7, 2H, 
CH2 Gly), 2-2,3 (m, 4H, 2 CH AGM), 1,8 (q7, 2H, CH2 AGM) and 0,64 (t7, 
3H, CH3 AGM). 
13
C NMR 300MHz 174 (1C, Cq, C=O AGM), 172 (1C, C=O 
Gly), 169 (1C, C=O AGM), 138 (1C, Cq, AGM), 135 (1C, Cq, AGM), 127 (2C, 
CH, Arom. AGM), 119 (2C, CH, Arom. AGM), 50 (1C, Cq, AGM), 44 (1C, 
CH2, Gly), 32 (1C, CH2, AGM), 29 (1C, CH2, AGM), 22 (1C, CH2, AGM), 10 
(1C, CH3, AGM). 
 GG-AGM: In order to synthesise GG-AGM a previous step was 
required, the Fmoc protection of GG. 
Fmoc-GG (Tomlinson et al., 2002) : GG (0,28 mmol, 37,8 mg) was dissolved in 
a NaHCO3 solution (10%) (1,6 mL), then dioxane was added (0,9 mL) and the 
reaction was cooled down in ice. Once the right temperature was achieved, 
fluorenylmethyloxycarbonyl chloride (Fmoc-Cl) (0,28 mmol, 80 mg) was 
carefully added dropwise. The reaction was left to react for 4 hours on an ice 
bath and overnight at room temperature. Fmoc-GG was purified by liq/liq 
extraction, 3x H2O (3 mL) was added and the aqueous phase was extracted with 
AcOEt (3x5 mL). The aqueous phase was acidified with HCl (1 M) up to pH 2 
and extracted with AcOEt (3x5 mL). The organic phase was collected, dried on 
Na2(SO4) and evaporated to yield 81% of a white product. Characterisation of 
Fmoc-G-G was performed by NMR. 
1
H NMR (300 MHz, DMSO): 8,2 (t7, 1H 
NH Gly), 7,85 (d9d3, 2H, CH, Arom. Fmoc), 7,65(d9d3, 2H, CH, Arom. Fmoc), 
7,53 (t7, 1H NH Fmoc), 7,37 (t9d3 2H, CH, Arom. Fmoc) 7,25 (t9d3, 2H, CH, 
Arom. Fmoc), 4,2 (m, 3H, CH CH2, Fmoc), 3,7 (d7, 2H, CH2, Gly) and 3,4 (d7, 
2H, CH2, Gly). 
Then the GG-AGM synthesis was carried out following the same procedure 
described above for G-AGM.  
 G-Dox: Benzyl chloroformate glycine Bz-G (0,083 mmol, 31,8 mg) was 
dissolved in DMF anhydrous (5 mL), then DIC (0,124 mmol, 20 µL) was added 
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and after 5 min HOBt (0,124 mmol, 22 mg) was also added as solid. After 10 
min activation, Dox.HCl (0,083 mmol, 45,5 mg) was finally incorporated to the 
reaction mixture. The pH was controlled and adjusted with DIEA to obtained pH 
= 8. The reaction was left to react for 36 h at RT. DMF was then evaporated at 
high vacuum. The dry pellet was dissolved in MeOH and the purification was 
carried out by RP-chromatography (C18) with 10 mL of 2-propanol/H2O (12:88) 
(v/v), 10 mL of 2-propanol/H2O (29:71) (v/v) and then 20 mL of MeOH 
(pH3,2). The purification procedure was monitored by TLC through a double 
detection system set at λ= 254 nm and λ= 366 nm. Z-GG-Dox was identified by 
Maldi-Tof. Then, the deprotection was carried out in H2 Pd/Cact overnight. The 
solution was filtrated through celite and with a filter of 0,2 µm. After the MeOH 
removal, a yield of 50% was achieved and GG-Dox was identified by Maldi-
Tof.  
GG-Dox: The synthesis of GG-Dox was performed following the same protocol 
above-described for G-Dox. 
      3.3.1.b. Single conjugates synthesis.  
PGA-OSucc synthesis and purification: For PGA-AGM synthesis, previous 
carboxylic group activation was necessary. Indeed due to the poor reactivity of 
the AGM aromatic amine, classic diimide activation was not enough for the 
coupling. The PGA carboxylic groups were activated first by succinic group. 
PGA (3,55 mmol, 471.4 mg) was dissolved in DMF anhydrous (5 mL), N-
hydroxy succinimid (2,33 mmol, 268.4 mg) was added to reach a maximum of 
60% of carboxylic group activation. When the solution was totally transparent, 
DIC (2.33 mmol, 350 µL) and a catalytic amount of DMAP were added. The 
reaction was left for 36 h. The DMF was evaporated by high vacuum and the 
PGA-OSucc was precipitated in Chloroform (CHCl3)/Acetone (4/1). The 
product was purified by ether wash (x3) in ultrasonic bath (5 min each). The 
yield was 77% and the activation rate was 41%. The product was characterised 
by 
1
H NMR (300 MHz, δ(ppm)). δ8, (s, CH, main chain PGA), δ4,3 (m, CH2, 
lateral chain of PGA), δ 2 (m, CH2, lateral chain of PGA), δ 2,35 (m, 4H, CH2 
Succ). 
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PGA-AGM synthesis and purification: PGA-OSucc (0,52 mmol, 91,3 mg) was 
dissolved in DMF anhydrous (5 mL), then AGM (0,026 mmol, 6 mg) and a 
catalytic amount of DMAP were added. The pH was controlled and adjusted 
with DIEA to pH 8. The reaction was left to react for 40 h at RT. The DMF was 
evaporated by high vacuum and the conjugate was precipitated with 
AcOEt/Acetone 4/1 at 4°C. PGA-AGM sodium salt was made by the addition of 
NaHCO3 1M (0,58 mmol, 285 µL). A purification step by SEC was carried out 
in order to remove the salt excess and the rest of unreacted products. If free 
DMAP is still detected by UV, dialysis against H2O should be performed. After 
lyophilisation, the reaction yield was 65% (65 mg). 
PGA-G-AGM synthesis and purification: The synthesis of PGA-G-AGM was 
performed using the following protocol. PGA (0,51 mmol, 80,3 mg) was 
dissolved in DMF anhydrous (5 mL), DIC (0,808 mmol, 126,2 µL) was added 
and after 5 min HOBt (0,808 mmol, 109 mg). After the activation of the 
carboxylic acid groups by DIC and HOBt, G-AGM (0,0269 mmol, 7,8 mg) was 
added. The pH was controlled and adjusted with DIEA to pH8. The reaction was 
monitored by TLC and was left to react for 36 h at RT. The DMF was 
evaporated by high vacuum and the polymer drug conjugate was precipitated by 
CHCl3/Acetone 4/1 at 4°C by stirring 30 min followed by a further 30 min 
without stirring. PGA-G-AGM sodium salt was obtained by the addition of 
NaHCO3 1M (0,51 mmol, 250 µL). Two purification steps (dialysis against 
water (membrane Mw cut off 3500 Da) and G25 column) were carried out in 
order to remove the excess of salt and any remaining impurities including free 
drug. After lyophilisation, the reaction yield was 60%. 
PGA-GG-AGM synthesis and purification: PGA-GG-AGM was synthesised 
following the same approach as described for PGA-G-AGM. 
PGA-DOX synthesis and purification: PGA (0,51 mmol, 80,3 mg) was dissolved 
in DMF anhydrous (5 mL), then DIC (0,808 mmol, 126,2 µL) was added and 
after 5 min HOBt (0,808 mmol, 109 mg) was also added as solid. After 10 min, 
Dox.HCl (0,0269 mmol, 14 mg) was incorporated to the reaction mixture and 
the pH adjusted with DIEA to 8. The reaction was monitored by TLC and left to 
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react for 36 h at RT. DMF was evaporated under high vacuum and the conjugate 
precipitated with a CHCl3:Acetone 4:1 solution at 4°C by stirring 30 min 
followed by a further 30 min without stirring. PGA-Dox sodium salt was 
obtained by addition of NaHCO3 1M (0,51 mmol, 250 µL). Two purification 
steps (dialysis against water (membrane Mw cut off 3500 Da) and G25 column) 
were carried out in order to remove the excess of salt and any remaining 
impurities including unreacted drug (yield 60% (60mg)).  
PGA-G-Dox and PGA-GG-Dox synthesis and purification: The PGA-G-Dox 
and PGA-GG-Dox were performed following the same procedure used for PGA-
Dox. 
      3.3.1.c. Combination Conjugates synthesis. 
PGA-AGM-Dox: PGA-OSucc (0,259 mmol, 85,45 mg) was dissolved in DMF 
anhydrous (5 mL). A catalytic amount of DMAP was added and pH was 
adjusted to 8 with DIEA. Then, AGM (0,027 mmol, 6,3 mg) was added. The 
reaction was monitored by TLC and was left to react for 36h at RT. Then DIC 
(0,036 mmol, 5,7 µL) was added and after 5 min HOBt (0,036 mmol, 4,9 mg). 
After the activation of the carboxylic acid groups by DIC and HOBt, Dox (0,024 
mmol, 13.6 mg) was then added, the pH was adjusted to 8 with DIEA and the 
reaction was left to react for 36h more at room temperature. The DMF was 
evaporated by high vacuum and polymer conjugate precipitated by adding 5 mL 
of CHCl3: Acetone (1:1). PGA-AGM-Dox sodium salt was obtained by the 
addition of NaHCO3 1 M (0,51 mmol, 250 µL). Two purification steps (dialysis 
against water (membrane Mw cut off 3500 Da) and G25 column) were 
performed to finally yield after lyophilisation the desired conjugate (60%). 
PGA-X-AGM-Y-Dox: PGA was dissolved in DMF anhydrous (5 mL). DIC (1,5 
eq) was added and after 5 min HOBt (1,5 eq) as solid. After the activation of the 
carboxylic acid groups by DIC and HOBt, X-AGM (1 eq) was then added and 
the pH was adjusted to 8 with DIEA. The reaction was left to react for 36 h at 
RT. Afterwards, DIC (1,5 eq) was again added and after 5 min HOBt (1,5 aq). 
After the activation of the remaining free carboxylic acid groups, Y-Dox (1 eq) 
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was then added, the pH was adjusted to 8 with DIEA and the reaction was left to 
react for further 36 h at RT. The DMF was evaporated under high vacuum and 
the polymer conjugate precipitated by adding 5 mL of CHCl3: Acetone (1:1). 
PGA-X-AGM-Y-Dox sodium salt was obtained by the addition of NaHCO3 1M 
(0,51 mmol, 250 µL). Two purification steps (dialysis against water (membrane 
Mw cut off 3500 Da) and G25 column) were carried out in order to remove the 
excess of salt and any remaining impurities including unreacted drug (yield 60% 
(60mg)). 
    3.3.2. Physico-chemical characterisation of conjugates synthesised. 
      3.3.2.a. Determination of Total AGM loading and Free AGM content. 
Determination of total AGM content by UV Spectroscopy: AGM or an 
aminoacid-AGM derivative X-AGM were first prepared for use as calibration 
standards. A stock solution of AGM derivative in HPLC grade MeOH was 
prepared (1 mg/mL). To obtain a calibration curve samples were diluted using 
MeOH to give a concentration range of 0-50 µg/mL for AGM or 0-130 µg/mL 
for X-AGM. The total drug loading of the conjugates was determined by 
measuring the optical density at 254 nm in milliQ H2O. PGA in the same 
concentration range as the conjugates analysed (0-5 mg/mL) was used as blank. 
Determination of total AGM content by HPLC, indirect analysis: The dried 
residue obtained from the conjugation reactions was dissolved in CH2Cl2 and all 
remaining precipitate was filtered off. AGM is completely soluble in CH2Cl2. 
The solvent was evaporated under reduced pressure and MeOH (10 mL) was 
added to make the stock solution. 3 different concentrations were injected to the 
HPLC (after filtered through 0,45 µm). The free amount of drug in the conjugate 
residues was determined by HPLC using a RP18 column (125x4 mm), with a 
flow rate of 1 mL/min and using a gradient elution [A: H2O milliQ+0,1%TFA, 
solvent B: ACN+0,1%TFA]. Total run time 25 min and the gradient profile was: 
t=0 A 90%, t=4 A 90%, t=19 A 10%, t=21 A=90%, t=25 A=90%, t=40 A 0%, 
t=42 A 0%. Oestradiol (1 µg/mL) was used as internal standard. A UV-Vis 
diode array (DAD) was used as detector. The retention time was 2 min for GG-
AGM, 6 min for G-AGM and 5 min for AGM.  
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Determination of free AGM content by HPLC: To evaluate the free drug 
loading, 100 µL of a known concentration of polymer conjugate was added with 
100 µL of sodium bicarbonate and 100 µL of oestradiol (1 µg/mL) as internal 
standard. Free X-AGM and oestradiol were thoroughly extracted with a mixture 
(5 mL) of AcOEt : Isopropyl alcohol 4:1 (3x10 s). The upper organic layer was 
carefully removed and dried through N2 flow. The dried residue was dissolved 
in 100 µL of HPLC grade ACN. In parallel to construct a standard curve, the 
same concentrations used for the determination of the total drug loading were 
used to obtain an HPLC standard curve. 100 µL of each concentration was 
added to a mixture of 100 µL of bicarbonate, 100 µL of oestradiol and 700 µL 
of milliQ H2O and thoroughly extracted as described above. The amount of free 
drug was determined by HPLC using the same HPLC protocol described for the 
determination of the total drug loading by HPLC (indirect measurement). The 
retention time was 2 min for GG-AGM, 6 min for G-AGM, 5 min for AGM and 
12 min for oestradiol. 
      3.3.2.b. Determination of Total and Free Dox by HPLC. 
Determination of total Dox content by HPLC: Aqueous solutions of PGA-Y-
Dox conjugates (1 mg/mL) were prepared, and an aliquot (100 L) was added to 
a polypropylene tube and made up to 1 mL with water. Then 1 mL of 2 M HCl 
was added and the tubes were heated at 80°C for 30 min in order to get Dox 
aglycone. After cooling down to RT. 1 mL 2 M NaOH and the pH of the 
samples was adjusted to 8,5 with ammonium formate buffer (100 µL, 1 M, pH 
8,5). In parallel the same procedure was carried out for the parent compound Y-
Dox (using 100 L of a 1 mg/mL stock aqueous solution). Daunorubicin (Dau) 
was used here as internal standard; 100 L of a 1 g/mL stock aqueous solution 
was added to each sample. Samples were then thoroughly extracted by vortexing 
(3x10 sec). The upper aqueous layer was carefully removed and the solvent was 
evaporated under N2. The dry residue was dissolved in 100 L of HPLC grade 
methanol. In parallel the same procedure was carried out for the parent 
compound Y-Dox (using 100 L of a 1 mg/mL stock aqueous solution). 
Addition of 1 L of methanol to redissolve the product gave a 100 g/mL stock 
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from which a range of concentrations were prepared (2-60 g/mL). The amount 
of total drug was determined by HPLC using RP18 column (125x4 mm), with a 
flow rate of 1 mL/min and using a gradient elution [A: 2-propanol/H2O 12:88 
(v/v), solvent B: 2-propanol/H2O 29:71 (v/v)] adjusted to pH 3,2 with o-
phosphoric acid. The total run time was 25 min and the gradient profile was: t = 
0 A 0%, t = 1 A 60%, t = 3 A 60%, t = 8 A 0%, t = 18 A 0%, t = 20 A 100%, t = 
20 A 100%. To monitor Dox and Dau standard a fluorescence detection at λ = 
485 nm for excitation and λ = 560 nm for emission was used. The retention time 
(tr) was 15 min for Dox aglycone and 20 min for Dau aglycone. 
Determination of free Dox content by HPLC: 100 µL of a known concentration 
of PGA-Y-Dox conjugate was added with 100 µL of NaHCO3 and 100 µL of 
Dau (1 g/mL) as internal standard. The free Dox and Dau were thoroughly 
extracted with CHCl3:Isopropyl alcohol 4:1 (3x30 sec). The upper aqueous layer 
was carefully removed and the organic phase dried through N2 flow. The dry 
residue was dissolved in 100 µL of HPLC grade MeOH. In parallel the same 
process was also carried out with a mixture of Dox and Dau to construct a 
standard curve. The standards were dissolved in 1 mL of HPLC grade MeOH to 
give us a 100 g/mL stock solution from which a range of concentration were 
prepared (5-100 g/mL). The amount of free drug was determined by HPLC 
using RP18 column (125x4 mm), with a flow rate of 1 mL/min and using a 
gradient elution [A: 2-propanol/H2O 12:88 (v/v), solvent B: 2-propanol/H2O 
29:71 (v/v)] adjusted to pH 3,2 with o-phosphoric acid. Total run time was 42 
min and the gradient profile was: t = 0 A 0%, t = 1 A 0%, t = 26 A 100%, t = 27 
A 50%, t = 37 A 50%, t = 40 A 0%, t = 42 A 0%. To monitor Dox and Dau 
standard, a fluorescence detection at λext = 485 nm for excitation and λem = 560 
nm for emission was used. The tr was 20 min for Dox and 30 min for Dau. 
      3.3.2.c. Molecular Weight (MW) determination by GPC. 
To evaluate the mass of the conjugates, 100 µL of 3 mg/mL conjugate 
solution in PBS was injected in the GPC using two TSK Gel columns in series 
G2500 PWXL and G3000 PWXL with a Viscoteck TDA
TM
 302 triple detector 
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with UV detection coupled. The mobile phase using is PBS 0,1 M, flow 0,8 
mL/min. 
      3.3.2.d. Small angle neutron scattering (SANS). 
Small-angle neutron scattering experiments were performed on the D11 
instrument at the Institute Laue-Langevin, Grenoble, France. Scattering data are 
sin(/2) where λ is wavelength and  the angle at which the neutrons are 
scattered. The incident neutron wavelengths were 6 ±1 Å and 12 Å, giving 
accessible Q-ranges of 0,0017 to 0,42 Å
 -1 
using four different sample-detector 
distances.  Sample solutions were prepared at a conjugate concentration of 0,5-2 
wt% on a 1g scale in D2O (pH 5,5, 0,1M phosphate buffer) and placed in 2 mm 
path length quartz cells, mounted in a sample changer thermostatted at 37 °C ( 
0,2).  These conditions allowed the study of the conjugates at a pH, temperature 
and ionic strength that mimic those physiologically encountered.  Data were 
corrected for transmission intensity, electronic background and normalised 
against a flat scatter according to the standard procedures for the instrument.  
The obtained scattering profiles I(Q) vs. Q were analysed according to I(Q)  
Vp P(Q) S(Q) + Binc where  is the volume fraction and Vp the particle 
volume. The FISH modelling suite was used for the analysis.  FISH incorporates 
parameterised form factors, P(Q) and structure factors, S(Q), to describe the 
dimensions of the scattering particle and inter-particle interactions (Heenan, 
R.K.. 1989). 
    3.3.3. Stability in plasma of conjugate and Kinetics of drug release in 
presence of cathepsin B. 
      3.3.3.a. Kinetics of drug release in presence of cathepsin B. 
Cathepsin B (5 U) was added last to a solution of 3 mg PGA-X-AGM, 
PGA-Y-Dox or PGA-X-AGM-Y-Dox in 1 mL of a pH 6 buffer composed by 20 
mM sodium acetate, 2 mM EDTA and 5 mM DTT. Incubation was carried out at 
37°C. Aliquots (150 μL) were taken at times up to 96 h, immediately frozen in 
liquid nitrogen, and stored frozen in the dark until assayed by HPLC (analysis of 
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100 μL aliquots after extraction procedure, as described above for free drug 
analysis) and/or GPC (direct analysis of 30 μL aliquots). In control experiments 
polymers were incubated in buffer alone (without addition of cathepsin B) to 
assess non-enzymatic hydrolytic cleavage. In addition, free drug (0,75 mg/mL) 
was also incubated under same conditions and later used as the reference 
control.  
GPC Evaluation of Polymer Mw loss: The 30 μL aliquots were diluted 
up to 200 μL with buffer (PBS) and the Mw determined by GPC. Generally 
degradation profiles for biomedical polymers are obtained under constant sink 
conditions and the results correlated with mass loss of the polymer. Since PGA 
polymers are water soluble, the relative peak areas used in the GPC derived 
molecular weight calculations provided a suitable alternative to indicate the 
relative amount of the polymer that remained at each time point. As the polymer 
degraded there was a loss of PGA conjugates molecular weight. Therefore, the 
loss with time of the area under the curve (AUC) for PGA conjugates was 
considered to evaluate the rate of backbone degradation. 
      3.3.3.b. Plasma stability. 
Conjugates (3 mg/mL) were incubated at 37°C in freshly extracted 
serum from Balb/c mice for up to 24h. At scheduled times, aliquots (100 µL) 
were collected. 10 µL of 100 µg/mL solution of oestradiol in MeOH was added 
as internal standard and then 110 µL of MeOH in order to precipitate serum 
proteins. Following centrifugation (12000 g, 5 min), supernatants were analysed 
by HPLC as reported above. 
      3.3.3.c. Metabolite identification by MS. 
The X-AGM metabolites were identified using a UPLC-MS system 
from Waters. The mass method optimised was capillary (kV) 3,50, cone (V) 20, 
Extractor (V) 6, RF Lens (V) 0,2. The source temperature was set at 120°C and 
the desolvation temperature at 380°C. Gas desolvation and the gas cone were 
950 and 50 L/H, respectively. The analyser and detector parameter were the 
normal one for this kind of ZQ mass. The UPLC method was 90/10 H2O+0,1% 
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formic acid /ACN+0,1% formic acid to 10/90 H2O+0,1% formic acid /ACN 
+0,1% formic acid in 15 min. The initial conditions were recovered in 2 min and 
the system was equilibrated in 4 min. After filtration, 20 L of the sample was 
injected. A double detection system was employed, UV (DAD, λ = 268 nm) and 
the total ion count (TIC) of mass. 
For the Y-Dox metabolites, the Mw were higher consequently a MALDI-Tof 
experiment was performed. The matrix used was α-cyano-4-hydroxisucinnamic 
acid, it was extracted with a laser pulsed at 337 nm. The acquisition was 
performed in reflection mode. 
    3.3.4 Cell culture assays. 
      3.3.4.a. Cell maintenance and passaging. 
For cell culture assays MCF7, MCF7 Ca, 4T1 and MDA-MB231 immortalised 
breast cancer cell lines were used. Human oestrogen-dependent, breast 
carcinoma cell lines MCF7 and MCF7 Ca (human aromatase-transfected) were 
from the Tenovus Centre for Cancer Research at Cardiff University. 4T1 is a 
metastatic breast cancer murine cell line and the MDA MB 231 is a non-
oestrogen dependent human breast cancer cell line (ER-) and used here as 
control. Cell culture conditions are specified for the different breast cancer cell 
lines utilised in table 2.1. Cells were cultured in P100 plates with the appropriate 
medium supplemented with 10% of foetal bovine serum (FBS) as standard 
tissue culture conditions (37ºC and 5% CO2). In order to maintain the 
transfected strain, the culture medium of MCF7 Ca was always (for routine 
tissue culture and for all the experiments) further supplemented with 0,75 
mg/mL of geneticin. Steroid-deprived FBS (SFBS) was used and prepared as 
described below. In order to mimic post-menopausal conditions, an aliquot of 
oestradiol was added at a final concentration of 10
-9
 M for MCF7 and MCF7 Ca 
cell cultures. In all cases, cell medium was changed every two days to induce 
cell growth. Once 70-90% cell confluence was reached, the medium was 
removed and the cells were washed with 10 mL PBS. Trypsin (1 mL) was then 
added and left 5 min at 37°C (until detached), 9 mL of free medium was added 
and cells were collected in universal container and centrifuged for 5 min at 200 
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rcf at RT. Supernatant medium was carefully removed and the cells resuspended 
in fresh medium. After cell counting using a Neubauer camera, cells were 
seeded in P100 plates at 40 000 cell/mL or at 20 000 cell/mL to reach 
confluence after one or two weeks, respectively.  
 
      3.3.4.b. Preparation of Steroid-deprived FBS (SFBS). 
500 mL of FBS was first deactivated at 56°C during 30 min. Once at RT, were 
adjusted to a pH of 4,2 adding HCl 5 M and equilibrated to a temperature of 
20
o
C. A charcoal solution was prepared adding 18 mL of ddH2O, 0,2 g of Norit 
A charcoal and 0,01 g of dextran T-80. 25 mL of the charcoal solution were 
added to the acidic FBS and the suspension was stirred for 16 h at 4 
o
C. Then, 
the suspension was centrifuged and coarsely filtrated with celite to remove the 
charcoal. The pH was adjusted to 7,2 with NaOH 5 M, the suspension was 
filtered with millipore filters 0,2 µm and stored in appropriate containers at -
20
o
C. 
Table 2.1. Summary of breast cancer cell lines culture conditions.  
Cell line Medium %FBS* Incubator condition source 
MCF7 Ca DMEM 10%** 37°C with 5% CO2 Cardiff university 
4T1 RPMI 10% 37°C with 5%CO2 ATCC 
MCF7 DMEM 10%** 37°C with 5%CO2 ATCC 
MDA MB 
231 
Leibovitz 10% ** 37°C without CO2 ATCC 
*: Foetal Bovine Serum (FBS) **: treated foetal bovine serum 
3.3.4.c. MTS assay for cell viability determination. 
In order to perform cell viability assays, a prior step based on the development 
of a growth cell curve for each breast cancer cell line used was performed, and 
the cell concentrations needed for the cytotoxic assays were determined. 
Cytotoxicity of free drugs (AGM and Dox), and their conjugates was evaluated 
using the MTS cell viability assay (72 h incubation). Both cell lines were seeded 
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in sterile 96-well microtitre plates (4x10
3
 cells/well for MCF7 Ca, 2x10
3
 
cells/well for 4T1 and 10x10
3
 cells/well for MDA MD 231) in the adequate 
medium as reported in Table 2.1. Plates were incubated for 24 h and compounds 
(0,2 µm filter sterilised) were then added to give a final concentration of 0-1 
mg/mL drug-equiv. After 72 h of incubation, [3 - (4,5-dimethylthiazol-2-yl) – 5 
- (3-carboxymethoxyphenyl) – 2 - (4-sulfopheyl)2H - tetrazolium] (MTS) (10 
L of manufacturer solution) was added to each well, and the cells were 
incubated for a further 2 h. Mitochondrial dehydrogenase enzymes of viable 
cells converted MTS tetrazolium into a coloured formazan product. The optical 
density of each well was measured at 490 nm. For High Throughput Screening 
(HTPS) studies, MCF7 and MDA MB 231 cell lines were cultured with the 
antibiotic P/S (1%) in order to avoid any possible contaminations while using 
TECAN robot for compounds dispensing under non-controlled sterile 
conditions. Cell viability was expressed as a percentage of the viability of 
untreated control cells. 
3.3.5. In vivo Tumour Model. 
      3.3.5.a. MCF7 Ca athymic mice model. 
All the animal experiments were performed in accordance with the guidelines 
established by the European Communities Council Directive (86/609/ECC) and 
by Spanish Royal Decree 1201/2005. All the experimental procedures were 
approved by the institutional Animal Care and Use Committee. Female Balb/c 
athymic mice 4-6 weeks of age were purchased from Harlan (Europe). The 
animals were housed in a pathogen-free environment under control condition. 
Ovarectomy was performed under sevofluorane 1 week before cell inoculation.  
MCF7 Ca cells were resuspended in matrigel and an aliquot (100 µL, 10 million 
cells) was then injected in each animal in the third mammary pad. Beginning 
one day after cell inoculation, animals received subcutaneously 100 µL of 
androstenedione (0,1 mg/mouse/day). Tumour Growth was followed twice a 
week by measuring tumour volume and calculating the tumours with a calliper. 
Once the tumour reached the maximum size authorised (1 cm
3
), mice were 
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sacrificed and tumour removed to perform histological and vascularisation 
studies. 
Following in vivo model optimisation, polymer conjugates were tested in order 
to evaluate antitumor activity. Then, 10
6
 MCF7 Ca cells were injected in the 
third mammary pad. Once the tumour size reached 0,2 cm
3
, the conjugates were 
injected intravenously 3 times every 3 days and the tumour size was followed 
twice a week. When the tumour achieved the maximum size authorised, heart, 
liver, kidney and spleen were extracted, weighed and fixed for histological 
studies. Tumours were also frozen for western blot analysis. 
      3.3.5.b. 4T1 mice model. 
Balb/c female 4-6 weeks mice were purchased in Harland (EU). The animals 
were housed in a pathogen-free environment under control condition. Two 
different concentrations (5x10
5
 and 10
6
 cells) of 4T1 cells were injected in the 
right third mammary pad. The tumour growth was followed every day. Once the 
tumour reached the maximum size authorised (1 cm
3
), mice were sacrificed and 
tumour removed in order to perform histological and vascularisation studies. 
Finally, in order to test polymer conjugates antitumour activity on 4T1 model 
mice, 5x10
5
 cells were injected in the third mammary pad. After 8 days the 
tumour size reached 0,1 cm
3
 then the conjugates were injected intravenously 3 
times every 3 days and the size was followed every day. When the tumour 
achieved the maximum size authorised, heart, liver, kidney and spleen were 
extracted, weighed and fixed for histological studies. Tumours were frozen 
instead for western blot analysis. 
      3.3.5.c. Polymer Conjugates treatment selection for in vivo models.  
Conjugates were injected at 5 mg/kg intravenously three times every three days 
and Dox at 3 mg/kg. The tumour growth was followed twice a week for MCF7 
Ca model and each day for 4T1 model. After 90 days for MCF7 Ca and 2 weeks 
for 4T1, the mice were sacrificed, heart, liver, kidney and spleen were extracted, 
weighed and fixed for histological studies experiment. Tumours were frozen 
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instead for western blot analysis and blood was removed to perform hepatic 
analysis. 
      3.3.5.d. Tumour vascularisation analysis. 
This experiment was conducted to visualize and also quantitate the behaviour of 
macromolecules at tissue level. A solution of Evans blue was injected into the 
tail vein of the tumour-bearing mice at a dose of 10 mg/kg. (Matsumura and 
Maeda, 1986; Wu et al., 1998; Maeda, 2001). One hour after the injection, solid 
tumours were removed, weighed and immersed in 3 mL of formamide followed 
by incubation at 60°C for 48 h to extract the dye. Then the quantification was 
performed spectrophotometrically at 620 nm. 
      3.3.5.e. Toxicological analysis. 
Hepatic evaluation in blood: Extracted blood from heart was centrifuged at 
4 000 g during 10 min to obtain the plasma. Plasma was sent to ‘Analitíca 
clínica veterinaria Lab (ACVLAB)’ to evaluate the levels of the different 
enzymes involved in hepatic damage such as Glutamic oxaloacetic transaminase 
(GOT), Glutamic pyruvate transaminase (GPT), Lactate dehydrogenase (LDH) 
and Alkaline phosphate (ALP). 
      3.3.5.f. Histological analysis. 
Tumour was removed from control animal after the model optimisation, washed 
in PBS and fixed in paraformaldehyde (PFA) overnight. Then the excess of PFA 
was removed by washing with PBS through a strong agitation (200 rpm) during 
20 min 3 times. Finally, samples were stored in a solution of PBS with 0,05% of 
sodium azide. In order to include the sample in paraffin, a previous dehydration 
of the sample through 2 min incubation in increased degree of alcohol solutions 
(30%, 50%, 70%, 96% and 2 baths of 100%) was performed, followed by 2 
xylene washes of 1 min to finally include the sample in paraffin. Then the 
paraffin block was cut in 4 µm slide and set up in superfrost plus glass slide to 
haematoxylin-eosin staining. 
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Haematoxylin has a deep blue-purple colour and stains nucleic acids of cells by 
a complex, incompletely understood reaction. Eosin is pink and stains proteins 
non-specifically. In a typical tissue, nuclei are stained blue, whereas the 
cytoplasm and extracellular matrix have varying degrees of pink staining. For 
haematoxylin-eosin staining, previously tissue slides were deparaffinized with 
xylene and then rehydrated with decreasing battery ethanols (100%, 95%, 70%, 
50%, 30%, water) and later samples were immersed in 2 water baths (5 min) 
followed by haematoxylin 2 min bath and 2 water washes (5 min). Then the 
slides were incubated 3 min in Lithium carbonate and HCl 0,25% in ethanol 
70% in order remove the haematoxylin staining excess. After 2 washes in water 
for 5 min, the incubation of the tissue slides in a fresh eosin-floxin solution was 
performed (0,35% of eosin, 1,1% of floxin at 2%, 83 mL of absolute alcohol, 3,3 
mL of distilled water and 450 µL Acetic acid) for 6 minutes. To finish, a last 
water bath was done (5 min) followed by a dehydration with increase alcohol 
degrees (5 min alcohol 70°, 2x 5 min 96°, 2x 10 min 100° and 2x Xylene), and 
finally the slide was mounted with Eukitt. 
      3.3.5.g. Western Blot analysis. 
Western blot analysis was performed to evaluate key protein expressions from 
removed tumours of mice after 8 and 16 days of treatment in the 4T1 model. 
Extracted tumours were homogenised in RIPA buffer (150 mM NaCl, 1% NP40, 
0,5% Sodium deoxycholate, 0,1% SDS, 50 mM Tris PH8, 50 mM NaF, 100 µM 
Na3VO4 and protease inhibitor cocktail tablet). After 15 min in agitation at 4°C, 
a series of 3x5 sec sonication and vortex was performed before leaving 1h at 
4°C in agitation. Then the solution was centrifuged 20 min at 13 500 g, 4ºC and 
supernatant protein was determined by Bradford assay. 30 µg protein was then 
mixed with 5x SDS sample buffer, boiled for 7 min at 95°C to denaturised the 
protein, and separated through 8% to 15% SDS-PAGE gels. After 
electrophoresis, the proteins were transferred to PVDF membranes (Amersham 
Pharmacia Biotech, UK) by electrophoretic transfer. The membranes were 
blocked in 5% skim milk for 2 h, rinsed, and incubated overnight at 4ºC with the 
following primary antibodies:  beta-Actin α-tubulin (Sigma), BAX, and VEGF 
(Santa Cruz Biotechnology), caspase 3, Beclin , LC3B, pAKt, and Bcl2 (Cell 
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Signalling), iNos (Cayman chemical), HIF1α (BD Biosciences Pharmigen). 
Excess antibody was then removed by washing the membrane in PBS/0,1% 
Tween 20, and the membranes were incubated for 1 h with horseradish 
peroxidase-conjugated secondary antibodies: goat anti-mouse IgG, donkey anti-
rabbit IgG or rabbit anti goat IgG (1:5000) (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA). After washes in PBS/0,1% Tween 20, immunodetection 
was performed with the use of the ECL Western blotting detection system 
(Amersham Pharmacia Biotech, UK), according to the manufacturer´s 
instructions. Relative protein levels were quantified by densitometry with Scion 
Image programme. Results were standardised using β-Actin as the reference. 
3.4. Statistical analysis. 
In vitro experiment results were expressed as mean ± SD where at least n = 3 
experiments per group and in vivo experiment results were expressed as mean ± 
SEM where at least n = 4 experiments per group. Statistical analysis was 
performed using GraphPad Prism 5 (Graph Pad Software, Inc., San Diego, 
http://www.graphpad.com). 
Values obtained from the experiments were analyzed using ANOVA and simple 
method of Dunnett's t for multiple comparisons. In all cases, we considered 
differences to be significant when p***  0,001; p**  0,01; p* 0,05; ns: non-
significant and NA non-applicable. 
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Chapter 4. In vivo evaluation of HPMA copolymer-AGM-Dox 
combination conjugate. 
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4.1. Introduction. 
The aim of this study was to achieve in vivo proof of concept for 
antitumour activity synergism with HPMA copolymer-AGM-Dox combination 
conjugate in breast cancer animal models. As already described in the 
introduction chapter, Vicent et al. (2005) showed that HPMA copolymer-AGM-
Dox induced a markedly enhanced in vitro cytotoxicity compared to the HPMA 
copolymer–Dox (FCE28068, PK1), a conjugate that had already demonstrated 
activity in chemotherapy refractory breast cancer patients during early clinical 
trials (Vasey et al., 1999). It should be emphasised that mixtures of polymer 
conjugates containing only AGM or only Dox did not show any synergistic 
benefit when tested in MCF7 cells in vitro (Vicent et al., 2005; Greco et al., 
2007). This result was even more remarkable as the PK1 conjugate that has 
demonstrated clinical benefits typically shows ~ 100 fold lower cytotoxicity in 
vitro than free Dox. This is due to their different cell pharmacokinetics i.e. 
endocytosis of the polymer-Dox conjugate followed by lysosomal cathepsin B 
mediated Dox release compared to cellular entry by diffusion for free Dox 
(Duncan, 2009; Duncan and Vicent, 2010). These preliminary in vitro results 
suggested for the first time that the combination of AGM and Dox in the same 
carrier would lead to a synergistic effect, and hence the increased activity of the 
combination polymer. Following these promising findings, the aim of the 
present study was to demonstrate if the previous in vitro results would 
extrapolate into an in vivo animal model. More specifically the following studies 
were performed:  
i) In order to investigate the reproducibility of the earlier studies IC 50 values 
were determined for HPMA copolymer-Dox and HPMA copolymer-Dox-AGM 
in MCF7 Ca and 4T1 cells. The activity of both compounds (as single agents or 
as combination) against both immortalised cell lines was evaluated in order to 
confirm drug synergism. ii) Two orthotopic breast cancer animal models were 
established (MCF7 Ca and 4T1) and the conjugates were evaluated to determine 
their pharmacokinetic profile and antitumour activity. 
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4.2. In vitro analysis of HPMA copolymer-AGM-Dox and HPMA 
copolymer-Dox conjugates. 
The protocol used to synthesise the combination conjugate was based 
on previous studies (Vicent et al., 2005; Greco et al., 2007). After conjugate 
synthesis using a carbodiimide mediated coupling reaction for HPMA 
copolymer-AGM-Dox and aminolysis for HPMA copolymer-Dox, the total drug 
loading and the free drug content were determined for both conjugates (see 
Table 4.1).  
Table 4.1. Conjugate characteristics.  
 Total drug loading 
(wt%) 
a
 
Free Drug content 
(wt% of total drug) 
a
 
Product AGM Dox AGM Dox 
HPMA copolymer-AGM-
Dox 6,20 6,10 0,45 0,35 
HPMA copolymer-Dox NA 5,60 NA 0,25 
 
a determined by HPLC. Free drug content expressed as a percentage of total drug; NA- not 
applicable 
    4.2.1. In vitro cell viability analysis against MCF7 Ca and 4T1 cells. 
In order to determine the HPMA conjugate and free Dox concentration 
required to inhibit 50% of cell viability (IC50) under our experimental 
conditions, previous cell growth curves were performed with MCF7 Ca and 4T1 
cells to determine the adequate cell seeding density (figure 4.1.).  
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Figure 4.1. Optimisation of cell seeding density for future cytotoxicity tests. Panels 
(a) shows MCF7 Ca cells and panel (b) shows 4T1 cells. Symbols relating to 
number of cells per well seeded are shown in the graphs. Data is expressed as mean 
± SD, n = 3. A.U. means absorbance unit. 
 
To evaluate the effect of the conjugates on cell viability, serial dilutions of both 
conjugates were tested (0,01 µg/mL to 0,01 mg/mL Dox-equiv.) (n = 4). 
Conjugates were solubilised directly into the medium, added to the cells and 
incubated for 72 h at 37ºC as described in detail in Chapter 3. 
 
 
(a) 
(b) 
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Figure 4.2. Cell viability of Dox and HPMA copolymer conjugates; Panel (a) MCF7 
Ca cell and Panel (b) 4T1 cell in presence of 10
-9
 M oestradiol. Cell viability was 
measured by a MTS assay after 72h incubation. Data expressed as mean ± SD, n = 4 
experiments per treatment.  
The serum used was previously deprived from oestrogens (see details in Chapter 
3) to avoid uncontrolled cell growth. A known oestrogen concentration was 
added mimicking the levels found in post-menopausal women (as described in 
Vicent et al., 2005) then MTS assay was performed (always n = 4). 
 
 
 
(b) 
(a) 
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Table 4.2. Determination of the IC50 value (µg/mL) for HPMA copolymer 
conjugate and free Dox in MCF7 Ca and 4T1 breast cancer cell lines. 
 
 
IC50
a 
(µg/mL)
 
MCF7 Ca cells 4T1 cells 
AGM-
equiv. 
Dox 
equiv. 
AGM-
equiv. 
Dox-     
equiv. 
Dox 
NA 0,2 ± 0.1 NA 0,08 ± 0,02 
HPMA copolymer- AGM-
Dox 2,3 ± 1,6 2,0 ± 1,0 1,75 ± 1,3 1,5 ± 0.4 
HPMA copolymer- Dox 
NA 8,0 ± 2,0 NA 15,0 ± 5,9 
HPMA copolymer-AGM 
> 100 NA > 100 NA 
 
a Mean value ± SD ( n = 4 ). 
The IC50 value determined for HPMA conjugate and free Dox against 
MCF7 Ca and 4T1 cell is shown in table 3.2. As it can be seen, the IC50 value 
of HPMA copolymer-AGM-Dox was significantly lower than that obtained for 
HPMA copolymer-Dox, showing higher cytotoxicity for the combination 
conjugate (2 g/mL vs. 8 g/mL for the combination and HPMA-Dox 
conjugate, respectively). To evaluate the synergistic effect between AGM and 
Dox in HPMA copolymer-AGM-Dox, a combination index (CI) was determined 
using the method described by Chou (2006). The CI is defined as follows 
CI =    IC50 Dox in HPMA-AGM-Dox  +  IC50 AGM in HPMA-AGM-Dox 
                  IC50 HPMA-Dox   IC50 HPMA-AGM  
When CI < 1, this indicates synergism,  
When CI = 1, this indicates an additive effect  
When CI > 1 this indicates an antagonism (Chou, 2006; Peer et al., 2007; 
Rodea-Palomares et al., 2010; Chou, 2010) 
 
In MCF7 Ca cells, the CI obtained for HPMA copolymer-AGM-Dox 
was 0,26, therefore, a strong synergistic effect was clearly observed with the 
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combination conjugate. The CI value in 4T1 cells was CI = 0,109, even better 
than that observed in MCF7 Ca cells suggesting a greater cytotoxic activity for 
this conjugate in the metastatic murine cell line.  
After cell analysis and to investigate whether HPMA copolymer-AGM-Dox 
could display synergism in vivo two orthotopic mouse models were established, 
(i) the human MCF7 Ca cell line was established in ovarectomised nude mice to 
mimic a post menopausal breast cancer; and (ii) the murine cell line 4T1 was 
inoculated into Balb/c mice to establish an aggresive tumour model in a mouse 
having a functional immunological system. Moreover, the 4T1 cells being cells 
extracted from a spontaneously arising Balb/c mammary tumour (Tao et al., 
2008) are capable of metastasis preferentially to the lungs, liver, bone and brain 
and thus give rise to a tumour model more closely resembling the behaviour of 
metastatic breast cancer in human patients (Gao et al., 2011). However before 
evaluating any of our conjugates, the aromatase enzyme levels were evaluated in 
4T1 tumor by western blot to ratify the suitability of this cell line for our studies. 
Levels in MCF7 Ca were already reported in (Greco et al., 2007) 
  
Figure.4.3. Determination of aromatase expression in 4T1 tumour by Western blot. 
Panel (a) after 16 days of cell inoculation. Panel (b) after 24 days of the cell 
inoculation.  
 
4.3. In vivo evaluation of HPMA conjugate and free Dox. 
    4.3.1. Optimisation of the MCF7 Ca and 4T1 tumour models. 
To optimise the selected tumour models the host animals were 
inoculated with different tumour cell numbers into the mammary fat pad, for 
MCF7 Ca 5,0x10
6
 and 10,0x10
6
 cells, and for 4T1 0,5x10
6 
and 1,0x10
6 
cells. 
The comparison between the two models in terms of tumour volume growth 
with time is shown in figure 4.3.  
(a) (b) 
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Figure 4.3. Determination of the optimum cell number required for tumour 
formation. Panel (a) shows MCF7 Ca in ovarectomised nude mice and Panel (b) 
shows 4T1 cells in Balb/c mice. Results are expressed as mean ± SEM, n = 4 
animals per group. Symbols relating to number of cells per animal are shown in the 
graphs. 
As can be seen in figure 4.3., 4T1 is a more aggressive tumour model, and only 
0,5x10
6 
cells were needed to reach a tumour volume of 1 cm
3
 in 20 days. In 
contrast, for the MCF7 Ca model, 10,0x10
6
 cells were necesary to reach 0,3 cm
3
 
after 110 days. MCF7 Ca can be considered then a more heterogeneous and time 
consuming model to be established and used than 4T1. MCF7 Ca is hormone 
dependent tumour, and in our proposal it was used to mimic post menauposal 
breast cancer patients as described in the literature (Yue et al., 1994; Brodie et 
al., 1999; Brodie et al., 2001). To compare the morphological differences 
between both tumours, a tumour histological study was performed.  
(a) 
(b) 
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Figure 4.4. Tumour histological study. Panel (a) orthotopic MCF7 Ca tumour model 
(b) orthotopic 4T1 tumour model.   
In both models, the tumour core exhibited lower vessel density surrounded by a 
peripheral area with bigger vessels, which may be involved in the angiogenesis 
process. The MCF7 Ca tumour, perhaps due to the slower tumour growth rate, 
appeared as a more compact and solid tumour than 4T1 model. The 4T1 is a 
murine model isolated from spontaneous breast tumours occurred in Balb/c mice 
and it is also known to metastasise as occurs in breast human cancer spreading 
mainly in bone, liver and lungs. Accordingly, three weeks after orthotopic 
injection of the 4T1 cells into the mammary fat pad, primary tumours displayed 
large areas of necrosis into which neutrophils and other inflammatory cells 
showed infiltrated blood vessels. In addition, tumour cells were observed at the 
surfaces of the blood vessels indicating metastasis (figure 4.4.b.). 
As tumour vascular permeability, the EPR effect (Matsumura and Maeda, 1986; 
Wu et al., 1998; Maeda, 2001), is a key factor in the clinical performance of 
polymer drug conjugates it was important to define the vascular permeability of 
both in vivo tumour models at different stages. Evans blue dye was used as 
(a) 
(b) 
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probe to quantify tumour permeability, and the effect of tumour Evans blue dye 
accumulation (doses (%)/tumour (g)) was determined.  
In the case of the MCF7 Ca tumours higher permeability was seen for very small 
tumours (size lower than 0,08 cm
3
). These tumours were almost undetectable, so 
due to experimental limitations when determining reliable tumour volume 
changes it was necessary to select a more easily detectable starting tumour size. 
Thus, the selected tumour volume used to start conjugate antitumour evaluation 
was ~ 0,1 cm
3
 for 4T1 model, and ~ 0,2 cm
3
 for the MCF7 Ca model, to allow in 
both cases starting with the same dose(%)/tumour(g) (~6%). It is noteworthy 
that up to a volume of 0,23 cm
3
 the 4T1 tumour displayed slightly more vascular 
permeability than MCF7 Ca model. 
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Figure 4.5. Characterisation of tumour EPR effect depending on tumour size by 
means of Evans blue dye. Panel (a) shows MCF7 Ca tumour model permeability and 
panel (b) shows 4T1 tumour model permeability. The tumour size selected for 
conjugate i.v. administration is remarked. 
(a) 
(b) 
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4.3.2. Biodistribution of HPMA conjugate and free Dox in 4T1 induced 
in vivo tumour model. 
In order to better understand the behaviour of both conjugates in vivo, new 
studies based on tumour accumulation and biodistribution were performed. Due 
to the experimental requirements (time length) with the MCF7 Ca in vivo model, 
the pharmacokinetics of HPMA conjugates and free Dox was carried out in the 
4T1 induced in vivo tumour model. 
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Figure 4.6. Tumour accumulation with time of HPMA conjugates and free Dox in 
4T1 induced tumours. The total Dox content was used to calculate dose (%) (see 
Chapter 3). Results are expressed as mean ± SEM where n = 4 animals per group. 
Table 4.3. Statistical analysis of tumour accumulation data with the HPMA 
conjugates and free Dox. 
 1h 4h 24h 
P value 1 3 2 3 
1 NA *** * *** 
2 * ** NA *** 
3 ns NA *** NA 
 
1- HPMA copolymer-AGM-Dox conjugate, 2- HPMA copolymer-Dox conjugate and 3- Dox. 
Significances calculated by one-way ANOVA. P*** < 0,001, P* *< 0,01, P* < 0,05, ns: non-
significance and NA: non applicable. Statistics at T = 0 and 30 min showed non-significance.  
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In good agreement with already reported data (Duncan, 2009), whereas free Dox 
tumour accumulation was faster than HPMA copolymer-Dox, its retention in the 
tumour was much lower than that observed with the conjugates. Dox highest 
accummulation was achieved at 1 h representing only 1,5% of the total 
administered dose. Regarding the conjugates, although the maximum % dose/g 
of tumour was similar in both cases, around 4,5%, HPMA copolymer-AGM-
Dox tumour accumulation  seemed to be faster than HPMA copolymer-Dox and 
showed a different kinetic profile. Whereas the combination conjugate reach a 
plateau after 1 h that was maintained after 24 h,  HPMA copolymer-Dox 
accumulation in the tumour started to decrease after 5 h post-injection. 
Summarising, with the conjugates approximately 5% of the injected dose 
reached the tumour after 24 h and as expected, this value was much greater than 
the 1% identified for free Dox.  
In order to understand better the whole conjugate body bioditribution, a 
quantitative analysis was performed at 1 h and 24 h in several organs including, 
heart, liver, kidney, spleen and tumour (figure 4.7.). As it can be observed in 
figure 4.7.a., the conjugation of Dox to HPMA copolymer completely changes 
its whole body biodistribution. At 1 h post-injection the highest accumulation of 
Dox was found in heart. This result is in good agreement with already reported 
data and explains the cardiotoxicity associated to this molecule. Upon 
conjugation, accumulation in heart was almost diminished. This decrease in the 
toxicity could allow us to increase the dose and its schedule. On the other hand, 
a clear renal filtration was observed for both conjugates but with different 
clearance rate as seen at 24 h profile. Differences in conjugate behaviour were 
also observed with time for liver and spleen as a significantly different 
accumulation of HPMA copolymer-AGM-Dox conjugate in the liver was 
observed at 1 h when compared with HPMA copolymer-Dox conjugate. 
Therefore, even if the quantity observed was low in the liver (4% of the dose 
(%)/ tissue (g)), a toxicology study was performed to ensure the safety of the 
combination conjugate not only in 4T1 but also in MCF7 Ca model (figure 4.8.) 
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Figure 4.7. Biodistribution study of HPMA conjugates and free Dox in 4T1 in vivo 
tumour model (n = 4 animals per group of treatment). Panel (a) shows Conjugates 
(c) 
(d) 
Liver 
Kidney 
Spleen 
Heart 
Tumour 
Liver 
Kidney 
Spleen 
Heart 
Tumour 
(a) 
(b) 
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and Dox quantification by HPLC at 1 h. Panel (b) shows quantification by HPLC at 
24 h post-administration. Results are expressed as mean ± SEM where n = 4 animals 
per group and significances calculated by one-way ANOVA. P*** < 0,001, P**< 
0,01, P* < 0,05. Panel (c) and (d) show fluorescence comparison of target organs 
with the different treatments by IVIS Spectrum® at (c) 1 h post-administration and 
(d) 24 h post-administration. 
Table.4.4. Statistical analysis of the biodristribution data with the HPMA conjugates 
and free Dox depending of the organs. Panel (a) show the statistique analysis at 1h 
and panel (b) shows the statistique analysis at 24h. 
(a) Liver Kidney Heart Spleen Tumour 
P value 1 3  3 3 2 
1 NA ** *** * * 
2 ** ** *** ns NA 
3 ns NA NA NA ns 
 
(b) Liver Kidney Spleen Tumour 
P value 3 2 2 1 3 
1 * * * NA *** 
2 * NA NA * *** 
3 NA ns * *** NA 
 
1- HPMA copolymer-AGM-Dox, 2- HPMA copolymer-Dox and 3- Dox. The total Dox 
content was represented (HPMA conjugate + free Dox, analysed by HPLC looking at 
aglycone, see Materials and Methods) (n = 6). Significances calculated by one-way ANOVA. 
P*** < 0,001, P* *< 0,01, P* < 0,05, ns: non significance. Statistics at of the other 
combination showed non significance.  
 
In MCF7 Ca animal model, blood analysis was performed after 60 days in order 
to better evaluate a possible long-term effect, and in the 4T1 model the analysis 
was performed 16 days after the administration of treatments, reproducing a 
short-term evaluation of therapies. In all cases non-significant differences were 
observed between both treatments in comparison to the control (figure 4.8.). 
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Importantly, GOT, GPT, LHD and ALP for the combination conjugate showed 
basal levels in all cases indicating its safety. 
Additionally, organ weight was also monitored 8 days post-injection as this was 
the time when all treatments were more efficient looking further for any 
toxicological sign. Two types of controls were used, a control group in non-
tumour bearing animal, and a control group in the 4T1 model (figure 4.8.). 
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Figure 4.8. Biochemical evaluation of treatments on liver toxicity from plasma 
samples. Panel (a) shows plasma extracted from 4T1 tumour mice model 16 days 
treatment post-administration. Panel (b) shows plasma extracted from the MCF7 Ca 
tumour mice model 60 days treatment post-injection. Results are expressed as mean 
± SEM where n = 4 animals per group. 
Regarding liver and kidney, a significant weight decreased was observed once 
tumour was present in the animals. On the other hand, the spleen was found to 
be much smaller in healthy animals than in those bearing tumour cells. This fact 
(a) 
(b) 
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has been already reported in the literature as splenomegaly caused by the growth 
factors stimuli triggered by tumour growth (DuPre et al., 2007). The differences 
in spleen size were directly correlated with tumour size (figure 4.10.) and 
indirectly correlated to the efficiency of each treatment, as it is shown in the 
figures 4.9. and 4.10. 
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Figure 4.9. Effect of the treatment on the organ weight after 8 days post-
administration. Results are expressed as mean ± SEM where n = 6 animals per 
organs.  
Table.4.5. Statistical analysis data of organ weigh evolution after treatment 
administration. 
 Liver Kidney Spleen tumour 
P value 5  5  4  5 1  1 2  
1 ** ** * *** NA NA ns 
2 ** ** ns ns * * NA 
3 ** ** ns ns * * ns 
4 ** ** NA *** ns ns ** 
5 NA NA ns NA ns ns ns 
 
1- HPMA copolymer-AGM-Dox, 2- HPMA copolymer-Dox and 3- Dox, 4-Ctr with tumour 
and 5-Ctr without tumour. (n = 6). Significances calculated by one-way ANOVA. P*** < 
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0,001, P* *< 0,01, P* < 0,05, ns: non significance. Statistics at of the other combination 
showed non significance. N.A. non applicable. 
 
Figure 4.10. Representative images of spleen size in direct correlation with tumour 
growth from the different animal groups. Panel (a) shows spleen images and panel 
(b) shows tumour images. 1: Ctr without tumour, 2: HPMA copolymer-AGM-Dox 
conjugate, 3: HPMA copolymer-Dox conjugate, 4: Ctr and 5: Dox.  
In conclusion, the conjugation of Dox to a polymer carrier induces a safer 
biodistribution in comparison to the free Dox, markedly decreasing Dox heart 
accumulation and enhancing tumour accumulation. Moreover, even if a slightly 
greater accumulation in liver was observed for HPMA copolymer-AGM-Dox 
conjugate, this fact did not trigger any associated toxicity either at short- or at 
long-term post-injection.  
4.3.3. Evaluation of the antitumour activity of HPMA conjugates and 
free Dox in the ovarectomised nude mice MCF7 Ca tumour orthotopic 
model. 
Initially based on literature data (St’astny et al., 2002) a Dox-equiv. dose of 5 
mg/kg was chosen and this was administered 3 times at intervals of 3 days. Dox 
toxicity was seen in mice after the third injection reflected by a rapid weight loss 
(figure 4.11.a.). Therefore, in a second experiment a lower Dox dose of 3 mg/kg 
was used, again administered 3 times at intervals of 3 days (Talelli et al., 2013). 
In contrast, the HPMA copolymer conjugates showed less toxicity compared to 
free drug and a higher dose could be used without any signs of toxicity. In 
summary, only the control group (no treatment) and the Dox 5 mg/kg treated 
group induced animal deaths before 90 days (figure 4.11.b.).  
(a) (b) 
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Figure 4.11. Effect of HPMA conjugates and free Dox in animal weight and overall 
survival. Panel (a) shows the compound effect on animal weight lose over 60 days, 2 
animals are shown as example; and panel (b) shows the Kaplan–Meier survival 
analysis, (n = 30, ns), in a MCF7 Ca orthotopic breast cancer model. The injection 
of treatments was performed on days 0, 3 and 6 as indicated by the arrows. 
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Table 4.6. Summary of treatment toxicity and long term survival effect. 
Treatment Dose  T/C
b
 
Toxic 
death
c
 
Long term 
survival 
c
 
Ctr 
  
0/6 0/6 
HPMA copolymer-AGM-Dox 5 mg/kg 100 0/6 6/6 
HPMA copolymer-Dox 5 mg/kg 100 0/6 6/6 
Dox 1 5 mg/kg 50 4/6 0/6 
Dox 2 3 mg/kg 100 0/6 5/6 
 
b: determined at 40 days, c: determined at 80 days. 
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Figure 4.12. Evaluation of HPMA copolymer-AGM-Dox, HPMA copolymer-Dox 
and Dox in MCF7 Ca induced tumour model. Both conjugates were administered at 
5 mg/kg and Dox at 5 and 3 mg/kg, injected 3 times every 3 days. Results are 
expressed as mean ± SEM where n = 6 animals per group. The injection of 
treatments was performed on days 0, 3 and 6 as indicated by the arrows. 
B 
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Both conjugates, HPMA copolymer-AGM-Dox and HPMA copolymer-Dox, 
achieved a complete tumour regression compared to the control group with non-
significant differences between them after 60 days. Figure 4.12. also shows  the 
effect of Dox at 5mg/kg and 3mg/kg. The 3 doses of 5 mg/kg inhibited the 
tumour growth in the same manner as the conjugates, however this effect was 
certainly due to the Dox-related toxicity induced in the animals.  
Importantly, if we focus on the 10 first days post-injection only when the 
conjugates were used, a significant tumour regression was achieved (figure 
4.13.). This could be explained by the greater accumulation due to the EPR 
effect and and efficient drug releae kinetics in the tumour tissue. 
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Figure 4.13. Zoom of figure 4.12. HPMA conjugates (5 mg/kg) and free Dox (3 
mg/kg) activity in MCF7 Ca in vivo model. Results are expressed as mean ± SEM 
where n = 6 animals per group and significances calculated by one-way ANOVA 
and P* < 0,05. The injection of treatments was performed on days 0, 3 and 6 as 
indicated by the arrows. 
In conclusion, MCF7 Ca tumour model has been established and characterised 
as a slow-growth tumour. Both conjugates showed after the 3 first injections a 
* 
* 
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significant decrease in tumour growth in comparison with the control followed 
by a complete remission of the tumour with non-significant differences between 
them but with greater activity than the parent free drug together with an absence 
of toxicity. Although the MCF7 Ca model could be considered an important and 
clinically relevant model, it grows so slowly that it would be difficult to use it in 
future studies devoted to define differences in molecular mechanism associated 
to the combination therapy. For this reason, after demonstration of antitumour 
activity, 4T1 model was used for all future studies (Chapter 5).  
  4.3.4. Evaluation of HPMA conjugate and free Dox in Balb/c mice 4T1 
induced tumour orthotopic model. 
 As it was previously described, in the 4T1 model only after 8 days 
following cell inoculation the tumour reached the selected 0,1 cm
3
 size. 
Treatments were then administrated 3 times every 3 days following the same 
strategy used with the MCF7 Ca in vivo model. 
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Figure 4.14. Evaluation of the antitumour activity of HPMA conjugates and free 
Dox in a 4T1 orthotopic mice model. Arrows indicate injection schedule and results 
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are expressed as mean ± SEM where n = 7 animals per group. The injection of 
treatments was performed on days 0, 3 and 6. 
The statistic analysis was performed with the non-parametric ANOVA one-way 
test and it is summarised in table 4.7. 
Table 4.7. Significance of HPMA conjugates and free Dox treatments on tumor 
growth in the 4T1 murine model. 
P value 1  2 3  4 
1 NA * ** ** 
2 * NA ** ** 
3 ** ** NA * 
4 ** ** * NA 
 
1- HPMA copolymer-AGM-Dox 5 mg/kg, 2- HPMA copolymer-Dox 5mg/kg, 3- Dox 3mg/kg 
and 4- Control. Significances were carried out by one-way ANOVA; P*** < 0,001, P** < 
0,01, P* < 0,05. Significant differences were obtained 10 day after the first injection. NA: non 
applicable. 
Both conjugates significantly diminished tumour growth in comparison 
to the Dox and control groups. Moreover, after the second injection, the 
antitumour activity of HPMA copolymer-AGM-Dox conjugate compared to 
HPMA copolymer-Dox conjugate was significantly greater, increasing with time 
up to day 16 (end of experiment). Therefore, in vivo proof of anticancer activity 
for the combination conjugate was achieved. Remarkably, the combination of 
both single conjugates (HPMA copolymer-Dox + HPMA copolymer-AGM) 
showed similar effect as HPMA copolymer-Dox up to day 12 (figure 4.14.), 
afterthat this combination lost efficiency. The results obtained ratify the 
importance of conjugating both drugs in the same polymer backbone. 
During the experiment, any animal weight loses or abnormal behaviour was 
monitored as shown in figure 4.15.a. 
B 
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Figure 4.15. Effects of HPMA copolymer-AGM-Dox, HPMA copolymer-Dox 
conjugates and Dox on survival in a 4T1 orthotopic breast cancer model. Panel (a) 
shows the evolution of animal weight after the administered treatment. The weight 
progression of 2 animals is shown as example. Panel (b) shows the Kaplan–Meier 
survival analysis (n=35, P** < 0,0081). The injection of treatments was performed 
on days 0, 3 and 6 as indicated by the arrows. 
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Table 4.8. Summary of treatment toxicity and long-term survival effect. 
Treatment 
Dose 
(mg/kg) 
T/C
b
 
Toxic 
death
c
 
Long term 
death
c
 
Ctr 
  
0/7 7/7 
HPMA copolymer-AGM-
Dox 
5 mg/kg 100 0/7 2/7 
HPMA copolymer-Dox 5 mg/kg 100 0/7 2/7 
Dox 3 mg/kg 71 0/7 5/7 
 
b: determined at 8 days, c determined at 16 days. 
In conclusion, HPMA copolymer-Dox and HPMA copolymer-AGM-Dox 
conjugates were evaluated in two different orthotopic breast cancer animal 
models, MCF7 Ca and 4T1, showing always better therapeutic effect than free 
Dox in terms of toxicity and efficacy. Importantly, in the 4T1 model, a 
significant difference was observed with HPMA copolymer-AGM-Dox 
conjugate in terms of antitumour efficacy when compared with HPMA 
copolymer-Dox or HPMA copolymer-Dox+HPMA copolymer-AGM 
combination ratifying the importance of having both drug in same polymer 
mainchain (family 3 combination therapy described in chapter 1.5.).  
Molecular mechanism studies were subsequently performed in cell models as 
well as in 4T1 tumour tissues as the next step towards the understanding the 
benefits of combination therapy. Looking at the possible reasons for the greater 
tumour growth inhibition observed with HPMA copolymer-AGM-Dox 
combination conjugate (see chapter 5). The conjugation of more than one drug 
in the same polymer backbone secures their release within the same cell and, 
therefore, synergism could be achieved if drug ratio and the kinetics of drug 
release are adequately designed (further discussion on this topic will be found in 
Chapter 6).  
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4.4. Discussion. 
The HPMA copolymer-AGM-Dox combination conjugate was first 
described by Vicent et al. in 2005 showing very promising results in human 
breast cancer cell models in comparison to HPMA copolymer-Dox conjugate. In 
this context and to move to a step further, HPMA conjugate and free drug in 
vitro evaluation was not only performed in MCF7 Ca breast cancer human cell 
line but also in 4T1 breast cancer murine cell line. The CI was calculated from 
the IC50 as described previously showing a clear synergic effect of the HPMA 
copolymer-AGM-Dox in comparison to HPMA copolymer-Dox. Vicent et al. 
reported CI = 0,114 in MCF7 Ca cells (Vicent et al., 2005) in comparion with 
the CI here obtained of CI = 0,26; this difference could be justified by the use of 
a different cell passaging number. The CI value in 4T1 cells (CI = 0,109) was 
even better than that observed in MCF7 Ca cells suggesting a greater cytotoxic 
activity for this conjugate in the murine cell line in vivo model. 
In order to confirm those in vitro results, two different orthotopic in 
vivo tumour models, established from human MCF7 Ca and murine 4T1 cells, 
were optimised and fully characterised. The Evans blue experiment allowed us 
to understand the permeability for both systems and choose the appropriate 
experimental conditions to take profit of the EPR effect (described in chapter 
1.4.2.). Moreover in this study a higher permeability, 12% of Evans blue, was 
observed in very small tumour sizes (0,08 cm
3
) in MCF7 Ca model when in 
palpable tumour (0,2 cm
3
) only 7% of Evans blue was quantified. Therefore, this 
confirms the opportunity for polymer drug conjugate to target especially small 
tumours as occurred in metastatic cancers.  
Both conjugates showed much lower toxicity and a significant delay in 
tumour growth in the MCF7 Ca mice model in comparison to free Dox. 
Moreover a significant tumour regression was also observed during the first 
days only for both conjugates. This result could be explained based on tumour 
accumulation (by the EPR effect), the drug release and uptake rates. Greco et al 
(2007) described a similar uptake for both HPMA conjugate starting after 1 h in 
MCF7 Ca. And once inside the lysosome, 20% of the Dox is released in 5 h for 
HPMA copolymer-AGM-Dox and 40% for HPMA copolymer-Dox. Therefore 
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the schedule of 3 injections each 3 days take profit of the time course needed in 
endocytosis and drug release occurred only with polymer drug conjugate in 
comparison to Dox diffusion inside the cell (Decorti et al., 1989). Therefore 
after the conjugate injection, Dox is progressively released during the 3 days and 
consequently induce a greater decrease in tumour growth than that observed for 
the free drug. After the 3
rd
 injection, this decrease was not further observed. 
However, MCF7 Ca was not an adequate model to differentiate the performance 
between the conjugates and, therefore, a murine model established from 4T1 
metastatic cell line was also optimised. The 4T1 model was chosen as a 
representative metastatic and aggressive model that closely resemble to human 
breast cancer inducing metastasis in lung, bone, liver and brain. In this scenario, 
both conjugates showed better performance than free Dox and more importantly, 
significant tumour inhibition was observed for HPMA copolymer-AGM-Dox 
conjugate in comparison to HPMA copolymer-Dox conjugate.  
In order to fully evaluate both conjugates and to explain these 
differences a full pharmacokinetics study was performed. Whole body 
biodistribution showed that the conjugation of Dox to a polymer backbone 
significantly reduced Dox accumulation in heart, in good agreement with 
already reported data. Renal excretion was observed for the conjugates but with 
a different pharmacokinetic profile showing faster clearance for HPMA 
copolymer-Dox versus HPMA copolymer-AGM-Dox. Tumour accumulation 
was also evaluated showing an increase tumour targeting for both conjugates in 
comparison to free Dox and possible differences on the endocytic mechanism in 
4T1 tumour cells was clearly observed with HPMA copolymer-Dox showing 
non-detectable Dox levels in the tumour before 1 h. A slight liver accumulation 
was also observed with the conjugates in comparison to free Dox being more 
important for HPMA copolymer-AGM-Dox. Consequently, a biochemical blood 
analysis was performed, including key proteins such as GOT, GPT, LDH, ALP, 
trying to identify any possible liver-related toxicity that would compromise the 
possible clinical benefit for the combination conjugate. No signs of toxicity were 
observed in any case.  
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Chapter 5. Study of the mechanism of action for HPMA 
conjugates in comparison with Dox in a 4T1 orthotopic breast 
cancer model. 
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5.1. Introduction. 
Following these promising in vivo findings, the aim of the present study 
was to obtain a better understanding of the molecular mechanisms for synergism 
observed in vivo as this could help in the design of improved polymer-based 
combination conjugates in the future. Based on previous in vitro studies, Vicent 
et al. (2005) and Greco et al. (2007) tried to determine the molecular 
mechanisms underlying this improved activity (Vicent et al., 2005, Greco et al., 
2007). When HPMA conjugate and free Dox were compared differences in drug 
release kinetic profile were observed due to their different solution 
conformation. Immunocytochemistry studies were also carried out to assess the 
effect of both conjugates on the proliferation marker ki67 and the anti-apoptotic 
protein Bcl-2 (Greco et al., 2007). A down regulation of ki67 protein expression 
following incubation of MCF7 and MCF7 Ca cells with both conjugates was 
observed but this was more pronounced with the combination polymer. As ki67 
is a well-described marker for the proliferating fraction of a cell population, this 
result was consistent with the higher cytotoxicity obtained with the combination 
polymer in cell viability assays. More importantly, HPMA copolymer-Dox had 
no effect on Bcl-2 anti-apoptotic protein expression, whereas a marked down 
regulation of Bcl-2 was achieved after incubation of MCF7 with the 
combination conjugate. Moreover Bcl-2 is described as a dual regulator 
involved in both apoptosis and autophagy cell death pathway, (Levine et al., 
2008). It was consequently proposed here to study the effect of HPMA 
conjugate and free Dox in both pathways. More specifically the following 
studies were performed:  
(i) The reproducibility of the earlier studies, Bcl-2 expression was 
evaluated for HPMA conjugates and free Dox in MCF7 Ca cell by western blot. 
And to move a step further cell cycle analysis in MCF7 Ca cells for HPMA 
conjugates and free Dox was studied by flow cytometry. 
(ii) New studies to better understand in vivo tumour growth inhibition 
(Chapter 4), including autophagy and apoptosis cell death mechanism as well as 
tumour proliferation pathways by means of the modulation of several key 
proteins by western blot analysis. [Protein kinase B (Akt), microtubule-associate 
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protein light chain 3 (LC3), caspase3, Bcl2, Bcl2 associated X protein (Bax), 
hypoxia-inducible factor-1 alpha (HIF1-α) induced nitric oxide synthase (iNOS) 
and vascular endothelial growth factor (VEGF)].  
5.2. Evaluation of HPMA conjugates and free Dox in MCF7 Ca 
cell line. 
As follow up of the previous reported results and in order to evaluate 
the conjugates effect on cell cycle, the conjugates and free Dox were incubated 
in MCF7 Ca cells for 72 h and the modulation on apoptosis markers and cell 
cycle analysed by flow cytometry.  
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Figure 5.1: Cell cycle analysis after 72 h incubation of conjugates and free Dox in 
MCF 7 Ca cell line at each compound IC50 value. Data expressed as mean ± SD 
where n = 3. PI means Propidium Iodide and Apop means apoptosis. 
Table.5.1. Statistical analysis data of cell cycle study in MCF7 Ca cell line.  
 Apop. G0/G1 S G2/M 
P value 2  4 2 4 2 4 3 
1 ** ns * ** ** ** ** 
2 NA *** NA ** NA ** ** 
3 ** ns ** ns ** ns NA 
4 ** NA  NA ns NA ns 
 
1- HPMA copolymer-AGM-Dox conjugate, 2- HPMA copolymer-Dox conjugate and 3- Dox 
and 4-Ctr. (n = 3). Significances calculated by one-way ANOVA. P*** < 0,001, P* *< 0,01, 
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P* < 0,05, ns: non significance. Statistics at of the other combination showed non 
significance. NA: non applicable. 
Whereas a significant apoptosis was observed only for HPMA copolymer-Dox 
in comparison with the other compounds tested, a stop in G2/M phase for both 
conjugates was achieved in contrast to free Dox. Western blot analysis was also 
carried out to ratify these studies looking at proteins involved in cell cycle as 
well as cell death mechanism. However due to the difficulty to achieve 
reproducible data, it was decided to performed a deeper analysis using tumour 
tissue from the 4T1 model activity experiment instead of cells. In this way it 
would be possible to correlate the activity graphs with the actual molecular 
mechanism responsible for antitumor activity as EPR-mediated targeted effects 
could be also taken into account.  
5.3. Evaluation of HPMA conjugates and free Dox by western 
blot. 
    5.3.1. Evaluation of protein expression modulation involved in 
autophagy by HPMA conjugates and free Dox. 
 
Differences between both conjugates regarding possible cell death 
pathways were analysed at two different times points, 8 days after 1
st
 injection 
(48 h after the last injection trying to keep the 72 h timeframe studied so far) and 
16 days after 1st injection (end of the experiment).  
Based on literature, different mechanisms of cell death including 
autophagy (Kondo and Kondo, 2006) or apoptosis (Kaufmann and Earnshaw, 
2000) need of Bcl2 as regulator protein. Autophagy is the basic catabolic 
mechanism that involves cell degradation of unnecessary or dysfunctional 
cellular components through the lysosomal machinery (from the Greek words, 
auto "self" and phagein" to eat") (Lin et al., 2012). At the beginning of 
autophagy, portions of the cytoplasm, as well as intracellular organelles, are 
sequestered in autophagosomes (figure 5.3.a.). Then, autophagosomes fuse with 
lysosomes to form autolysosomes, and the sequestered contents are degraded by 
lysosomal hydrolases (Kondo et al., 2005). Numerous proteins such as Kinases, 
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mammalian targets of rapamycin (mTOR), (Akt), Beclin, (LC3) (Kondo et al., 
2005; Kondo and Kondo, 2006; Noda et al., 2009; Chen and Karantza, 2011) are 
involved in this mechanism of action, therefore they could be used as molecular 
targets to evaluate autophagy under specific conditions (figure 5.3.a.). It is 
important to note that, Bcl-2 is a cross-talk protein involved in both autophagy 
and apoptosis (Hoyer-Hansen et al., 2007; Levine et al., 2008). mTOR has been 
described as a major protein in the autophagy signalling pathway but it also 
regulates many other aspects of cell function, including transcription, 
translation, cell size and cytoskeletal organisation (Schmelzle and Hall, 2000). 
Due to the lack of selectivity, mTOR was not considered a good molecular 
marker to evaluate autophagy in our tumour models. mTOR study was replaced 
by p-Akt protein expression analysis, the activated form of p-Akt is involved in 
the down regulation of mTOR and consequently in the formation of the pre-
autophagosome through beclin-1. Beclin-1 is the first molecule that has been 
demonstrated to have a direct link between tumorigenesis and disruption of 
autophagy and has also been described to be involved in the autophagosome 
formation. Exogenous expression of beclin-1 in MCF7 cells, which do not 
express beclin-1 endogenously, resulted in induction of autophagy, decreased 
cell proliferation and tumorigenesis inhibition (Kondo et al., 2005; Kondo and 
Kondo, 2006; Esclatine et al., 2009). Beclin-1 was down-regulated by different 
co-repressors as for example Bcl-2. Finally, it is well-known the key role of LC3 
in the autophagosome closure (Noda et al., 2009). LC3 became proteolytically 
activated, thereby generating a cytosolic LC3-I that subsequently conjugates 
with phosphatidylethanolamine (PE) to form the membrane associated LC3-II 
(Juenemann and Reits, 2012). LC3-II persists in the autophagosomal membrane 
even after fusion with the lysosomes and therefore can be considered as a key 
maker for autophagosome monitoring. The number of autophagosomes present 
in the cell is a key parameter to confirm an autophagic cell death mechanism. In 
terms of LC3 analysis by western blotting, it is important to note that the 
immunoreactivity of LC3-B I and II considerably differs. The increase in LC3-B 
II expression is usually greater than the decrease in LC3-B I levels. Therefore, 
LC3-B II/LC3-B I ratio could be considered a good marker for autophagy 
(Mizushima and Yoshimori, 2007). The levels of p-Akt, Bcl-2, Beclin-1 and 
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LC3 proteins in control tumours were found to be in good agreement with 
literature (Kondo et al., 2005; Levine et al., 2008; Chen and Karantza, 2011).  
 
 
Figure 5.3. Evaluation of the autophagic protein cascade triggered by the HPMA 
copolymer-AGM-Dox conjugate, HPMA copolymer-Dox conjugate and Dox 
treatments in 4T1 animal model. Panel (a) shows a schematic diagram with target 
proteins involved in autophagy. Panel (b) and (c) shows the quantification of 
autophagy-related protein; (b) 8 days after the first treatment injection (n = 4 
animals per group) and (c) 16 days after the first treatment injection (n = 6 animals 
per group). Mean values ± SEM.  
 
 
(a) 
(b) 
(c) 
-1 -1 
 131 
 
Table.5.2. Statistical analysis data of protein expression involved in autophagy.  
 
 pAkt 8 d 
pAkt 
16d 
LC3 II/ LC3 
I 8 d 
LC3 II/ LC3 
I 16 d 
Beclin-1 
16 d 
P value 2 4 4 4 3 1 1 
1 ** ns * ** * NA NA 
2 NA * * * * ** ** 
3 ** * * ** NA ** ** 
4 ns NA NA NA ** ** ** 
 
1- HPMA copolymer-AGM-Dox conjugate, 2- HPMA copolymer-Dox conjugate and 3- Dox 
and 4-Ctr. (n = 3). Significances calculated by one-way ANOVA. P*** < 0,001, P* *< 0,01, 
P* < 0,05, ns: non significance. Statistics with tother combinations showed non significance. 
NA: non applicable. 
As it can be seen in figure 5.3., 8 days after the first treatment injection both 
conjugates showed a significant increased in LC3-B II/LC3-B I ratio. Moreover 
free Dox presented a significant increased in comparison to control and the 
conjugates. This result was confirmed by a decrease in pAkt expression with 
HPMA copolymer-AGM-Dox conjugate and free Dox. However, an unexpected 
increased in pAkt expression for HPMA copolymer-Dox conjugate was obtained 
together with the non-significant changes observed for beclin-1. On the other 
hand, 16 days after the first treatment injection, HPMA copolymer-AGM-Dox 
conjugate showed a significant increased in LC3-B II/LC3-B I whereas this 
effect was not observed either with HPMA copolymer-Dox conjugate or free 
Dox. This differential result was confirmed by the down-regulation of p-Akt and 
a significant overexpression in beclin-1 in the HPMA copolymer-AGM-Dox 
conjugate treated mice.  
    5.3.2. Evaluation of protein modulation involved in apoptosis by 
HPMA conjugates and free Dox. 
To complement the study on death mechanisms, apoptosis, known as 
programmed cell-death, was also explored. Apoptosis is a fundamental 
mechanism of programmed cell death regulated physiologically and genetically 
that plays a central role in development, normal cell turnover and immune 
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system function. Moreover, abnormal apoptotic processes are important and 
influence the severity of disease progression in a number of pathologies. The 
mechanism of apoptosis is executed by a family of highly conserved proteases 
known as caspases, which in a cascade of sequential initiator and effector 
members dismantle the cell. Different cell death stimuli can initiate the 
mechanism. In particular, defined apoptotic signals activate the mitochondria- 
mediated or intrinsic pathway that utilizes caspase-9 as its initiator. Caspase-9 
activation is triggered by the release to the cytoplasm of proapoptotic proteins 
from the mitochondrial inter-membrane space, in particular cytochrome c and 
Smac/Diablo. The formation of the macromolecular complex named 
apoptosome is a key event in this pathway. The apoptosome is a holoenzyme 
multiprotein complex formed by cytochrome c-activated Apaf-1 (apoptosis 
protease-activating factor), dATP and procaspase- 9 activating caspase 3 and 7 
and inducing cell death. It was also described an extrinsic pathway induced by 
ligation of death receptors (TNF receptor) and through the formation of the 
oligomerisation of the adapter molecule FADD, caspase-8 and 10 were trigged 
and finally induced cell death through caspase 3 activation. (Douglas et al., 
2005). Key proteins involved and studied in this cascade are Bcl2, Bax, and 
caspase 3 (figure 5.4.a.). 
As it can be seen in figure 5.4., 8 days after the first injection, an increase in 
caspase 3 expresion was observed for both conjugates and free Dox. However, 
after 16 days only HPMA copolymer-Dox conjugate was capable of up-
regulating caspase 3 expresion in comparison to the control group, suggesting 
that HPMA copolymer-Dox conjugate triggers cell death through an apoptotic 
pathway. Nevertheless, the protein expressions of Bcl2 and Bax were kept 
unchanged, therefore it could be hypothesised that the extrinsic pathway of 
apoptosis is the one taking place.  
Altogether, it could be hypothesised that at the beginning a mix mechanism of 
cell death is taken place in all treatments. However, at long-term a 
differenciation in cell death mechanisms occur and HPMA copolymer-AGM-
Dox combination conjugate was mostly involved in autophagy when solely 
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apoptosis was modulated by HPMA copolymer-Dox conjugate in good 
agreement with already reported data (Minko et al., 2000; Malugin et al., 2007). 
 
  
Figure 5.4. Evaluation of the apoptosis-related protein expression in 4T1 tumour 
tissue after treatment with Dox-derivatives. Panel (a) shows a schematic diagram 
showing the target proteins involved in apoptosis. Panel (b) and (c) show the 
quantification of proteins involved in apoptosis mechanism (Bcl2, Bax, casp3) after 
(b) 8 days of treatment and (c) 16 days of treatment. The experiment was performed 
with n = 6 animals per group. Mean values ± SEM.  
 
 
 
(a) 
(b) (c) 
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Table.5.3. Statistical analysis data of protein expression involved in apoptosis cell 
death.  
 Caspase3 8 d Caspase3 16d 
P value 4 2 
1 * * 
2 * NA 
3 * * 
4 NA * 
 
1- HPMA copolymer-AGM-Dox conjugate, 2- HPMA copolymer-Dox conjugate and 3- Dox 
and 4-Ctr. (n = 3). Significances calculated by one-way ANOVA. P* < 0,05, ns: non 
significance. Statistics at of the other combination showed non significance. NA: non 
applicable. 
 
    5.3.3. Evaluation of protein modulation involved in angiogenesis 
pathways by HPMA conjugates and free Dox. 
Solid tumour malignancies including breast, lung and prostate 
carcinomas are considered to be angiogenesis dependent. Tumour angiogenesis 
could be induced by different mechanism but always depending of VEGF. 
VEGF is one of the most widely studied hypoxia-inducible proteins. It is often 
observed that the hypoxia encountered in the tumour core induced tumour 
growth and activates oncogenic protein signalling cascades. Both mechanisms 
result in an increased expression of the hypoxia-inducible factor (HIF)-1α and 
its transcriptional target VEGF (Ellis et al., 2009). HIF-1α is an heterodimeric 
transcription factor composed of HIF-1α which dimerises with a constitutively 
expressed β subunit and subsequently binds to hypoxia response elements 
(HRE) in the promoters of target genes (Semenza, 2003; Semenza, 2012). HIF-
1α regulates the expression of numerous genes involved in various cellular 
signalling pathways, including angiogenesis, via the increased expression of 
VEGF. Moreover two distinc pathways by which VEGF expression is regulated 
have been identified, one through HIF-1α translation already decribed and one 
HIF independent, both involving Akt. VEGF is one of the genes under control of 
HIF-1α in hypoxic conditions but it is also activated in normoxic conditions 
through the PI3-K/Akt pathways by growth factor receptors and estrogen 
receptors activation targeting the proximal transacting transcription factor 1 
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(SP1)-binding sites on proximal core of VEGF promoter (Pore et al., 2004; Pore 
et al., 2006; Kazi and Koos, 2007; Curry et al.,2008; Kazi et al., 2009). 
 
Figure 5.5. Mechanism of VEGF transcription in normoxia and hypoxia. 
After VEGF induction, a down-stream cascade of proteins involved in vascular 
permeability (iNOS), cell proliferation (Extracellular signal-regulated kinase 
Erk), survival (PI3K, pAkt) and migration (MAPK) are also activated. All those 
mechanisms have been reported in tumour growth, dissemination and metastasis 
(Semenza, 2003; Semenza, 2012). In addition, it has also been described that 
HRE are present in NOS promoter, triggering the transcription of (iNOS) under 
hypoxia (Tendler et al., 2001; Singh and Gupta, 2011). In this context, it was 
reported that breast tumours showed predominantly localised iNOS expression 
in tumour cells differentiating them from normal tissues with no detectable 
iNOS activity. This suggests a clear relationship between iNOS and malignancy 
(Thomsen et al. 1994; Singh and Gupta, 2011). Moreover, a study carried out in 
1997 based on the iNOS expresion in primary breast tumours, suggested that 
iNOS played a key role in the facilitation of tumour metastasis (Duenas-
Gonzalez et al., 1997).  
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In order to study the different expression of proteins involved in tumour 
angiogenesis, tumours were isolated after 8 and 16 days treatment and proteins 
were extracted for western blot analysis.  
  
 
 
Figure 5.6. Protein expression analysis of HIF-1α, VEGF and iNOS in 4T1 tumour 
tissue after 8 and 16 days treatment post-administration. Panel (a) shows the 
schematic diagram showing a possible mechanism of action with the target proteins 
involved in angiogenesis. Panel (b) and (c) show the protein quantification done by 
densitometry analysis protein expression showing the effect of different treatments; 
(a) 
(c) 
 
(b) 
130 kDa 
(d) 
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(b) 8 days after the first injection and (c) 16 days after the first injection. β-Actin 
was included as a loading control. Panel (d) shows a representative Western blot of 
iNos protein. The experiment was performed with n = 4 animals per group for the 8 
days and n = 6 for the 16 days. C+ is an extract of MCF7 cell used as positive 
control in our study. Mean values ± SEM.  
 
Table.5.4.Statistical analysis data of protein expression involved in angiogenesis. 
 
 
HIF 1α 
8d 
HIF 1α 
16d 
VEGF 
8d 
VEGF 
16d 
pAkt 8d pAkt 16d 
P value 3 3 2 4 2 4 4 
1 * * ** ** ns ns * 
2 * * * ** NA * * 
3 NA NA ** ** ** * * 
4 * * NA NA ns NA * 
 
1- HPMA copolymer-AGM-Dox conjugate, 2- HPMA copolymer-Dox conjugate and 3- Dox 
and 4-Ctr. (n = 3). Significances calculated by one-way ANOVA. P*** < 0,001, P* *< 0,01, 
P* < 0,05, ns: non significance. Statistics with other combinations showed non significance. 
NA: non applicable. 
Interestingly, two different behaviours were observed at 8 and 16 days. At 8 
days after the first injection, a significant decrease in VEGF protein expression 
was observed only for free Dox and HPMA copolymer-AGM-Dox conjugate. A 
decrease in HIF-1α was only observed for Dox, however, the same protein 
expression profile of HIF-1α was obtained for pAkt. After 16 days, an inhibition 
of VEGF in all treatments was observed and confimed by pAkt showing the 
same expression profile. However, non expectived protein expression 
modulation was obtained for HIF-1α, as none of the treatments achieved any 
effect. Unfortunately, due to the limitation of the iNOS antibody or its expresion 
levels in tissue, quantification of iNOS could not be performed although a clear 
trend was observed with iNOS inhibition levels by HPMA copolymer-AGM-
Dox combination conjugate and free Dox in comparison to HPMA copolymer-
Dox. More studies need to be carried out in order to evaluate the effects of these 
conpounds on migration and metastasis.  
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5.4. Discussion. 
In order to better understand the molecular mechanisms responsible for 
antitumour drug synergism, first Bcl-2 expression was studied by western blot 
(in order to corroborate previously reported data) together with cell cycle 
analysis by flow cytometry in MCF7 Ca cells for HPMA conjugates and free 
Dox. Whereas a significant apoptosis was observed only for HPMA copolymer-
Dox in comparison with the other compounds tested, a stop in G2/M phase for 
both conjugates was achieved in contrast to free Dox. Western blot analysis was 
also carried out to ratify these studies looking at proteins involved in cell cycle 
as well as cell death mechanism. However, due to the difficulty to achieve 
reproducible data in cells, a deeper analysis using tumour tissue from the 4T1 
model activity experiment was instead performed. In this way it would be 
possible to correlate the activity graphs with the actual molecular mechanism 
responsible for antitumor activity as EPR-mediated targeted effects could be 
also taken into account.  
Firstly, differences between both conjugates regarding possible cell death 
pathways were analysed at two different time points, 8 days after 1
st
 injection 
(48 h after the last injection trying to keep the 72 h timeframe studied so far) and 
16 days after 1
st
 injection (end of the experiment). Whereas a mix mechanism of 
apoptosis and autophagy was observed at short-term for both conjugates, at 
long-term (16 days) only autophagy was observed with HPMA copolymer-
AGM-Dox and an apoptotic death mechanism for HPMA copolymer-Dox 
conjugate. This fact was one of the major differences between both conjugates. 
Then, the effect of our conjugates in tumor proliferation and angiogenesis was 
also studied mainly focusing on VEGF expression. Two days after the last 
injection, and contrarily from the HPMA copolymer-Dox conjugate, a strong 
difference was obtained in the tumour angiogenesis pathways for the 
combination conjugate. Indeed HPMA copolymer-AGM-Dox conjugate 
triggered significant inhibition of VEGF mainly due to two phenomena 1) the 
oestrogen reduction induced by AGM (Kazi and Koos, 2007; Koss, 2010; Koos, 
2011) and 2) the inhibition of p-Akt protein expression that triggered the down-
regulation of VEGF (Pore et al., 2004). However, at the end of the experiment 
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(16 days after the first injection), a decrease of VEGF was observed with all 
treatments. This pharmacokinetic effect on VEGF inhibition could be explained 
first by differences observed in tumour accumulation, HPMA copolymer-AGM-
Dox was accumulated faster in the tumour than HPMA copolymer-Dox 
conjugate although the accumulated Dox dose in the tumour is very similar. 
After tumour accumulation, drug release kinetics would also play a key role. As 
described by Vicent et al., 2005, in the combination conjugate the presence of 
AGM induce dramatic changes in Dox release profile due to a different solution 
conformation of the conjugate as demonstrated by Small Angle Neutron 
Scattering (SANS) (Vicent et al., 2005). AGM was first released followed by an 
exponential Dox release up to 20% of drug in both cases after 5 h.  
Importantly, together with the pk differences and as described before (chapter 
1), AGM blocked the aromatase enzyme involved in oestrogen production. It 
has been described that oestrogen triggered VEGF expression and therefore a 
down-regulation in the oestrogen levels could induced a down-regulation on 
VEGF expression (Kazi and Koos, 2007; Kazi et al., 2009; Koss, 2010; Koss, 
2011).  
Based on VEGF modulation, cell migration and metastatic processes were 
evaluated in a first approach by means of iNOS expression. Unfortunately, due 
to the limitation of the iNOS antibody or its expresion levels in tissue, 
quantification of iNOS could not be performed. However a clear trend of iNOS 
expression inhibition was observed by HPMA copolymer-AGM-Dox 
combination conjugate and free Dox in comparison to HPMA copolymer-Dox. 
Therefore other experiments are currently perfomed to complete and confirm the 
effect of HPMA copolymer-AGM-Dox on cell migration and metastases. 
Regarding the results obtained with free Dox, it is clear that the 
pharmacokinetics play an important role. Indeed it was described in literature 
that Dox was evaluated with single dose (Kimberley et al., 2013) or other 
schedule injection (Woessner et al., 2000). However in our experiment, Dox was 
injected at 3 mg/kg each 3 days. Based on the 4T1 activity model, Dox showed 
significant lower efficacy in comparison to the HPMA conjugates. However, 
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when tumour tissue protein expression was evaluated, greater levels of cell death 
markers were observed at short-term in comparison with the conjugates, this 
levels significantly decreased at long-term. Dox is accumulated rapidly inside 
the tumour but not retained (chapter 4). On the contrary, Dox effect on 
angiogenesis was conserved even at the end of the experiment.  
As conclusion it could be said that, the antitumour activity observed for both 
conjugates in comparison with Dox was mainly relating to the pharmacokinetic 
and the capacity of the conjugate to accumulate an get retained in the tumour 
(EPR effect) (Maeda, 2001; Maeda, 2010). When both conjugates are compared 
there are also pharmacokinetic parameters influencing their different antitumour 
behaviour. However, we believe that the differences observed in cell death 
mechanisms and VEGF modulation are the key factors inducing a greater 
antitumour effect for the combination conjugate. 
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Chapter 6. PGA-based combination conjugates. Optimisation of 
PGA-X-AGM-Y-Dox conjugates. 
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6.1. Introduction. 
As already described in the introduction section, in an adequate design 
of a polymer-drug conjugate, the selection of the polymer carrier is a key factor. 
The polymer has to be non-toxic, non immunogenic, water-soluble to allow i.v. 
administration and ideally multivalent to allow high drug loading. The most 
widespread polymers transferred to the clinic in the last 20 years have been the 
non-biodegradable HPMA copolymer, PEG and the biodegradable polyglutamic 
acid (PGA) (Deladriere et al., 2011; Duncan and Gaspar, 2011). Biopersistent 
carriers (PEG, HPMA) present disadvantages if chronic parenteral 
administration and/or high doses are required as there is the potential to generate 
lysosomal storage disease syndrome. Preclinical evidence of intracellular 
vacuolation with certain PEG-protein conjugates is raising awareness of the 
potential advantage of biodegradable polymers regarding safety benefit apart 
from the possibility to use higher molecular weight (Mw) carriers allowing PK 
optimisation (Barz et al., 2011). Taking this into account and aiming to move a 
step further with our polymer-based combination strategy, the aim in this study 
was to substitute the non-biodegradable HPMA by the multivalent, 
biodegradable PGA. Due to its intrinsic characteristics, PGA presents a more 
favourable pharmacological profile as already demonstrated in the clinics with 
Opaxio
TM 
(PGA-Paclitaxel conjugate, Cell Therapeutics Inc.) in phase III 
clinical trial and recently designated as orphan drug in combination with 
radiotherapy for glioblastoma (Singer et al., 2003; Oldham et al., 2006; 
http://www.celltherapeutics.com/pdf/OPAXIO_facts-4pg.pdf.2008).  
For this purpose, a family of PGA-AGM-Dox conjugates was synthesised to be 
directly compared with the previously synthesised HPMA copolymer-AGM-
Dox model conjugate, investigating the maintenance of the synergistic effect. 
Moreover, as drug release kinetics is thought to be a possible reason of these 
phenomena, we proposed to evaluate its influence on cell cytotoxicity. 
The first objective was to confirm that AGM and Dox was in fact a synergistic 
drug combination independently of the polymer carrier, therefore, we aimed to 
reproduce at least the same in vivo results obtained with HPMA copolymer-
AGM-Dox conjugate in the 4T1 model. Secondly, by means of PGA carrier we 
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would like to demonstrate the possible advantages provided by the use of a 
multivalent, biodegradable carrier. The development of this study was divided in 
two phases, firstly, linker optimisation for PGA-AGM and PGA-Dox families 
were performed separately. Drug release profile studies and cell toxicity were 
carried out with the single conjugates to systematically determine the blocks to 
conform theoretically the best PGA-AGM-Dox combination conjugate.  
For a lysosomotropic drug delivery two types of linkers could be developed, (i) 
a pH labile linker, or (ii) an enzymatic sensitive linker. Following the same 
strategy used for HPMA copolymer-AGM-Dox, the linker optimisation was first 
based on an enzymatic cleavage (i.e. -G-, -GG-, no linker). The peptidic linkers 
were bound to the drug through an amide bond.  
In this chapter, it is reported the synthesis, characterisation and biological 
evaluation of the families PGA-X-AGM, PGA-Y-Dox and PGA-X-AGM-Y-
Dox. The appropriate linkers have been selected from the kinetics of drug 
release in presence of cathepsin B together with the cell viability data gained 
against MCF7 Ca cells. After the selection of the best candidates from in vitro 
cytotoxicity assays, the evaluation of their antitumour activity was also 
performed in the 4T1 breast cancer murine model. 
6.2. Synthesis and characterisation of PGA-X-AGM. 
    6.2.1. Synthesis of X-AGM. 
The first linker used was Glycine (-G-) as mono- and dipeptide, as it is simple 
and has previously demonstrated its value as cathepsin B labile sequence with 
other hydrophobic drugs (Vicent and Pérez-Payá, 2006). The 9-fluorenyl 
methyl-oxy carbonyl (Fmoc)-based peptide synthesis approach was followed to 
avoid any side reactions. G-AGM synthesis was finalised by a deprotection step 
with piperidine as described in figure 6.1. all intermediates as well as the final 
product were characterised by NMR as shown in Figure 6.2. 
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Figure 6.1. Synthetic scheme of the G-AGM reaction.  
 
 
 
Figure 6.2. 
1
H-NMR spectrum of Fmoc-G-AGM, 300Hz, DMSO.  
Fmoc-G 
Fmoc-G-AGM G-AGM 
AGM 
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Figure 6.3. 
13
C and DEPT135 NMR spectrum of Fmoc-G-AGM, 300Hz, d6-DMSO. 
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1
H and 
13
C/ DEPT135 NMR analysis confirmed the identity of Fmoc-G-AGM. A 
shift from 3 ppm to 8 ppm was observed corresponding to the amide bond 
formation. Furthermore, AGM aromatic protons showed greater chemical shifts 
in Fmoc-G-AGM than in the parent AGM due to the electron delocalisation 
induced by the Fmoc group (from 7 to 7,5 ppm).  
 
Figure 6.4. 
1
H-NMR spectrum of G-AGM, 300Hz, d6-DMSO. 
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Figure 6.5. 
13
C and DEPT135 NMR spectrum of G-AGM, 300Hz, d6-DMSO. 
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As mentioned above, Fmoc deprotection was carried out with piperidine and 
product identity and purity was also confirmed by 
1
H-NMR by the 
disappearance of the Fmoc aromatic peaks at 7, 7,8 and 8 ppm. The aromatic 
1
H 
corresponding to AGM remained (at 7,2 and 7,6 ppm) (figure 6.5.). 
The same synthetic protocol was used to synthesise G-G-AGM. It is important 
to note that in this case, a previous protection step for G-G with the Fmoc 
moiety had to be carried out.  
 
Figure 6.6. 
1
H-NMR spectrum of Fmoc-GG, 300Hz, d6-DMSO. 
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Figure 6.7. 
13
C and DEPT 135 NMR spectrum of Fmoc-GG, 300Hz, d6-DMSO. 
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Based on
 1
H-NMR analysis, the protection of GG with Fmoc was successfully 
achieved with the appearance of the Fmoc aromatic peak (7,2, 7,3, 7,7 and 7,8 
ppm) in good relation with the Gly -CH2- corresponding peak (3,5 and 3,7 ppm). 
Then, the synthesis of GG-AGM followed the procedure as described above.  
To conclude, two AGM derivatives bearing a peptidic chain were successfully 
synthesised, purified and characterised, G-AGM and GG-AGM. Then, their 
polymer conjugations to PGA were successfully performed as described in the 
next section. 
    6.2.2. Synthesis of PGA-X-AGM. 
The synthetic strategy used for PGA-X-AGM family was based on 
carbodiimide coupling reactions. The mechanism of the reaction was divided in 
three different steps. First, the activation of PGA carboxyl group with N,N’-
diisopropylcarbodiimide (DIC) and the stabilisation of the complex with 
hydroxybenzotriazole (HOBt) to favour the nucleophilic substitution reaction 
with amino-terminated X-AGM derivative. Reaction pH was adjusted to 8 with 
di-isopropyl ethylamine (DIEA) (figure 5.7. and 5.8.).  
 
Figure 6.7. Synthetic scheme followed to obtain PGA-X-AGM conjugates. 
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Figure 6.8. Carbodiimide activation mechanism taking place during PGA-X-AGM 
synthesis. 
Once the conjugate was obtained, purification and full characterisation 
was performed with the determination of the total drug loading and the possible 
free drug still entrapped inside the conjugate after purification.  
PGA-AGM conjugate was achieved by direct conjugation of AGM to the PGA 
mainchain. AGM bears an aromatic amine group with poor reactivity due to the 
electronic delocalisation. The activation of the –COOH with DIC/ HOBt did not 
allow an appropriate drug loading, therefore, a previous PGA activation strategy 
by means of succinimide (NHS) was used before AGM conjugation and its 
mechanism of activation is described in figure 6.9.  
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Figure 6.9. Activation of PGA using N-hydroxy succinimide to obtain PGA-OSuc. 
In order to limit the side reactions during AGM conjugation, PGA-OSuc was 
previously purified and the percentage of activated carboxylic groups 
determined by 
1
H-NMR. 
 
Figure 6.10. Determination of PGA-OSuc activation rate by 
1
H-NMR.  
The succinimide activation rate was determined by the relation with the e-c 
integral peak and the theoretical protons (x4) corresponding to 100% activation. 
 Activation rate = e-c integral peak x 100 
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The activation rate in this case was 37%. NHS-activated PGA was then allowed 
to react with AGM in the presence of catalytic amounts of DMAP during 36 h at 
RT in order to achieve PGA-AGM conjugate as described in figure 6.11.  
 
Figure 6.11. Reaction mechanism followed in NHS mediated PGA-AGM conjugate 
synthesis. 
The conjugate reaction conditions were optimised regarding temperature and 
concentration. The conjugate was then purified as described in chapter 3.  
6.3. Synthesis and characterisation of the PGA-Y-Dox family. 
    6.3.1. Synthesis of Y-Dox. 
The strategy used to synthesise Y-Dox was the same as described before for the 
protected group. Indeed Carboxybenzyl (Cbz, Z) was selected in this case 
instead of Fmoc- as amino-protecting groups allowed deprotection by 
hydrogenation avoiding any basic/acid media during the synthesis in order to 
protect the Dox structure.  
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Figure 6.12. Synthetic scheme for the obtention of G-Dox.  
The GG-Dox synthesis followed the same strategy as shown above for G-Dox.  
    6.3.2. Synthesis of PGA-Y-Dox family. 
As in the case of X-AGM conjugates, PGA-Y-Dox conjugates were achieved by 
a carbodiimide-mediated coupling of a previously synthesised amino-termiated 
–Y-Dox derivative.  
 
Figure 6.13. Synthetic approach followed with PGA-Y-Dox conjugate. 
Due to the instability of Dox in basic media at RT or even in acid environment 
at high temperatures (figure 6.13.), the synthetic approach used for Dox 
derivatives (Y-Dox) was different from that reported for X-AGM. The following 
side-reactions occurred deactivating Dox. 
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Figure 6.14. Dox hydrolysis under acidic pH. 
6.4. Synthesis of PGA-X-AGM-Y-Dox combination conjugates. 
The synthesis of X-AGM and Y-Dox described above were used to synthesise 
the combination conjugates. 
 
Figure 6.15. Synthetic scheme used for PGA-X-AGM-Y-Dox combination 
conjugate. 
The PGA-X-AGM-Y-Dox synthetic approach was based on subsequent 
carbodiimine couplings similar to those described above (figure 6.8.).  
6.5. Physico-chemical characterisation of the synthesised 
conjugates. 
PGA-X-AGM, PGA-Y-Dox and PGA-X-AGM-Y-Dox families were design in 
order to have a total drug loading around 5 mol% to allow direct comparison 
with the model HPMA-AGM-Dox combination conjugate. To fully characterise 
our polymer-drug conjugates several parameters were determined, including: (i) 
total drug loading, (ii) free drug content, (iii) Mw and polydispersity (Mw/Mn) 
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and (iv) conjugate solution conformation (size and shape) by small angle 
neutron scattering (SANS). The results obtained are summarised in the 
following table. 
Table 6.1. Characteristics of PGA-X-AGM, PGA-Y-Dox and PGA-AGM-Dox 
conjugates. P (PGA), A (AGM), D (Dox), G (Glycine). 
 
Yield 
(%) 
Total drug
a 
(%w/w) 
Free drug 
b 
(%w/w of total 
drug) 
Mw 
c 
(Da) 
PDI
d
 
Conjugates  A D A D   
P - - - - - 18 000 1,2 
P-A 68 6,8 - 1.12 - 18 200 1,2 
P-G-A 48 9,1 - 0,92 - 18 500 1,2 
P-GG-A 62 10,8 - 0,92 - 22 200 1,2 
P-D 68 - 14,2  0,14 19 000 1,2 
P-GG-D 50 - 2,5  0,24 20 600 1,2 
P-A-D 68 8,1 15,8 0,89 0,18 23 104 1,2 
P-G-A-D 65 7,8 20,1 1,14 0,32 23 510 1,2 
P-A-GG-D 70 7,6 4,2 0,82 0,36 23 960 1,2 
P-GG-A-D 64 7,6 18,9 0,87 0,22 23 958 1,2 
P-G-A-GG-D 65 7,1 3,1 0,78 0,28 26 135 1,2 
 
a. Total drug and free drug content determined by HPLC expressed in [%w/w]. b. Free drug 
content expressed as a percentage of total drug [%w/w total drug]. c. Mw determinated by Gel 
permeation chromatography (GPC) expressed in Da. d. Polydispersity (PDI) determined by 
GPC. 
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The total drug loading was determined by HPLC after a hydrolytic protocol as 
described above (Chapter 3). In the clinical setting, the control on any residual 
impurity in synthesised polymer conjugates is a critical issue that could 
compromise its safety. Therefore, any traces of residual solvent or entrapped 
free drug are parameters to carefully control in order to ensure an effective and 
reproducible therapy. It has been reported that free drug content should be 
always less than 2 wt% of the total drug loading (Gaspar and Duncan, 2009). 
When conjugating potent drugs such as Dox, free drug content is a key 
parameter to control as the different pharmacokinetics (diffusion vs. 
endocystosis) could mask the real benefits obtained upon conjugation. 
As it can be seen in table 3.2., free drug content was lower than 0,5 wt% in all 
conjugates synthesised. 
    6.5.1. Conjugate characterisation by GPC. 
Other important features in polymer conjugate design is the control on polymer 
molecular weight (Mw) and polydispersity index (PDI), important challenges 
when synthesising polymeric carriers. A high PDI in a conjugate could be the 
reason of a lower therapeutic efficacy due to an un-controlled pharmacokinetics. 
For this reason, in the Polymer Therapeutics laboratory a versatile and simple 
methodology for the preparation of well-defined polyglutamate nanocarriers has 
been recently reported (Conejos-Sánchez et al., 2013). For the first time 
ammonium salts with non-nucleophilic tetrafluoroborate anions has used as 
initiators for the ring opening polymerisation of α-N-carboxyanhydrides (NCAs) 
allowing a large scale polyglutamate synthesis with defined Mw (up to 800 
units), low PDI (< 1,2), controlled chain end functionality, adequate 
stereoselectivity and absence of any toxic impurity required for biomedical 
applications. 
Applying this novel methodology a well-defined PGA of Mw = 17 000Da and 
PDI = 1,2 was achieved and used in the present work as our selected polymeric 
carrier. Although only post-polymerisation modifications have been carried out 
here, Mw and PDI of the final conjugates were also confirmed by GPC to ensure 
conjugate integrity. A Viscotek
TDA
 triple detection system was used bearing a 
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Refractive Index (RI), Light Scattering (LALS and MALS) and Viscosimetry. 
As an example, a spectrum of PGA-GG-AGM is presented below (figure 6.16.). 
As expected, in all cases the conjugation of the drug(s) did not dramatically 
change the PDI of the starting PGA carrier. 
Finally, it is important to consider that polymer conjugate composition clearly 
influence the final solution conformation in terms of size, shape, and the 
dynamic changes that occur in response to physiological microenvironment. 
Therefore, not only conjugate identity but also solution conformation are key 
parameters to determine. In the laboratory we pioneered the use of advanced 
physico-chemical techniques, such as Small Angel Neutron Scattering (SANS) 
to explore conjugate solution conformation (Vicent et al, 2005; Giménez et al., 
2012). In this work, SANS together with circular dichroism (CD) have been also 
used to determine solution conformation of the different conjugates synthesised 
and to try to understand/identify predictors that could help in polyglutamate-
based combination therapy design. 
 
 
Figure 6.16. Refractive Index (RI) of PGA-GG-AGM GPC spectrum. 
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    6.5.2. Characterisation of the conjugate by SANS. 
 
 
Figure 6.17. SANS curve effect of the drug conjugation on the PGA size and shape. 
Panel (a-c) show the effect of the AGM Linker with Dox on PGA. Panel (b) shows 
the effect of the drug combination on PGA. Panel (d) shows the effect of AGM 
linker on the PGA. Effect of Dox linker on the combination therapy shape and size 
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when the linker chosen for AGM was –G-. Panel (e) shows the effect of Dox linker 
on PGA shape and size when AGM was linked through –G-. 
The final determination of the size and the shape has not been achieved yet as 
difficult mathematical calculations are required. These studies are performed in 
collaboration with Dr Paul at Cardiff University and the calculation of PGA 
based conjugate came to be new and more complex than expected due to 
different conformational arrangements observed. Therefore, more time would be 
needed to achieve the concrete size and shape of our polyglutamates. However, 
comparing the shape and the slope of the different conjugate curves, some 
comparisons and the first conclusions could be already drawn. Based on panel 
(d) comparisons, it could be clearly seen that the AGM linker had an influence 
on the conjugate conformation and on the PGA conformation. Also with the 
graphic (a) and (c), it was clearly demonstrated that the AGM linker changed 
drastically the conformation of the conjugate when Dox was either directly 
linked or through a –GG- linker. However, based on the panel (d) and only 
regarding to the single AGM conjugate, it was demonstrated that AGM linker 
had no strong effect on the PGA conjugate nevertheless a change was achieved 
in comparison to PGA conformation. Moreover based on panel (b) observations, 
it could be said that the most important change on the scatter curves was 
observed when both drugs were linked to the PGA. Therefore, Dox played an 
important role on the conformational changes maybe due to a strong π-π staking 
effect. Nevertheless, in combination with AGM, PGA conformation changes are 
induced from both drugs as observed in panel (b). These results suggest that, 
each drug alone had an effect on the PGA conformation but this effect clearly 
becomes much stronger when both drugs are conjugated together in the same 
polymeric backbone.  
Summarising, data from SANS experiments demonstrated that the combination 
of both drugs in the same PGA carrier induced a much stronger effect on its 
solution conformation than the single counterparts. The influence of Dox on 
conjugate solution conformation is much stronger than that triggered by AGM 
due to its more hydrophobic and planar structure. It is expected that changes in 
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conjugate solution conformation would influence conjugate therapeutic output 
(see next section for detailed cell and in vivo data). 
6.6. Linker evaluation and drug release kinetics. 
In order to evaluate the linker, a simulation of the drug release as occurred in 
lysosomes was performed. Polymer drug conjugates were incubated with the 
lysosomal enzyme cathepsin B up to 1 week. The kinetics of drug release was 
monitored by HPLC and the polymer conjugate degradation followed by the % 
Mw loss as determined by GPC (figure. 6.18. and 6.19.). 
    6.6.1. Kinetics of drug release of single conjugates and identification 
of the main metabolites. 
 
       6.6.1.a. Drug release study. 
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Figure 6.18. Kinetics of drug release from the conjugates synthesised in presence of 
Cathepsin B. Measured by HPLC. Data are expressed as mean ± SD where n = 3.  
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Figure 6.19. Mw loss of the polymer conjugates synthesised in presence of cathepsin 
B. Measured by GPC. Data are expressed as mean ± SD where n = 3.  
 
       6.6.1.b. Identification by LC-MS of the main metabolites released in presence of 
cathepsin B. 
Apart from the rate of drug release, other important task to performed was the 
identification of the main metabolites released from the conjugates in order to 
identify any possible inactivation effects. Therefore, LC-MS experiments were 
performed for the PGA-X-AGM family and MALDI-Tof analyses for PGA-Y-
Dox conjugate. Only a MALDI-Tof experiment was performed for the 
combination therapies.  
The metabolite identification was first carried out for PGA-X-AGM family. The 
samples injected were PGA-AGM after 48 h incubation with cathepsin B, PGA-
G-AGM after 24 h incubation with cathepsin B and PGA-GG-AGM after 24 h 
incubation in presence of cathepsin B.  
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Figure 6.20. PGA-AGM conjugate metabolite identification after 48 h in presence of 
cathepsin B. Panel (a) shows the chromatogram of PGA-AGM degradation extract 
after 48 h in presence of cathepsin B. The retention time (tr) of AGM is 5 min and 7 
min for 7 min. Panel (b) shows the mass spectrum corresponding to the AGM peak 
tr. Peak m/z 233,1, AGM [M+H
+
]. Panel (c) shows the mass spectrum 
(a) 
(b) 
(c) 
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corresponding to the Glutamic acid peak retention time. Peak m/z 130,4, Glutamic 
acid [M+H
+
]. 
LC-MS confirmed the release of AGM after 24 h, Glutamic acid units were also 
identified. However, different peaks were observed in the chromatogram 
although any correspondence was identified with any PGA fragments or other 
parts of our system. 
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Figure 6.21. PGA-G-AGM metabolite identification after 24h in presence of 
cathepsin B. Panel (a) shows the chromatogram of PGA-G-AGM degradation 
extract after 24h in presence of cathepsin B. The tr for AGM is 5 min, 6 min for G-
AGM and 7 min for glutamic acid is. Panel (b) shows the mass spectrum 
corresponding to the AGM peak retention time. Peak m/z 233,1, AGM [M+H
+
]. 
Panel (c) shows the mass spectrum corresponding to the G-AGM peak retention 
time. Peak m/z 264,3, G-AGM [M+H
+
]. Panel (d) shows the mass spectrum 
corresponding to the Glutamic acid peak retention time. Peak m/z 130,4, Glutamic 
acid [M+H
+
]. 
 
The HPLC and LC-MS analysis confirmed that G-AGM was first released and 
finally converted to AGM after 5 h. Glutamic acid units were also observed.  
130,4 
(c) 
(d) 
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Figure 6.22. PGA-GG-AGM metabolite identification after 24 h in presence of 
cathepsin B. Panel (a) shows the chromatogram of PGA-GG-AGM degradation 
extract after 24 h in presence of cathepsin B. The tr for AGM is 5 min, 6min for G-
AGM and 7 min for glutamic acid. Panel (b) shows the mass spectrum 
corresponding to the AGM peak retention time. Peak m/z 233,1, AGM [M+H
+
]. 
Panel (c) shows the mass spectrum corresponding to the G-AGM peak retention 
time. Peak m/z 264,3, G-AGM [M+H
+
]. Panel (d) shows the mass spectrum 
corresponding to the G-AGM peak retention time. Peak m/z 130,4, glutamic acid 
[M+H
+
]. 
The LC-MS analysis confirmed that AGM, G-AGM and GG-AGM fragments 
were released from PGA-GG-AGM conjugate, also glutamic acid units were 
observed. For the PGA-X-Dox family, MALDI experiments were also carried 
out to identify the main metabolites after incubation with cathespin B.  
As it can be seen in figure 6.18. and figure 6.19., the kinetics of drug release and 
the degradation of the polymer mainchain were directly influenced by the linker 
used. For example, PGA-AGM conjugate showed an unusual degradation 
profile in comparison with PGA alone (Vicent and Pérez-Payá, 2006) achieving 
complete degradation only after 24 h, which corresponds to AGM release. This 
could be explained due to AGM 3D conformation as a non-planar molecule that 
could difficult the compactation of the expected unimollecular micelle to be 
formed giving as result a more open structure. Therefore the degradation of the 
PGA was first necessary to allow the access of cathepsin B and therefore to 
trigger drug release. Once again the polymer drug conjugate conformation is a 
key parameter to achieve and understand an efficient control on drug release 
(d) 
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kinetics. Regarding linker evaluation, the –G- for AGM with a 60% of drug 
released seems to be an adequate candidate for our first combination. 
Furthermore, with PGA-G-AGM similar degradation profile was achieved when 
compared to the parent PGA (Vicent and Pérez-Payá, 2006). For the PGA-Y-
Dox family, the linker offering the greatest rate of drug release was –GG- with 
only 20% of drug released after 96 h. 
    6.6.2. Kinetics of drug release from the combination conjugates. 
        6.6.2.a. Drug release kinetics. 
As it was already proved with the SANS experiment, the conjugation of both 
drugs in the same polymeric backbone induced a dramatic change in the solution 
conformation in comparison with PGA and the single conjugates. The 
degradation of the combination conjugates was performed in presence of 
cathepsin B and the results were always compared with the single conjugates. 
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Figure 6.23. Drug release kinetic profile from the combination conjugates 
synthesised. Panel (a) shows the comparison of AGM and Dox release from PGA-
AGM-Dox vs PGA-Dox and PGA-AGM. Panel (b) shows the comparison of AGM 
and Dox release from PGA-G-AGM-Dox vs PGA-Dox and PGA-G-AGM. Panel (c) 
shows the comparison of AGM and Dox release from PGA-AGM-GG-Dox vs PGA-
GG-Dox and PGA-AGM. Panel (d) shows the comparison of AGM and Dox release 
from PGA-GG-AGM-Dox vs PGA-Dox and PGA-GG-AGM. Panel (e) shows the 
comparison of AGM and Dox release from PGA-G-AGM-GG-Dox vs PGA-GG-
Dox and PGA-G-AGM. An ANOVA Analysis was performed in order to evaluate 
the significance between the data. * P < 0,05, ** P < 0,01, *** P < 0,001. Data is 
expressed as mean ± SD (n = 3).  
(d) 
(e) 
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Table 6.2. Statistical analysis data of drug release. 
 
 PGA-G-AGM-GG-Dox 
P value 0,5 h 1h 2h 5h 8h 24h 72h 96h 
PGA-G-AGM ns ns * * ** * ** * 
PGA-GG-Dox * ** * ** * ns ns ns 
 
 PGA-AGM-Dox PGA-G-AGM-Dox 
P value 24h 8 h 24 h 48 h 72h 96h 
PGA-Dox * ns ns ns ns ns 
PGA-G-AGM NA ** * * ** ** 
 
The degradation of each combination (continuous line) was compared with the 
single conjugate drug release (doted line). For the majority of the combinations, 
Dox release was not significantly different than that observed for the single 
conjugate. Except for PGA-G-AGM-GG-Dox, significant differences were 
observed in the beginning of the release, up to 8 h 14% of Dox liberation was 
achieved in comparison to 6% for the single conjugate. In addition, drug release 
was observed only after 1 h for the single conjugate in contrast with the release 
in the combination therapy that started from time zero. However after 48 h, the 
same rate of Dox release was achieved in both cases. Regarding the AGM 
liberation more differences were observed in the rate as well as in the kinetic 
profile. PGA-G-AGM-Dox and PGA-G-AGM-GG-Dox, presented similar drug 
release kinetics however a significant lesser amount of Dox was released around 
15 % in both cases in contrast to the 55% obtained from the single conjugate. 
Regarding the combination with the AGM linked directly to the PGA (i.e. PGA-
AGM-Dox and PGA-AGM-GG-Dox) the kinetic profile was different. In both 
cases, Dox release started from the beginning and not after 24 h, as it was 
observed with the single conjugate. A significant difference in the AGM release 
rate was also achieved only for the PGA-AGM-Dox up to 24 h. Regarding the 
last combination, PGA-GG-AGM-Dox no significant differences were observed 
on Dox or AGM release in comparison to the single conjugates. 
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       6.6.2.b. Identification of the main Dox metabolite released by MALDI-Tof. 
The release rate is not the only parameter to take into account as the metabolic 
profiling is also very important. Therefore Dox-bearing metabolites released 
from conjugate degradation were analysed by MALDI Tof.  
 
Figure 6.24. MALDI-Tof spectrum of PGA-Dox conjugate after 24 h in presence of 
Cathepsin B. The peak m/z 656,0952 is the [M+H]
+
 of Glu-Dox. The peak m/z 
806,2994 is the [M+Na]
+
 of GluGlu-Dox. The peak m/z 935,3424 is the [M+Na]
+
 of 
GluGluGlu-Dox. 
 
The main peaks obtained were, 656,09 m/z, 806,29 m/z and 935,34 m/z 
corresponding respectively to [Glu-Dox], [GluGlu-Dox + Na
+
] and [GluGluGlu-
Dox+ Na
+
]. Peaks between 400 m/z and 450 m/z belong to the matrix. The 
release occurred only after polymer mainchain degradation, which was in fact 
the expected result from our design. MALDI-Tof experiment confirmed the 
release of Dox through the polymer mainchain cleavage as Glu-Dox, GluGlu-
Dox and GluGluGlu-Dox were the main fragments observed.  
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Figure 6.25. MALDI-Tof spectrum of PGA-GG-Dox conjugate after 24 h in 
presence of cathepsin B. The peak m/z 543,4283 is the [M+H]
+
 of Dox. The peak 
m/z 606,4573 is the [M+Na]
+
 of GluNa-GluNa-GluNa-GluNa. The peak m/z 
656,0290 is the [M+H]
+
 of GlyGly-Dox. 
Regarding the PGA-GG-Dox, first a release of GG-Dox was observed followed 
by free Dox release after 120 h. The release of Dox only after 120 h could result 
in a lower therapeutic effect in future in vitro and in vivo experiments.  
 
Figure 6.26. MALDI-Tof spectrum of PGA-G-AGM-GG-Dox conjugate after 72 h 
in presence of cathepsin B. The peak m/z 656,0390 is the [M+H]
+
 of GlyGly-Dox. 
The peak m/z 682,2971 is the [M+Na]
+
 of GlyGly-Dox. 
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Regarding the PGA-G-AGM-GG-Dox, release of GG-Dox was observed as in 
the single conjugate. 
 
Figure 6.27. MALDI-Tof spectrum of PGA-GG-AGM-Dox conjugate after 24 h in 
presence of cathepsin B. The peak m/z 656,0261 is the [M+H]
+
 of Glu-Dox. 
More importantly main peaks obtained were, 656,09 m/z, corresponding to 
[Glu-Dox]. The release occurred only after polymer mainchain degradation, 
which was in fact the expected result from our design. 
 
Figure 6.28. MALDI-Tof spectrum of PGA-AGM-GG-Dox conjugate after 24 h in 
presence of cathepsin B. Regarding the PGA-G-AGM-GG-Dox, a release of GG-
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Dox was observed as in the single conjugate. The peak m/z 656,0290 is the [M+H]
+
 
of GlyGly-Dox. 
 
Figure 6.29. MALDI-Tof spectrum of PGA-AGM-Dox conjugate after 24 h in 
presence of cathepsin B. The peak m/z 656,0383 corresponds to the [M+H]
+
 of Glu-
Dox. The peak m/z 806,2096 is the [M+Na]
+
 of GluGlu-Dox. The peak m/z 
935,2428 is the [M+H]
+
 of GluGluGlu-Dox. 
More importantly main peaks obtained were, 656,09 m/z, 806,29 m/z and 
935,34 m/z corresponding respectively to [Glu-Dox], [GluGlu-Dox + Na
+
] and 
[GluGlu-Dox + Na
+
]. Also in this case, the release occurred only after polymer 
mainchain degradation as expected. 
To conclude, a clear time-dependent enzymatic drug release kinetics was 
observed for all conjugates tested as single agents or in combination. The 
greatest percentage of AGM release was observed for PGA-G-AGM conjugate 
with a 55% AGM released after 96 h. By LC-MS, it was determined that G-
AGM was the main metabolite obtained up to 48 h in presence of cathepsin B, 
yielding free AGM already after 5 h. The highest Dox release was observed for 
PGA-GG-Dox with a 20% of GG-Dox found after 96 h yielding free Dox only 
after 120 h. In the combination conjugates, i.e. PGA-X-AGM-Dox there was not 
possible to make a direct correlation with the drug release data obtained for the 
single conjugates. PGA-X-AGM-Dox showed a release from the PGA backbone 
producing metabolites, such as, Glu-Dox and GluGlu-Dox. However, the 
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combination conjugate PGA-X-AGM-GG-Dox showed a release through the 
linker liberating GlyGly-Dox metabolite. 
6.7. Biological evaluation of PGA-X-AGM-Y-Dox combination 
conjugates. 
Regarding the literature encountered for HPMA copolymer-AGM-Dox (Greco 
et al., 2005; Vicent et al., 2005), the synergistic effect was observed when AGM 
was released first and subsequently Dox. In this study, the only combination 
conjugate showing a similar kinetic profile was PGA-G-AGM-Dox. To move a 
step further, in vitro tests were performed in human hormone dependent breast 
cancer cell line MCF7 Ca with a stable aromatase plasmid transfection as those 
performed with the model conjugate HPMA copolymer-AGM-Dox conjugate 
(Chapter 3).  
 
(a) 
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(b) 
(c) 
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Figure 6.30. Effect of Dox and PGA conjugates family on MCF7 Ca cell viability 
after 72 h incubation. Panel (a) shows the cytotoxicity of PGA-GG-AGM-Dox in 
comparison with the single conjugates and their mixture. Panel (b) shows the 
cytotoxicity of PGA-G-AGM-Dox in comparison with the single conjugates and 
their mixture. Panel (c) shows the cytotoxicity of PGA-G-AGM-GG-Dox in 
comparison with the single conjugates and their mixture. Panel (d) shows the 
cytotoxicity of PGA-AGM-Dox in comparison with the single conjugates and their 
mixture. Data are expressed as mean ± SD where n = 3.  
 
In order to evaluate the best combination conjugate synthesised based on its 
cytotoxic activity on MCF7 Ca, a comparative 72 h incubation MTT assay was 
perfermed between each designed polymer combination conjugate, the single 
conjugates, and the mixture of the single conjugates. As it could be seen in 
figure 6.30., three combination conjugates could already be discharged, PGA-
AGM-Dox, PGA-AGM-GG-Dox and PGA-G-AGM-GG-Dox. Those 
combination conjugates presented lower toxicity or non-significant differences 
than the single conjugates against MCF7 Ca cells. In addition, PGA-AGM-GG-
Dox presented no toxicity in the tested concentration range probably due to the 
low amount of Dox released. The two possible candidates with lower IC50 
values than that for PGA-Dox were PGA-G-AGM-Dox and PGA-GG-AGM-
Dox (figure 6.30.a. and figure 6.30.b.). Moreover by SANS, a comparison of the 
(d) 
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solution conformation adopted by the four different combination conjugates was 
studied by looking at their scattering curves.  
 
 
 
 
 
 
 
Figure 6.31. Comparison on combination conjugates scattering profile. 
Remarkably, the conjugates presenting the best biological profile (PGA-G-
AGM-Dox and PGA-GG-AGM-Dox, empty symbol lines) also presented 
similar scattering profiles and different from those not-biologically active. This 
could be a sign of a preferred conjugate solution conformation to achieve 
synergism. PGA-G-AGM-Dox seemed to be more compact than the other due to 
its higher Q value. In order to find out the final conjugate solution conformation 
capable of inducing better biological profile in breast cancer models further 
SANS studies are being performed looking for a clear correlation between 
conformation and the cell death results achieved against MCF7 Ca cells. 
6.8. In vivo evaluation of PGA-X-AGM-Y-Dox combination 
conjugates. 
Due to the experimental difficulties to perform an orthotopic animal model with 
MCF7 Ca cells as described in chapter 4, and in order to evaluate our conjugate 
in a representative model with functional immune system that also allowed the 
comparison with the previous studied model conjugate HPMA copolymer-
AGM-Dox, a 4T1 metastatic murine model was used (see details in chapter 4).  
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Figure 6.33. In vivo evaluation of PGA-G-AGM-Dox conjugate in 4T1 orthotopic 
murine model. Panel (a) shows the tumour growth with and without treatment, Ctr, 
(a) 
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PGA-Dox, PGA-G-AGM-Dox and PGA-G-AGM + PGA-Dox. Results are 
expressed as mean ± SEM where n = 6 animals per group. The injection of 
treatments was performed on days 0, 3 and 6 as indicated by the arrows. Panel (b) 
shows the animals weight during the experiment. The weight progression of 2 
animals is shown as example.  
Table 6.2. Significance of PGA conjugates and free Dox in the 4T1 murine model 
 d 7 d 9 d 10 d 11 d 13 
P value 2 2 2 1 1 4 
1 * * * NA NA ns 
2 NA NA NA * * ns 
3 ns ns ns ** *** ns 
4 ns ns ns ns * NA 
5 ns ns ns ns * *** 
 
1- PGA-G-AGM-Dox, 2- PGA-G-AGM + PGA-Dox and 3- PGA-Dox. 4 – CTR. 5 – Dox. 
The total Dox content was represented (PGA conjugate + free Dox, analysed by HPLC 
looking at aglycone, see Materials and Methods) (n = 4). Significances calculated by one-way 
ANOVA. P*** < 0,001, P* *< 0,01, P* < 0,05, ns: non significance. The statistics at T = 0 d 
to T = 6 d showed non significance.  
 
PGA conjugates were injected intravenously at 5 mg/kg, 3 times every 3 days 
following the same strategy as described in chapter 4. Due to Dox toxicity as 
previously explained, only 3 mg/kg was injected as free Dox treatment, 
corroborating the better therapeutic outcome of the Dox conjugates in 
comparison to the toxic free drug. As it can be seen in figure 6.33.a., none 
significant differences for tumour volume were observed with all treatments 
compared to the control group up to day 10, except for PGA-G-AGM+PGA-
Dox treatment, which showed an early significant down-regulation of tumour 
volume. However, after day 10, an interesting antitumor effect was observed 
with PGA-G-AGM-Dox presenting significantly better activity than PGA-G-
AGM+ PGA-Dox, and consequently than the other treatments. Furthermore, 
treatment with PGA-G-AGM-Dox was capable to constrain the tumour growth 
in contrast with the other treatments. Regarding PGA-Dox, significant 
differences were observed when compared with the control group after day 11, 
however, its effect was similar to that observed with free Dox. PGA as a carrier 
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was also evaluated and non-differences with the control were achieved. None 
toxicity was observed regarding the weight evolution and the animal behaviour 
(figure 6.33.b.).  
6.9. Discussion.  
In order to design an efficient PGA-AGM-Dox combination conjugate, 
firstly, a family of PGA-X-AGM conjugates based on different peptide linkers 
was synthesised, characterised and fully evaluated. Two linkers were used with 
drug loadings around 5 mol% and free drug content lower than 1 wt%. The Mw 
of all conjugates was set to be around 19 000 Da. The PDI was determined to be 
the same as the PGA carrier due to the synthetic approach used, a post-
polymerisation modification. Regarding the polymer degradation experiment, 
some differences were observed in terms of degradation kinetics. PGA-AGM 
conjugate showed a fast degradation to reach a 100% Mw loss of the starting 
conjugate only after 24 h. One of the explication of this phenomenon could be 
the change in the solution conformation of the conjugate after AGM 
conjugation. This conjugate did not showed any side-chain linkers so a quite 
compact structure could result from the conjugation of the AGM and could favor 
the degradation in some specific site of the PGA main chain. This hypothesis 
was confirmed by the AGM release which occured only after 24 h when the 
PGA mainchain was degraded. For the PGA-G-AGM a totally different release 
profile was observed. The use of -G- as linker generated a more expanded 
structure and allowed better enzyme accessibility. Moreover regarding the AGM 
release, first a fast liberation was observed up to reaching a plateau after 10 h. 
Possibly a change in the conjugate solution conformation occurred during the 
degradation process. The same conclusion could be drawn for PGA-GG-AGM. 
To confirm our hypothesis further studies evaluating the solution conformation 
of conjugates have been carried out by SANS including a cathepsin B 
degradation study. Regarding the kinetics of drug release, a clear time dependent 
drug release was observed in presence of the lysosomal enzyme cathepsin B 
directly correlated with the linker. The linker allowing the greater rate of drug 
release was the –G- reaching 55% of AGM released, first as –G-AGM that was 
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transformed in AGM after 5 h. Consequently, it was selected as the best 
candidate to be part of the combination conjugate.  
In parallel, a family of PGA-Y-Dox were successfully synthesised and 
characterised. The same linkers were selected. Around 5 mol% Dox loading was  
achieved with a free drug content always lower than 0,4 wt%. The Mw was 
determined to be around 25 000 Da. The PDI were not achieved due to problems 
with Dox retention in the GPC column inducing calculation errors, however, due 
to the synthetic approach followed (post-polymerisation modification) a PDI 
approximately of 1,2 would be expected. Regarding the polymer degradation, 
both PGA-Y-Dox conjugates showed a slower degradation profile in 
comparison to PGA-Na. The presence of Dox could induce a π-π stacking 
phenomena (Gu et al., 2011; Hynek et al., 2012) resulting in the stability of the 
complex. Based on the MS experiment, Dox was released from PGA-Dox as 
Glu-Dox and Glu-Glu-Dox as described for the Opaxio® (Singer et al., 2003; 
Singer, 2005). For PGA-GG-Dox, drug release occurred through -GG-Dox first, 
and transformed into Dox only after 120 h. Our first idea was to evaluate and 
select Dox and AGM linkers from the evaluation of the single conjugates. 
Regarding the drug release and metabolite identification from the single 
conjugate, the two selected linkers were –G- for AGM and –GG- for Dox. 
However the final combination conjugate showed a different drug release profile 
in comparison with the parent single conjugates possibly due to the adopted 
solution conformation that compromised drug release kinetics and therefore 
therapeutic output.  
Consequently, a family of 5 different combinations were synthesised playing 
with the linkers studied in the single conjugate without any prior rational. The 
drug loading was around 5 mol% for both drugs and the Mw around 25 600 Da. 
For the same reason than PGA-Y-Dox the PDI was not determined but expected 
to be around 1,2. Regarding drug release kinetics, most of the Dox release was 
not changed in comparison to the single conjugate. However, regarding the 
AGM drug, differences in drug release profile were observed. For the 
combination bearing –G- as linker for the AGM, the kinetic profile presented the 
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same scattering curve shape however the amount released was 3 times less after 
96 h. For the combination with AGM linked directly to the polymer the kinetic 
profile changed and AGM release started from t0 achieving the same rate after 
96 h. Drug release from the combination PGA-GG-AGM-Dox conjugate was 
the same than the one observed with the single conjugate.  
Importantly, the kinetics of drug release for the model HPMA copolymer-AGM-
Dox conjugate showed first the release of AGM and then Dox (Vicent et al., 
2005). The combinations showing the same profile were PGA-G-AGM-Dox and 
PGA-AGM-GG-Dox, in fact those showing better performance. The PGA-
AGM-GG-Dox was discharged because of its only 2% of Dox release after 96 h. 
Once the drug release kinetics from the different conjugates were fully analysed, 
an in vitro test was performed in MCF7 Ca cells to evaluate the cytotoxic 
activity of the combination conjugates. It was confirmed that PGA-GG-AGM-
Dox and PGA-G-AGM-Dox presented a synergistic effect in comparison to the 
PGA-Dox regarding cytotoxic activity. Moreover, both conjugates presented a 
clear different solution conformation when studied by SANS in comparison with 
the other non-biologically active combination conjugates.  
Finally, the selected PGA-G-AGM-Dox conjugate was evaluated in a 4T1 
orthotopic breast cancer murine model trying to achieve in vivo proof of 
antitumour activity. After day 10, PGA-G-AGM-Dox was capable to stop 
tumour growth in comparison to the control and with significantly better 
performance than the PGA-G-AGM+PGA-Dox. The results obtained with this 
PGA conjugate could be understood and related to the kinetics of Dox release. 
The drug release from PGA-G-AGM-Dox was low in comparison to HPMA 
conjugate explaining the lower antitumour effect. The faster rate of AGM 
release from PGA-G-AGM single conjugate could explain the greater early 
antitumour effect of the combination of the single conjugates. Indeed, separately 
AGM release achieved a 60% in 5 h when in the combination conjugate 15%. 
One hypothesis could be that somehow AGM was turning the 4T1 tumour cells 
more sensitive to Dox treatment, therefore for a future design would be 
important to secure a fast AGM release before any free Dox is present in the 
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cell. After day 10, the benefits of the combination of the single conjugates in 
comparison to the combination conjugate disappeared demonstrating the 
importance to secure the delivery of both drugs in the same tumour cell, only 
possible with the combination conjugate.  
An experiment is currently ongoing with a higher conjugate dose 10 mg/kg. 
Moreover, a new design of PGA-G-AGM-Dox with higher AGM content is also 
being performed as this fact could enhance the AGM effect in tumour cells and 
consequently, could induce an earlier tumour inhibition.  
    6.9.1. HPMA copolymer-AGM-Dox versus PGA-G-AGM-Dox 
combination conjugates.  
In order to understand better the design of efficient combination conjugates it 
was decided to carry out an in vitro and in vivo comparison between the results 
obtained with PGA-G-AGM-Dox and the model conjugate HPMA copolymer-
AGM-Dox. Regarding MCF7 Ca cell viability inhibition, the IC50 obtained 
were 0,0038 mg/mL and 0,002 mg/mL Dox equivalent for PGA-G-AGM-Dox 
and HPMA copolymer-AGM-Dox, respectively, much lower for the model 
conjugate (figure 6.34.). However, the synergism seemed to be greater for the 
PGA conjugate with a CI of 0,21 in comparison to a CI 0,27 for the HPMA 
conjugate  
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Figure 6.34. Comparison between HPMA conjugate and the best candidate of PGA 
conjugates on cell viability inhibition. Panel (a) shows cell death analysis in MCF7 
Ca cell line induced by HPMA conjugates. Panel (b) shows cell death analysis in 
MCF7 Ca cell line induced by PGA-G-AGM-Dox family. Data are expressed as 
mean ± SD where n = 3. 
When both combination conjugates were compared in the 4T1 in vivo mice 
model, HPMA conjugate showed greater efficiency than the selected PGA 
(a) 
(b) 
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combination conjugate (figure 6.35.) probably due to a greater and faster drug 
release kinetics (figure 6.36.). Indeed a 20% drug release was achieved from 
HPMA copolymer after 5 h whereas to reach those levels with PGA conjugate 
the period required was 96 h. Therefore, in an aggressive tumour model such as 
4T1, to enhance the performance of PGA conjugates its design and 
administration schedule have to be optimised. PGA-G-AGM-Dox combination 
conjugate is a good starting point as significant differences on tumour growth 
inhibition have been already achieved but it is believed that a faster and greater 
AGM release from the PGA carrier could significantly enhance this value. 
Experiments are ongoing in this respect. 
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Figure 6.35. Evaluation of tumour growth in 4T1 orthotopic mice model. Panel (a) shows 
HPMA conjugates effect on tumour growth. Panel (b) shows PGA conjugates effect on 
tumour growth. Arrows indicate injection schedule and results are expressed as mean ± SEM 
where n = 6 animals per group. Treatment administration was performed on days 0, 3 and 6. 
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Figure 6.36. Comparison of AGM and Dox release kinetic profiles when both drug 
are linked to either HPMA copolymer or PGA as polymer carrier. Panel (a) shows 
the drug release from PGA-G-AGM)-Dox. Panel (b) shows the drug release from 
HPMA copolymer-AGM-Dox. Results are expressed as mean ± SD where n = 3 
experiments. 
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Chapter 7. Hight Trough Put screening to find new combination. 
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7.1. Introduction. 
As it has been previously described AGM and Dox drug combination 
within the same polymer backbone showed very promising results for the 
treatment of breast cancer as demonstrated firstly by its cytotoxic activity in 
vitro against breast cancer cells, and secondly acting as antitumor therapy 
administered in an in vivo orthotopic breast cancer model (Chapter 4). However, 
AGM belongs to a first generation aromatase inhibitors (AI) with a non-specific 
mode of action and most probably if substituted with a more advanced AI the 
antitumour effects already achieved could be even enhanced. In fact, AGM not 
only acts on aromatase enzyme, but it also blocks other P-450 enzymes like 11-
β-hydroxylase, involved in the biosynthesis of corticosteroids. Therefore, 
patients treated with AGM need to be supported by simultaneous administration 
of cortisol (Njar and Brodie, 1999) (figure 7.1.). 
 
Figure 7.1. Steroid genesis pathways (Njar and Brodie, 1999).  
Nowadays, new generation AIs have been developed with higher 
selectivity and potency than AGM, such as Letrozole, Anastrozole and 
Exemestane (Exe) (Jordan, 2003). Apart from AI, other endocrine treatments, 
such as Tamoxifen, with a mechanism of action based on oestrogen receptor 
blockade, have been also successfully used in the clinics for the treatment of 
hormone dependent breast cancer (Jordan and Brodie, 2007; Zilli et al., 2009; 
Rao and Cobleigh, 2012). In the case of tamoxifen the clinical activity was 
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found mostly in pre-menopausal woman (Bowles et al., 2012; Su et al., 2012) 
although it also demonstrated important activity in post-menopausal patients 
(Bowles et al., 2012). On the other hand, other chemotherapeutic drugs than Dox 
have been also described for breast cancer treatment, such as Paclitaxel (PTX), 
(Jeansonne et al., 2011) and 5- Fluorouracil (5-FU) (Tan and Swain, 2001; 
Alvarez et al., 2012). Therefore, trying to increase the combination therapy 
armory and benefiting of the already developed technological platform (Chapter 
6), our aim along this last chapter was to find new drug combinations with 
antitumour synergistic potential that could allow the design of advanced PGA-
based combination conjugates. To reach this goal in a systematic but efficient 
manner, a high throughput screening (HTPS) approach was implemented using 
4 chemotherapeutic drugs and 3 endocrine therapy agents, which were selected 
from the current clinical treatments for advanced breast cancer. 
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The 4 chemotherapeutic drugs chosen were Camptothecin (CPT), PTX, 
Dox and 5-FU, whereas AGM, Exe and 4-OH-Tamoxifen (4 OH) were used as 
endocrine agents. Dox, PTX and the endocrine agents mechanism of action was 
already described in the introduction chapter. With respect to 5-FU, it could be 
said that is a thymidylate synthase inhibitor that blocked the synthesis of the 
pyrimidine thymidine, a nucleoside required for DNA replication. Therefore, 
cell cycle arrest and apoptosis are induced as a direct consequence of blocking 
the cell’s abilities to synthesise DNA (Liu et al., 2000; Alvarez et al., 2012). 
CPT can be considered as a cytotoxic quinoline alkaloid inhibitor of the DNA 
enzyme topoisomerase I and therefore apoptosis inductor (Liu et al., 2000). 
In the experimental screening platform design, the cell viability of the 7 
different drugs at 3 different concentrations, either alone or in the different 
possible combinations was evaluated against MCF7 (ER+) and MDA MB231 
(ER-) cell lines. MCF7 is a hormone dependent breast cancer cell line. On the 
other hand MDA MB 231 is a breast cancer cell line oestrogen receptor 
negative, used here as our negative control. The concentration inhibiting 50% of 
cell viability (IC50) was evaluated for each single compound in both cell lines 
MCF7 and MDA MB 231. Then, each chemotherapeutic agent was tested at 3 
serial concentrations and combined with each endocrine agent also at 3 different 
concentrations for both cell lines. In all cases, the 3 concentrations selected for 
the drugs were their IC50 and concentrations inducing 35% and 70% cell death 
(IC35 and IC70, respectively).  
7.2. IC50 evaluation for each compound. 
To determine the IC50 of all compounds, cells were seeded onto 96 
well plates (P 96) at 10 000 cells/well for MCF7 and 20 000 cells/well for MDA 
MB 231. After 24 h for MCF7 and 48 h for MDA MB 231, cells were incubated 
for 72 h with serial dilutions of the different compounds (n = 6) and cell 
viability was determined by MTS assays (chapter 3, see material and methods 
for more detailed explanation). Appropriate control cells were treated 
identically. Each plate was then read at a wavelength of 496 nm being the 
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absorbance directly proportional to the number of living cells in culture. Cell 
viability was expressed as a percentage of the viability of untreated control cells.  
In order to determine the rate of significance, the raw data (n = 6) 
obtained for each experiment (n = 3) was evaluated in comparison to the 
standard (untreated control cells). The level of statistical significance was 
determined by analysis of variance (ANOVA) followed by Dunnett’s t-test for 
multiple comparisons.  
    7.2.1. Determination of IC50 value in MCF7.  
The concentrations evaluated for IC50 calculation are summarised in the 
following table. 
Table 7.1. Concentrations evaluated for each compound in MCF7 cells to determine 
their IC50 value. 
 AGM Exe 4 OH PTX CPT Dox 5-FU 
a
Conc (µM) 
4000 6 20 18 3,7 13,5 20 
1300 2 13.5 12 2,7 9 15 
440 0,6 8 6 1,7 6 7,5 
140 0,2 6,6 3 0,7 4 6,6 
  6 1,5  2 6 
   0,22  0,22 3,7 
 a: Concentration tested to determine the IC50. 
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Figure 7.3. Determination of IC50 value for each compound in MCF7 cell line. 
Panel (a) shows the IC50 of 4 OH (IC50 = 13 µM, R
2
 = 0,927), panel (b) shows the 
IC40 of PTX (IC40 = 18 µM, R
2 
= 0,93), panel (c) shows the IC 50 of 5-FU (IC50 = 
23,9 µM, R
2 
= 0,947), panel (d) shows the IC50 of Dox (IC50 = 11 µM, R
2 
= 0,95) 
and panel (e) shows the IC50 of CPT (IC50 = 0,7 µM, R
2 
= 0,94). Results are 
expressed as mean ± SD where at least n=4 experiments per group and significances 
calculated by one-way anova and P*** < 0,001, P* *< 0,01, P* < 0,05 in 
comparison to cell control without treatment. 
The IC50 obtained for AGM and Exe were higher than 1000 µM. This 
result could be explained due to the fact that both compounds are not cytotoxic 
agents but cytostatics. Therefore, the IC50 of cell survival for AGM and 
exemestan was not determined, however based on literature (Vicent et al., 2005; 
http://www.pfizer.ca/en/our_products/monograph/123 2009) the concentrations 
selected for both compounds were the concentration needed to inhibit 100 % of 
aromatase enzyme activity. For AGM the value was 0,862 µM (Vicent et al., 
2005) and for exemestane, the value was 0,033 µM (http://www.pfizer.ca/en/our 
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_products/monograph/123 2009). Moreover, 5-FU IC50 was quite high 
regarding the other IC50 values.  
As already described in the introduction chapter, the selection of the 
drug(s) to be conjugated to a polymer carrier in the design of an anticancer 
conjugate strongly depends on its potency. Therefore, chemotherapeutic drugs 
with high IC50 values could be abandoned as important amounts of the resulting 
conjugate should be administered to the patient in order to reach the adequate 
doses. Consequently, 5-FU (IC50 = 23,9 µM) was not viable for our design and 
was not considered for further studies. It is important to note that, due to the 
poor solubility of PTX only concentrations that resulted in a 40% cell death in 
the MCF7 cell line were reached being the highest PTX concentration 18 µM 
offereing results non-significantly different to 12 µM concentration which was 
here considered as IC50. The same study was performed against MDA MB 231 
cells. 
    7.2.2. Determination of IC50 value in MDA MB 231 cell. 
The same statistic analysis was done for data obtained with the drugs 
tested on MDA MB 231 cells. The concentrations used to determine IC50 values 
are described in the following table. 
Table 7.2. Concentrations tested for each compound to determine the IC50 value in 
MDA MB 231 cell line. 
 AGM Exe 4 OH PTX CPT Dox 5-FU 
a
Conc (µM) 
4000 6 20 12 4 2 240 
1300 2 13,5 6 2 1 120 
440 0,6 8 3 1 0,5 60 
140 0,2 6 1,5 0,5 0,25 30 
   0,375    
a: Concentration tested to determine the IC50. 
The resulting cell viabilily curves are shown in figure 7.4. 
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Figure 7.4. Determination of the IC50 value for each compound in MDA MB 231 
cell line. Panel (a) shows the IC50 of AGM (IC50 = 3,78 mM, R
2 
= 0,9328), panel 
(b) shows the IC50 of 5-FU ( IC50 = 425 µM, R
2 
= 0,9976); panel (c) shows the 
IC50 of PTX (IC50 = 7,6 µM, R
2 
= 0,947 ), panel (d) shows the IC 50 of (Dox IC50 
= 1,078 µM, R
2 
= 0,9394 ), panel (e) shows the IC 50 of CPT (IC50 = 2,058 µM, R
2 
= 0,9857) and panel (f) shows the IC50 of 4 OH (IC50 = 15 µM, R
2
=0,9936 ). 
Results are expressed as mean ± SD where n = 4 experiments per group and 
significances calculated was done by one-way anova and P*** < 0,001, P* *< 0,01, 
P* < 0,05. 
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In MDA MB 231 cells, an IC50 value was able to be reached for AGM 
(3738 µM) but not for Exe. However, to keep coherence within the study the 
AGM concentration used for the HTPS combination studies was the same as in 
MCF7 cells, following the same pattern chosen for the selected aromatase 
enzyme inhibitors. Finally, as in the MCF 7 cells, the 5-FU IC50 was very high 
(450 µM) and therefore this compound was not taken further. 
Table 7.3. Summary of the IC50 values obtained with selected compounds in both 
cell lines. 
 IC50 (MCF7) IC50 (MDA MB 231) 
Dox 11 µM 1,1 µM 
CPT 0,7 µM 2,1 µM 
5-FU > 20 µM 425 µM 
PTX > 18 µM* 7,6 µM 
4 OH 15 µM 15 µM 
Exe > 1000 µM > 1000 µM 
AGM > 3738 µM 3402 µM 
 
 * Concentration inducing only 40 % of cell death as the IC50 was not reached.  
7.3. Evaluation of drug combinations 
As described above, in order to identify possible synergic combinations 
(chemo ± endocrine therapy) a HTPS experiment was performed with 3 
different drug concentrations: (i) concentration inducing 70% cell death (IC70, 
Conc 1), except in the case of PTX where IC40 in MCF7 cells or IC60 in MDA 
MB 231 cells was used instead due to solubility issues, (ii) the IC50 
concentration (Conc 2) and, (iii) the concentration triggering 35% cell death 
(IC35, Conc 3). The PTX in MCF7 cells induced only 40% cell death therefore 
Conc 1 and Conc 2 induced the same cell death and Conc 3 was equivalent at 90 
% of cell survival.  
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Table 7.4. Concentration chosen for new combination in MCF 7 and MDA MB 231 
cell lines. 
 MDA MB 231 MCF7 
 Conc Cell death Conc Cell death 
Dox 1 (IC70) 2 µM 70 % 22 µM 75 % 
Dox 2 (IC50) 1 µM 50 % 11 µM 50 % 
Dox 3 (IC35) 0,5 µM 35 % 2,2 µM 25 % 
CPT 1 (IC70) 4 µM 70 % 5 µM 70 % 
CPT 2 (IC50) 2 µM 50 % 0,7 µM 50 % 
CPT 3 (IC35) 0,5 µM 33 % 0,05 µM 30 % 
PTX 1 (IC60) 12 µM 60 % 18 µM 40 % 
PTX 2 (IC50) 7,6 µM 50 % 12 µM 40 % 
PTX 3 (IC35) 0,7 µM 35 % 2,4 µM 15 % 
AGM 1  4,3 µM 0 % 4,3 µM 0 % 
AGM 2 0,86 µM 0 % 0,862 µM 0 % 
AGM 3 0,172 µM 0 % 0,172 µM 0 % 
Exe 1 0,164 µM 0 % 0,164 µM 0 % 
Exe 2 0,033 µM 0 % 0,033 µM 0 % 
Exe 3 0,006 µM 0 % 0,006 µM 0 % 
4 OH 1 (IC70) 20 µM 70 % 18 µM 90 % 
4 OH 2 (IC50) 15 µM 50 % 15 µM 50 % 
4 OH 3 (IC25) 8 µM 25 % 10 µM 20 % 
    7.3.1. Evaluation of new combinations in MCF7 cell line. 
For each chemotherapeutic agent concentration, the combination with the three 
endocrine agents at all concentrations was evaluated. The aim was to find new 
synergisms, drug combinations capable of enhancing the antitumour activity if 
compared with the parent single drugs. 
Surprisingly, in both cell lines, only the combination of a chemotherapeutic 
agent with 4 OH showed synergism. A careful statistic analysis was carried out 
to evaluate if the differences observed in cell viability with the designed 
combination in comparison to the single drug were significant. The level of 
statistical significance was determined by analysis of variance (ANOVA) 
followed by Dunnett’s t-test for multiple comparisons. P*** < 0,001, P** < 
0,01, P* <0,05, ns non-significative.  
 205 
 
 
C
PT
1
4 
O
H
1
4 
O
H
2
4 
O
H
3
C
PT
1 
+ 
4 
O
H
1
C
PT
1 
+ 
4 
O
H
2
C
PT
1 
+ 
4 
O
H
3
0
20
40
60
80
100
120
***
ns vs T1
***
*** vs T2
*
*** vs T3
Conc ( µM )
C
el
l v
ia
bi
lit
y 
( 
%
 )
 
CP
T2
4 
O
H
1
4 
O
H
2
4 
O
H
3
CP
T2
 +
 4
 O
H
 1
CP
T2
 +
 4
 O
H
 2
CP
T2
 +
 4
 O
H
 3
0
20
40
60
80
100
120
***
ns vs T1
***
** vs T2
ns
Conc ( µM )
C
el
l v
ia
bi
lit
y 
( 
%
 )
 
 
CP
T3
4 
O
H
1
4 
O
H
2
4 
O
H
3
CP
T3
 +
 4
 O
H
1
CP
T3
 +
 4
 O
H
2
CP
T3
 +
 4
 O
H
3
0
20
40
60
80
100
120
***
***
ns
Conc ( µM )
C
el
l v
ia
bi
lit
y 
( 
%
 )
 
Figure 7.5. Evaluation of the combination formed by CPT with 4 OH in MCF 7 cell 
line. CPT1 = 5 µM, CPT2 = 0,7 µM and CPT3 = 0,05 µM. 4 OH1 = 18 µM, 4 OH2 
= 13 µM and 4 OH3 = 10 µM. Panel (a) shows the effect of CPT1 and 4 OH1, 4 
OH2 and 4 OH3 on cell viability alone and in combination. Panel (b) shows the 
effect of CPT2 with 4 OH1, 4 OH2 and 4 OH3 on cell viability alone and in 
combination. Panel (c) shows the effect of CPT3 with 4 OH1, 4 OH2 and 4 OH3 on 
(c) 
(b) 
(a) 
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cell viability alone and in combination. Results are expressed as mean ± SD where n 
= 3 experiments per group and significances calculated by one-way ANOVA, P*** 
< 0,001, P* < 0,05. 
As it can be seen in figure 7.10., the first star represented the significance of the 
combination compared to the single chemotherapeutic agent. And the second 
level of stars represented the significance of the combination vs. 4 OH. For 
example, in figure 7.5.a., the cytotoxicity induced with the combination CPT1 + 
4 OH1 in comparison with CPT1 was significant (P***). However, the 
combination CPT1 + 4 OH1 in comparison with 4 OH1 alone was not 
significant (ns). Following our criteria, this combination was considered not 
synergistic as significant differences should be obtained with both single drugs.  
Whereas the cell viability obtained for all 4 OH concentrations was in good 
agreement with our previous results (IC50 determination), the values obtained 
for CPT differed from those expected. Unfortunately, a possible experimental 
error could take place here but we decided to move forward with IC40 as CPT1, 
IC60 as CPT2 and IC50 as CPT3 instead of IC70, IC50 and IC35 and in any 
case explore possible synergisms.  Taking these modifications into account, the 
combinations inducing a greater cell death were: (i) CPT1 (5 µM) + 4 OH2 (13 
µM) (*** / ***) with 40% cell viability and (ii) CPT2 (0,7 µM) + 4 OH2 (13 
µM) (* / ***) with a resulting 50% cell viability. In both cases the cell survival 
achieved with the combination was significantly lower than that with the single 
treatments however, CPT1 + 4 OH2 showed the best significance and therefore 
selected as possible drug combination for future conjugations.  
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Figure 7.6. Evaluation of the combination Dox with 4 OH in MCF7 cell line. Panel 
(a) shows the effect of the combination of Dox at Dox1 = 22 µM with different 
concentrations of 4 OH, 4 OH1 = 18 µM, 4 OH2 = 13 µM and 4 OH3 = 10 µM. 
Panel (b) shows the effect of the combination of Dox at Dox2 = 11 µM with 
different concentrations of 4 OH, 4 OH1 = 18 µM, 4 OH2 = 13 µM and 4 OH3 = 10 
µM. Panel (c) shows the effect of the combination of Dox at Dox3 = 2,2 µM with 
(c) 
(b) 
(a) 
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different concentrations of 4-OH, 4 OH1 = 18 µM, 4 OH2 = 13 µM and 4 OH3 =10 
µM. Results are expressed as mean ± SD where n = 3 experiments per group and 
significances calculated by one-way ANOVA and ns: non significant, P*** < 0,001, 
P* < 0,05. 
As it can be seen in figure 7.6. several Dox + 4 OH combinations showed 
possible synergisms.  These are summarised in Table 7.5.  
Table 7.5. Possible synergistic combinations for Dox and 4 OH obtained after data 
mathematical treatment.  
Combination Cell viability (%) 
Dox1 + 4 OH1 10%   (***/***) 
Dox1 + 4 OH2 12%  (***/***) 
Dox2 + 4 OH2 30%  (***/***) 
Dox3 + 4 OH2 35%  (***/***) 
Dox3 + 4 OH3 50%   (***/***) 
 
Although all 5 combinations showed in Table 7.5. demonstrated similar 
significances, looking at possible combination conjugates as clinical candidates 
and to prevent side toxicities due to the use of high Dox doses our selected 
combinations in this case were Dox3 (2,2 µM) + 4 OH2 (13 µM) and Dox2 (11 
µM) + 4 OH2 (13 µM). 
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Figure 7.7. Evaluation of the combination of PTX with 4 OH in MCF7 cell line. 
Panel (a) shows the effect of the combination of PTX at PTX1 = 18 µM with 
different concentrations of 4 OH, 4 OH1 = 18µM, 4 OH2 = 13µM and 4 OH3 = 
10µM. Panel (b) shows the effect of the combination of PTX at PTX2 = 12 µM with 
different concentrations of 4 OH, 4 OH1 = 18 µM, 4 OH2 = 13 µM and 4 OH3 = 10 
µM. Panel (c) shows the effect of the combination of PTX at PTX3 = 2,4 µM with 
different concentrations of 4 OH, 4 OH1 = 18 µM, 4 OH2 = 13 µM and 4 OH 3 = 10 
µM. Results are expressed as mean ± SD where n = 3 experiments per group and 
significances calculated by one-way ANOVA and ns: non significant, P*** < 0,001, 
P* < 0,05. 
PTX was the chemotherapeutic agent showing better results upon combination 
with 4 OH in MCF7 cells. As mentioned aboved it was not able to achieve PTX 
IC50 value due to solubility issues, however with the presence of even the 
smallest concentration of 4 OH its cytotoxic potential was significantly 
enhanced. The best possible combinations after mathematical treatment are 
shown in Table 7.6. 
(b) 
(c) 
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Table 7.6. Possible synergistic combinations for paclitaxel and 4-OH-Tamoxifen. 
Combination Cell viability (%) 
PTX1 + 4 OH1 10%  (**/***) 
PTX1 + 4 OH2 20%  (***/***) 
PTX2 + 4 OH1 10%  (**/***) 
PTX2 + 4 OH2 25%  (***/***) 
PTX3 + 4 OH2 45%  (**/***) 
 
The combinations with the highest PTX concentration, PTX1 (18 µM), were 
very efficient but even with PTX2 (12 µM) similar results could be achieved 
being more beneficial as lower PTX doses would be required for the same 
therapeutic output. The combination PTX3 (2,4 µM) + 4 OH2 (13 µM) induced 
45% cell viability with a really low PTX concentration.  
Summarising, in MCF7 cells the best drug combinations encountered and 
therefore selected for future polymer conjugate design were: CPT1 (5 µM) + 4 
OH2 (13 µM) (*** / ***), CPT2 (0,7 µM) + 4 OH2 (13 µM), Dox3 (2,2 µM) + 
4 OH2 (13 µM) (*** / ***), PTX2 (12 µM) + 4 OH1 (18 µM) and PTX3 (2,4 
µM) + 4 OH2 (13 µM) and PTX2 + 4 OH2 (*** / ***). 
    7.3.2. Evaluation of new combinations in MDA MB 231 cell line. 
As seen for MCF7 cells, in the case of MDA MB 231 cell line only 
combinations of chemotherapeutics with 4-OH showed synergisms if compared 
with the parent single compounds. Therefore only the results obtained with 4 
OH are shown here. 
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Figure 7.8. Evaluation of the combination PTX with 4 OH in MDA MB 231 cell 
line. Panel (a) shows the effect of the combination of PTX at PTX1 = 12 µM with 
different concentrations of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH3 = 8 
µM. Panel (b) shows the effect of the combination of PTX at PTX2 = 7,6 µM with 
(c) 
(a) 
(b) 
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different concentrations of 4 OH, 4 OH1 = 20 µM, T4 OH2 = 15 µM and 4 OH3 = 8 
µM. Panel (c) shows the effect of the combination of PTX at PTX3 = 0,7 µM with 
different concentrations of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH3 =8 
µM. Results are expressed as mean ± SD where n = 3 experiments per group and 
significances calculated by one-way ANOVA and ns: non significant, P*** < 0,001, 
P* < 0,05. 
Data obtained with single drugs was in good agreement with our previous data. 
In this case the selected combinations are shown in Table 7.7.  
Table 7.7. Possible combinations for paclitaxel and 4-OH-Tamoxifen after 
mathematical treatment in MDA MB 231 cell line. 
Combination Cell viability ( % ) 
PTX1 + 4 OH1 10% (***/**) 
PTX1 + 4 OH2 20% (***/**) 
PTX1 + 4 OH3 50% (**/***) 
PTX2 + 4 OH1 10% (***/*) 
PTX2 + 4 OH2 20% (***/**) 
PTX2 + 4 OH3 50% (*/***) 
PTX3 + 4 OH1 15% (***/**) 
 
Summarising, the best choice was found to be the combination PTX 2 (7,6 µM) 
+ 4 OH 2 (15 µM) showing a 80% cell death in comparison with the parent 
single drugs with only a 50%. An even better combination could be PTX3 (0,7 
µM) + 4 OH1 (20 µM) with the induction of a 85% cell death with a low PTX 
concentration. 
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Figure 7.9. Evaluation of the combination CPT with 4 OH in MDA MB 231 cell 
line. Panel (a) shows the effect of the combination of CPT at CPT1 = 4 µM with 
different concentrations of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH3 = 8 
µM. Panel (b) shows the effect of the combination of CPT at CPT2 = 2 µM with 
different concentrations of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH3 = 8 
µM. Panel (c) shows the effect of the combination of CPT at CPT3 = 0,5 µM with 
different concentrations of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH3 =8 
µM. Results are expressed as mean ± SD where n = 3 experiments per group and 
significances calculated by one-way ANOVA and ns: non significant, P*** < 0,001, 
P* < 0,05. 
With camptothecin, the only combination which showed a significant synergistic 
effect was CPT1 (4 µM) + 4 OH1 (20 µM) (*** / *). Nevertheless, the result 
was obtained with the highest concentration of both drugs, and comparing with 
(c) 
(b) 
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the effect obtained from 4 OH1 alone the difference was not so significant. 
Therefore, CPT1 + 4 OH1 was not selected.  
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Figure 7.10. Evaluation of the combination of Dox with 4 OH in MDA MB 231 cell 
line. Panel (a) shows the effect of the combination of Dox at Dox1 = 2 µM with 
different concentrations of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH3 = 8 
µM. Panel (b) shows the effect of the combination of Dox at Dox2 = 1 µM with 
different concentrations  of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH3 = 8 
µM. Panel (c) shows the effect of the combination of Dox at Dox3 = 0,5 µM with 
different concentrations of 4 OH, 4 OH1 = 20 µM, 4 OH2 = 15 µM and 4 OH 3 = 8 
µM. Results are expressed as mean ± SD where n = 3 experiments per group and 
significances calculated by one-way ANOVA and ns: non significant, P*** < 0,001, 
P* < 0,05. 
 
The combination of Dox and 4 OH did not give any benefit if compared 
with the single drugs in MDA MB 231. This cell line seems to be highly 
responsive to Dox being this the possible explanation (Dox1 and Dox2 ).  
To conclude, in MDA MB 231 cells we were not able to identify any 
outstanding combination with AGM or Exe due to the absence of aromatase 
enzyme in this cell line, the small concentration used (reported concentration 
needed to inhibit the aromatase enzyme) and their non cytotoxic behaviour 
against MDA MB 231 cells. Unexpectedly, 4 OH was cytotoxic against MDA 
MB 231 cells (ER-) and more importantly, in combination with PTX cytotoxic 
synergism was observed. The best combination achieved and selected for future 
polymer conjugation were PTX2 (7,6 µM) + 4 OH2 (15 µM) (*** / **) and 
PTX3 (0,7 µM) + 4 OH1 (20 µM) (*** / **).  
7.4. Discussion 
In order to find new drug combinations for the future design of PGA-
based combination conjugates, an HTPS experiment including four different 
chemotherapeutics and three different endocrine agents was performed in two 
different cell lines MCF7 (ER +) and MDA MB 231 (ER-). The 
chemotherapeutics chosen were Dox, PTX, CPT and 5-FU and as endocrine 
agents AGM, Exe and 4 OH were selected. Firstly, the IC 50 value for each drug 
was determined. Exe and AGM were cytostatic compounds, therefore, their 
IC50s were not reach (> 1000 µM for Exe and > 3738 µM for AGM). In this 
case, the concentration chosen for further experiments was that reported in 
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literature as the one required to achieve the inhibition of 100% of the aromatase 
enzyme activity, 0,862 µM for AGM and 0,033 µM for Exe. Within the 
chemotherapeutics, 5-FU showed a high IC50 and therefore discharged for 
further studies. Due to solubility issues the IC50 for PTX was not reached and 
the maximum concentration used for the combination studies was that only 
triggering 40% cell death in MCF7 cells. Once the IC50 values were identified, 
three different concentrations for each drug were chosen to proceed with the 
combination studies (IC70, IC50 and IC35; concentrations showing a 70%, 50% 
and 35% cell death, respectively). Each selected concentration of the 
chemotherapeutic agent was combined with all concentrations of the endocrine 
agent and the effect on cell death was studied. In all cases, only combinations 
with the ER blocker 4 OH showed significant cytotoxicities if compared with 
the parent single drugs. This was expected as for the ER+ character of MCF7 
cells. Even if MCF7 possess a basal expression of aromatase enzyme (Greco et 
al., 2007), this is not sufficient to observe AI effects as it could be in the 
transfected MCF7 Ca cell line (these studies are ongoing). Surprisingly, in the 
ER- MDA MB 231 cell line a cytotoxic behaviour for 4 OH was also observed. 
In the ATCC web site (http://www.atcc.org), the MDA MB 231 cell line is 
described as ER-, epidermal growth factor receptor (EGFR) positive and 
transforming growth factor alpha (TGF- α) receptor positive. Taking into 
account the bibliography on ER negative breast cancer cell lines, the 4 OH could 
be involved in other pathways apart from ER and also the cross-talk between 
EGFR and ER (Nicholson and Gee, 2000) could play a role here. It has been 
already described that 4 OH is capable to inhibit cell proliferation via up-
regulation of growth factor (TGF- β) and (TGF- α) involved in growth inhibition 
(Butta et al., 1992; MacGregor Schafer et al., 2001) and down-regulation of the 
potent mitogen IGF II which promoted cell proliferation (Seeger et al., 2003). 4 
OH also induced apoptosis by inhibiting kinase C protein involved in oncogene 
transcription and by binding calmodium, a calcium binding protein involved in 
several physiological processes such as inflammation or apoptosis (Gelmann, 
1996). All these reported results could explained our data of 4 OH in MDA MB 
231 cells. 
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The best identified anticancer combinations in MCF 7 cell line were (i) CPT1 
(5µM) + 4 OH2 (13 µM) with a 70 % cell death, (ii) CPT 2 (0,7 µM) + 4 OH2 
(13 µM) with a 50 % cell death, (iii) PTX 2 (12 µM) + 4 OH 1 (18 µM) with a 
90% cell death, (iv) PTX 3 (2,4 µM) + 4 OH 3 (10 µM) with a 30 % cell death, 
and (v) Dox 3 (2,2 µM) + 4 OH 2 (13 µM) with a 35 % cell death. Looking at 
possible risk-benefit ratios, those combinations involving lower 
chemotherapeutic concentration could offer benefits in front of the others. So, 
trying to choose the best of all of them we considered CPT2 + 4 OH2, PTX3 + 4 
OH3 and Dox3 + 4 OH2 due to the high cell death percentage achieved with a 
low chemotherapeutic agent concentration. Another really efficient combination 
was PTX2 + 4 OH1 with a 90% cell death using only PTX IC60 concentration. 
Therefore, our first choice for PGA-based combination conjugate design would 
be PTX2 + 4 OH1 in a ratio 1:1,3. This combination was ratified in MDA MB 
231 cells. 
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8.1. Discussion. 
Statistics recently reported (www.cancerresearchuk.org/cancer-
info/cancerstats/reports/about-cancerstat-reports) state that the number of people 
who will get cancer during their lifetime will increase to nearly half the 
population by 2020, mostly due to the ageing population. Breast cancer is one of 
the most common cancers in women and although more patients are now 
surviving this disease compared to 20 years ago, in advanced stages (III and IV) 
the 5-year survival rate achieved is still really low (≈20%). Therefore, more 
efficient therapeutic approaches are still needed and we believe nanomedicine 
and in particular polymer therapeutics could offer significant clinical benefits. 
Different types of breast cancer have been described (Luminal A, B, HER2 + 
and the triple negative); however this study was focused on hormone dependent 
breast cancer (Luminal A and B) as it is one of the most common.  
Due to the molecular complexity of cancer combination approaches are 
required. The discovery of new molecular targets and the subsequent 
development of novel anticancer agents are opening new possibilities for drug 
combination therapy as anticancer treatment. Polymer–drug conjugates are well 
established for the delivery of a single therapeutic agent, but only in very recent 
years their use has been extended to the delivery of multi-agent therapy. The use 
of polymer-drug conjugates in combination therapy represents an important 
opportunity to enhance tumour response rates. These early studies revealed the 
therapeutic potential of this application but raised new challenges (namely, drug 
loading and drug ratio, characterisation, and development of suitable carriers) 
that need to be addressed for a successful optimisation of the system (Greco and 
Vicent, 2009). 
The first polymer drug combination conjugate HPMA copolymer-
AGM-Dox was described by Dr Vicent et al, showing higher cytotoxic effects in 
breast cancer cells than the parent HPMA copolymer-Dox conjugate, thus 
confirming the necessity to move from single drug to combination therapy 
(Vicent et al., 2005; Greco et al., 2005; Greco et al., 2007). In a first stage of this 
project and in order to confirm the synergistic effect of HPMA copolymer-
AGM-Dox on cell viability inhibition observed in cell models, two in vivo 
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orthotopic breast cancer models were stablished, fully characterised (regarding 
vasculature, growth rate and histological parameters) and used to achieve in vivo 
proof of concept for anticancer synergism with combination conjugates. This 
approach would also help us to elucidate those mechanisms responsible for drug 
synergism and consequently, it would help in the design of novel generation of 
polymer-based combination conjugates. 
Two different breast cancer animal models were stablished in order to 
carry out these studies, both of them orthotopic but with very different 
behaviour in order to represent better clinical situations: (i) a post menopausal 
human MCF7 Ca cells induced model (Yue et al., 1994; Brodie et al., 2007) and 
(ii) an aggressive metastatic murine 4T1 model (Aslakon and Miller, 1992; 
Yang et al., 2004; Tao et al., 2008). The transfected MCF7 Ca human tumour 
cell line induced slow and heterogeneous growing tumours in ovarectomised 
nude mice treated daily with hormone-replacement therapy to mimic 
postmenopausal patient situation. The evaluation of single drug conjugate 
HPMA copolymer-Dox, combination drug conjugate HPMA copolymer-AGM-
Dox and free Dox in this model, demonstrated greater efficiency in comparison 
to free Dox regarding tumor growth inhibition and toxicological profiling. 
However, no differences between both cojugates were observed. With the 4T1 
model, the idea was to reproduce breast tumours at advanced stages in a fully 
immunocompetent environment. 4T1 in vivo tumour model has been described 
to metastasize in lung, bone, liver and brain as occurs in human breast cancer 
patients (Tao et al., 2008; Gao et al., 2011). In this fast growing aggressive 
model a significant difference on tumour growth was obtained with both 
conjugates in comparison to control and free Dox. Furthermore, tumour growth 
inhibition achieved by both conjugates was statistically analysed, and HPMA 
copolymer-AGM-Dox combination conjugate proved to be more efficient 
reducing tumour growth than HPMA copolymer-Dox conjugate. These results 
confirm in vitro data and importantly, allowed to achieve in vivo proof of 
concept for antitumour synergism with polymer-drug combination conjugates. 
Conjugate whole body biodistribution and half-life were also studied together 
with compound toxicological profile. Both conjugates showed greater tumour 
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accumulation than the free Dox, being the drug better retained in the tumour 
with the combination conjugate maybe due to a slightly greater half-life. 
Important heart accumulation observed by free Dox was completely diminished 
upon conjugation in good agreement with data already reported (Vassey et al., 
1994) and clearly explaining the better toxicological profile obtained with the 
conjugates.  
 Once in vivo proof was achieved, the molecular mechanisms responsible for the 
observed antitumour synergim were also studied trying to better understand the 
parameters that would help us in the future design of polymer-based 
combination conjugates. This was performed looking at key protein expression 
in 4T1 tumour tissues with and without treatments at 2 different time points; end 
of the experiment (16 days) and at 48 h after the last treatment injection (8 days) 
trying to correlate with data in cell models. It is important to point out that 
pharmacokinetics play a major role in this complex process, not only at the 
whole organism level (EPR effect) but also at cellular level (uptake and drug 
release kinetics). When comparing free drug with polymer conjugates and also 
cell data with in vivo data we have to be aware that it is not easy to select all 
time points for study and to draw final conclusion. In any case, we believe the 
results obtained here under the parameters considered represent some of the key 
mechanisms responsible for the antitumour activity differences observed. 
First, cell death signalling pathways were explored. At short-term both 
conjugates and free Dox seems to induce tumour cell death by a mix mechanism 
using both apoptosis and autophagy. However, at long-term autophagy is the 
main mechanism involved in cell death when animals are treated with the 
combination conjugate HPMA-copolymer-AGM-Dox in contrast to HPMA 
copolymer-Dox conjugate where apotosis plays a major role. A difference was 
also obtained when looking at proteins involved in the angiogenic and 
proliferative pathways. HPMA-copolymer-AGM-Dox induced from early stage 
an inhibition of VEGF protein expression as a result of two main phenomena: (i) 
the oestrogen reduction induced by AGM due to the relation between oestrogen 
levels and VEGF expression (Kazi and Koos, 2007; Koos, 2010; Koos, 2011) 
and, (ii) the inhibition on p-Akt protein expression and consequently the down 
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regulation of p-Akt target genes including VEGF protein expression (Pore et al., 
2004; Pore et al., 2006). At long-term, VEGF inhibition was observed for all 
compounds studied (conjugates and free Dox). Importantly, preliminary results 
looking at iNOS protein expression seemed to indicate that HPMA copolymer-
AGM-Dox combination conjugate is also involved in cell migration and 
dissemination in a greater manner than the single HPMA copolymer-Dox 
conjugate or free Dox. Consequently, the greater antitumour effect observed 
with the HPMA copolymer-AGM-Dox combination conjugate in comparison to 
the single HPMA copolymer-Dox conjugate, could be justified on one side by 
the different Dox tumour accumulation observed for the combination conjugate 
that could induce a faster and longer-lasting antitumour effect. On the other 
hand, looking at the molecular mechanisms involved, the combination conjugate 
showed a stronger inhibition on the proliferative-metastatic processes modulated 
by angiogenesis (Kazi and Koos, 2007; Koos, 2010; Koss, 2011) and this effect 
was complemented by a major role of autophagy vs. apoptosis. These features 
could clearly enhance its antitumour efficiency in comparison with the single 
conjugate. More mechanistics studies are ongoing trying to corroborate these 
statements and to better understand this complex process. 
Despite the good results achieved with the model combination conjugate HPMA 
copolymer-AGM-Dox, some limitations need also to be considered. 
Biopersistent carriers, such as PEG or HPMA copolymers, present 
disadvantages if chronic parenteral administration and/or high doses are 
required. Preclinical evidence of intracellular vacuolation with certain PEG-
protein conjugates (Knop et al.,2010) is raising awareness of the potential 
advantage of biodegradable polymers regarding safety benefit apart from the 
possibility to use higher molecular weight carriers allowing PK optimisation 
(Barz et al., 2011). Taking this into account and aiming to move a step further 
with our polymer-based combination strategy, we substituted the non-
biodegradable HPMA copolymer by the multivalent, biodegradable poly-L-
glutamic acid (PGA) as carrier. Due to its intrinsic characteristics, PGA presents 
a more favourable pharmacological profile as already demonstrated in the clinics 
with Opaxio
TM 
(PGA-Paclitaxel conjugate, Cell Therapeutics Inc.) in phase III 
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clinical trial and recently designated as orphan drug in combination with 
radiotherapy for glioblastoma (Singer et al., 2003; Oldham et al., 2006; 
http://www.celltherapeutics.com/pdf/OPAXIO_facts-4pg.pdf.2008).  
In Chapter 6, the synthesis, characterisation and biological evaluation of a 
family of PGA-AGM-Dox derivatives have been described including three 
different subfamilies: PGA-X-AGM, PGA-Y-Dox and PGA-X-AGM-Y-Dox. 
After their structural evaluation and cell viability inhibition analysis against 
MCF7 Ca and 4T1 cell lines, two combination candidates ratify the synergism 
of AGM + Dox cocktail and as in the case of HPMA copolymer-AGM-Dox 
conjugate, they also demonstrated the importance of conjugate solution 
conformation and, consequently, of the drug release kinetics. The selected 
candidates were PGA-G-AGM-Dox and PGA-GG-AGM-Dox, with IC50 values 
of 0,0038 and 0,0042 mg/mL Dox equivalent, respectively against MCF7 Ca 
cells and CI values of 0,21 and 0,22, respectively. Then, PGA-G-AGM-Dox 
combination conjugate was evaluated in vivo to explore its antitumor activity 
versus PGA-Dox single conjugate using the same protocol followed for HPMA 
copolymer-AGM-Dox in the 4T1 mice tumour model. Due to the slower drug 
release kinetics of the PGA-G-AGM-Dox in comparison to the HPMA 
copolymer-AGM-Dox conjugate none significant differences on tumour volume 
were observed with all treatments compared to the control group up to day 10, 
except for PGA-G-AGM+PGA-Dox group, which showed an early significant 
down-regulation of tumour volume. However, after day 10, an interesting 
antitumor effect was observed with PGA-G-AGM-Dox presenting significantly 
better activity than PGA-G-AGM+PGA-Dox group, and consequently than the 
other treatments.The differences observed could be explained by a faster and 
greater AGM release from PGA-G-AGM in comparison to PGA-G-AGM-Dox. 
Indeed separately AGM release achieved 60% after 5 h when in the combination 
conjugate only 15% AGM was achieved at the same time. It has been already 
reported that AGM molecular mechanism is directly related with angiogenesis 
modulation in tumours (Kazi and Koos, 2007; Koos, 2010; Koss, 2011), this 
could easily justify the better performance at early stages of the PGA-G-AGM + 
PGA-Dox combination. However, the presence of both drugs in the same cell 
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could be only secured by means of PGA-G-AGM-Dox combination conjugate 
and this is the reason of its enhanced long-term antitumour activity. In order to 
improve the results obtained so far it is clear that a faster and greater AGM 
release combination conjugate should be designed. Ongoing experiments are 
directed towards this aim. 
Once a clinical relevant platform was designed, as a final approach towards 
more efficient conjugates, novel drug combinations were evaluated to replace 
AGM-Dox. Our aim here was to find new drug combinations with antitumour 
synergistic potential that could allow the design of advanced PGA-based 
combination conjugates. To reach this goal in a systematic but efficient manner, 
a high throughput screening (HTPS) approach was implemented using 4 
chemotherapeutic drugs (Dox, PTX, CPT and 5-FU) and 3 endocrine therapy 
agents (AGM as control, 4 OH and Exe), which were selected from the current 
clinical treatments for advanced breast cancer. In vitro evaluation was 
performed in two cell lines MCF7 (ER+) and MDA MB 231 (ER-). In MCF7, 
the better combination were PTX (2,4 µM) and 4 OH (10 µM) inducing 70% 
cell death, Dox (2,2 µM) and 4 OH (13 µM) with a 65% cell death. Another 
really efficient combination was the PTX (12 µM) and 4 OH (18 µM), which 
triggered a 90% cell death only with the IC60 PTX concentration. Those drug 
combinations in the adequate ratio (i.e. PTX + 4 OH, 1 : 1,5) are currently being 
the based of novel PGA-based combination conjugates. 
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9.1. Conclusions. 
 
- Two breast cancer in vivo mice models from MCF7 Ca human cell line 
and 4T1 murine cell line were established, optimised and fully 
characterised.  
- In vivo proof of concept for synergism was achieved with HPMA 
copolymer-AGM-Dox conjugate, showing significant differences in 
tumour growth inhibition if compared with free Dox, the single 
conjugate (HPMA copolymer-Dox) or the combination of single 
conjugates (HPMA copolymer-AGM + HPMA copolymer-Dox). 
Important tumor recurrence in the first 5 days of treatment was also 
achieved for the combination conjugate in comparison to Dox in the 
MCF7 Ca model.  
- Differences in the molecular mechanisms responsible for antitumour 
activity were observed for HPMA copolymer-AGM-Dox conjugate if 
compared with HPMA copolymer-Dox conjugate. Two days after the 
last injection, HPMA copolymer-AGM-Dox triggered a significant 
inhibition of proteins involved in angiogenesis pathways (VEGF) in 
comparison to HPMA copolymer-Dox and Control and therefore 
triggered the tumour inhibition growth before than the HPMA 
copolymer-Dox. This was complemented with a different cell death 
mechanism (autophagy vs. apoptosis) at long-term treatment. 
- A more clinically relevant combination platform has been achieved 
based on the use of PGA as carrier. Three families PGA-X-AGM, PGA-
Y-Dox and PGA-X-AGM-Y-Dox conjugates were successfully 
synthesised, fully characterised and evaluated in cell culture.  
- A direct relation between solution conformation and in vitro activity 
was demonstrated for the PGA-based combination conjugates. 
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- The best candidate, PGA-(G-AGM)5mol%-(Dox)5mol%, was selected for in 
vivo evaluation and showed a significant inhibition on tumour growth in 
4T1 mouse model 10 days after the first injection when compared to the 
other groups. 
- New drug candidates were evaluated by means of a cell-based HTPS 
experiment in order to identify novel synergistic drug combinations. 
The best combination found was PTX + 4 OH in a ratio of 1,15 : 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 231 
 
 
 
 
 
 
 
 
 
 
Annexe I. Objectives, Methodology and Conclusions of the Project 
in Spanish. 
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1. Objetivos de la Investigación. 
Los conjugados poliméricos son nanoconstrucciones multicomponente presentes 
actualmente en clínica como terapia anticancerígena, tanto como agentes únicos, 
como formando parte de combinaciones. Estos nanoconjugados tienen el 
potencial de mejorar farmacológicamente el tratamiento de tumores sólidos, 
debido a una acumulación pasiva en el tumor (efecto ‘EPR’) y a un diferente 
mecanismo de internalización celular y posterior liberación del fármaco(s). La 
transferencia de conjugados polímero-proteína a uso clínico rutinario, y el 
desarrollo clínico de conjugados polímero-fármaco anticancerígeno sitúa a los 
conjugados poliméricos como una de las primeras clases de nanomedicinas con 
potencial terapéutico antitumoral ya demostrado. La experiencia obtenida con 
los primeros nanoconjugados en clínica, ha proporcionado las bases para el 
desarrollo de polímeros conjugados más sofisticados de segunda generación con 
propiedades terapéuticas mejoradas. El desarrollo de nuevos portadores 
poliméricos biodegradables con propiedades mejoradas, la utilización de terapia 
de combinación o el diseño de conjugados dirigidos a nuevas dianas moleculares 
son algunas de las aproximaciones a seguir para conseguir conjugados más 
específicos y efectivos considerados de segunda generación. La propiedad de 
multivalencia que poseen los polímeros nos permite la conjugación de varios 
compuestos activos en el mismo esqueleto polimérico, la combinación del 
modulador activo con un citotóxico, otra sustancia activa o un residuo dirigente 
puede aumentar marcadamente el valor terapéutico de estas macromoléculas. En 
este sentido, el punto de partida de la presente propuesta es un nuevo concepto 
establecido por nosotros en 2005 con el desarrollo de HPMA copolimero-AGM-
Dox, basado en la terapia de combinación (terapia endocrina + quimioterapia 
dentro de la misma matriz polimérica) para el tratamiento de cáncer de mama 
hormono-dependiente (Vicente et al., 2005). El valor terapéutico de esta nueva 
estrategia ha sido previamente demostrado en modelos celulares, lo que 
implicaría una clara aplicación potencial en el tratamiento de tumores hormono-
dependientes en mujeres postmenopáusicas. 
En el presente proyecto, se plantea corroborar la actividad antitumoral del 
nanoconjugado de combinación HPMA copolimero-AGM-Dox utilizando 
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modelos in vivo, así como elucidar las bases moleculares responsables de su 
destacada actividad anticancerígena. La comprensión del mecanismo de acción 
molecular nos permitirá el diseño futuro de nanoconjugados de combinación con 
propiedades mejoradas. En una segunda etapa se propone mejorar el valor 
terapéutico de esta nueva terapia de combinación mediante la utilización de un 
polímero biodegradable como portador, ácido poli-L-glutámico (PGA), 
desarrollando un nuevo conjugado de combinación PGA-AGM-Dox y 
evaluando su actividad antitumoral en modelos in vitro e in vivo. La etapa final 
de la presente tesis doctoral consiste en el desarrollo de un cribado 
farmacológico utilizando 5 quimio agentes y 3 agentes de terapia hormonal para 
evaluar su actividad citotóxica en las líneas celulares de cáncer de mama con el 
objetivo de seleccionar una combinación sinérgica de fármacos con mayor 
potencial citotóxico que AGM-DOX, que sirva de base para el desarrollo de 
futuras terapias de combinación. 
 
    1.1. Antecedentes.  
Para comprobar la hipótesis de partida se desarrolló un conjugado modelo 
HPMA copolímero-AGM-Dox que transporta una combinación de terapia 
endocrina (inhibidor de aromatasa (AGM) y quimioterapia (Dox) para el 
tratamiento de cáncer de mama (figura 1.) (Greco, et al., 2005; Vicent et al., 
2005; Greco et al., 2006). Su diseño se basó en dos observaciones 
principalmente: (i) el copolímero HPMA copolímero-Dox (PK1, FCE28068) es 
un conjugado en fase clínica II con demostrada actividad en pacientes con 
tumores de mama quimioresistentes (Vasey et al., 1999) y (ii) los inhibidores de 
aromatasa pueden actuar de forma sinergíca con quimioterapia (Johnston and 
Dowsett, 2003). La elección de AGM (inhibidor de aromatasa de primera 
generación) se debió principalmente a que presenta una funcionalización 
adecuada para ser conjugado al polímero y está disponible comercialmente, por 
tanto, AGM fue considerado como el fármaco adecuado en esta primera fase de 
prueba de concepto (Goss and Strasser, 2001; Pool and Paridaens, 2007). 
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Figura 1. Estructura del conjugado de combinación HPMA copolímero-AGM-Dox. 
El conjugado de combinación (HPMA copolímero-AGM-Dox) mostró un 
aumento muy marcado de citotoxicidad frente a modelos celulares de cáncer de 
mama positivos en receptores de estrógenos (ER+) (MCF7 y MCF7 Ca 
(transfectada de forma estable con el gen humano aromatasa (Yue et al., 1994)) 
en comparación a la actividad citotóxica obtenida con los conjugados 
individuales por separado (HPMA copolímero-Dox) o una mezcla simple de 
ambos (HPMA copolímero-Dox + HPMA copolímero-AGM) (Figura 2). 
Además, experimentos llevados a cabo con una familia de conjugados 
sintetizados que contienen AGM (los primeros conjugados con terapia endocrina 
descritos), confirmaron que era necesaria la liberación de AGM para conseguir 
la inhibición del enzima aromatasa (Greco et al., 2005; Greco et al., 2007). 
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Figura 2. Comparación de la actividad citotoxica de HPMA copolímero-AGM-Dox 
y mezcla de conjugados simples en células MCF7 (Panel a) y en células MCF7 Ca 
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(panel b).  Dox;  HPMA copolímero-AGM-Dox;  HPMA copolímero-
Dox + HPMA copolímero-AGM; HPMA copolímero-Dox. 
En una segunda fase se evaluó el mecanismo de acción de HPMA 
copolímero-Dox y HPMA copolímero-AGM-Dox para entender el efecto 
sinérgico de citotoxicidad  únicamente observable cuando los dos fármacos se 
hallan covalentemente unidos a la misma matriz polimérica. En este sentido, se 
analizaron exhaustivamente las diferencias en el tráfico intracelular (unión e 
internalización celular, mecanismo de endocitosis con diferentes inhibidores de 
rutas endocíticas y fagocitosis) y en la cinética de liberación de fármaco 
(transporte lisosomotrópico) (Greco et al., 2005; Vicent et al., 2005; Greco et al., 
2006).  
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Figura 3. Perfil de liberación de Dox y AGM de los diferentes conjugados de HPMA 
en presencia de enzimas lisosomales de rata (tritosomas). 
Por otra parte, estudios preliminares de posibles diferencias en el mecanismo 
de acción molecular también se realizaron mediante técnicas de 
immunohistoquímica (Greco et al., 2007). Los resultados obtenidos sugieren que 
el aumento de actividad obtenido con el conjugado de combinación es debido 
principalmente a la diferente cinética de liberación intracelular de los fármacos 
(Figura 3). Al hallarse en la misma matriz polimérica poseen un perfil de 
liberación distinto en comparación a los conjugados simples, este cambio en la 
cinética de liberación induce un aumento de apoptosis celular en las células 
MCF7 y MCF7 Ca a través de la disminución de la proteína anti-apoptótica Bcl-
2 (Greco et al., 2007). 
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 De los datos obtenidos hasta ese momento, era evidente que el conjugado de 
combinación HPMA copolímero-AGM-Dox muestra un aumento en la actividad 
antitumoral in vitro y que mecanismos moleculares complejos parecen ser los 
responsables de este efecto sinergístico. 
Esta aproximación nos ofrece, claramente, una nueva oportunidad para el 
tratamiento de cáncer de mama metastático quimioresistente. Además de 
aumentar la actividad del citotóxico, esta plataforma tecnológica es de 
aplicación sistémica intravenosa (muy adecuada para el tratamiento de 
metástasis con elevada angiogénesis) y su mecanismo de internalización celular 
es diferente evitando mecanismos de resistencia como la sobreexpresión de la p-
glicoproteína en membrana celular. 
En consecuencia, a la vista de los resultados preliminares obtenidos con 
HPMA copolimero-AGM-Dox como potente agente antitumoral en modelos in 
vitro, en este proyecto de tesis doctoral se pretende (i) completar el estudio del 
mecanismo de acción molecular del conjugado de combinación HPMA 
copolímero-AGM-Dox y evaluar su potencial terapéutico en modelos animales. 
De este modo podríamos definir el potencial antitumoral de esta terapia de 
combinación polimérica para el tratamiento de pacientes con cáncer de mama.  
La especificidad tumoral debido al efecto EPR depende de la concentración en 
plasma del polímero circulante, de este modo, portadores poliméricos no-
biodegradables tales como el copolímero HPMA o polietilenglicol (PEG) 
(Mw<40 000 g/mol para asegurar una eliminación renal efectiva), tienen un 
perfil farmacocinético menos favorable. Por este motivo, una vez demostrada la 
actividad in vivo del conjugado HPMA copolímero-AGM-Dox se propone (ii) 
mejorar el valor terapéutico de esta nueva terapia de combinación mediante la 
utilización de un polímero biodegradable como portador, ácido poli-L-glutámico 
y finalmente (iii) el desarrollo de un cribado farmacológico utilizando  5 quimio 
agentes y 3 agentes de terapia hormonal en las líneas celulares MCF7 y MDA-
MB 321 con el objetivo de seleccionar una combinación sinérgica de fármacos 
con mayor potencial citotóxico, que sirva de base para el desarrollo de futuros 
polímeros de conjugados. 
 237 
 
2. Metodología. 
    2.1. Síntesis de conjugados. 
        2.1.a. PGA-OSucc síntesis y purificación. 
Para la síntesis de PGA-AGM, se requiere la activación previa de los grupos 
carboxílicos. Debido a la pobre reactividad de la amina aromática AGM, una 
clásica activación de diimida no fue suficiente para el acoplamiento. Los grupos 
carboxílicos de PGA fueron activados primero por grupo succinimico. PGA 
(3,55 mmol, 471.4 mg) se disolvió en di-metil-formamida (DMF) anhidra (5 
mL), los grupos succínicos (2,33 mmol, 268.4 mg) se añadió hasta alcanzar un 
máximo del 60% de la activación del grupo carboxílico. Cuando el medio de 
reacción era completamente transparente, N, N'-diisopropil carbodiimine (DIC) 
(2,33 mmol, 350 μL) y una cantidad catalítica de 4, dimetilaminopiridina 
(DMAP) fueron añadidos. La reacción se dejó durante 36 h. El DMF se evaporó 
por alto vacío y el PGA-OSucc se precipitó por Chloroformo (CHCl3) / acetona 
(4/1). El producto se purificó mediante lavado con éter (x3) en baño de 
ultrasonidos (5 min cada uno). El rendimiento fue de 77% y la tasa de activación 
fue de 41%. 
        2.1.b. PGA-AGM síntesis y purificación. 
PGA-OSucc (0,52 mmol, 91,3 mg) se disolvió en DMF anhidro (5 mL), a 
continuación, AGM (0,026 mmol, 6 mg) y una cantidad catalítica de DMAP fue 
añadida. El pH se controló y se ajustó con N, N-diisopropiletilamina (DIEA) a 
pH 8. La reacción se dejó reaccionar durante 36 h a temperatura ambiente (RT). 
El DMF se evaporó a vacío elevado y el polímero conjugado se precipitó con 
acetato de etilo (AcOEt) / acetona 4/1 a 4 ° C. PGA-AGM sal sódica se realizó 
mediante la adición de bicarbonato de sodio (NaHCO3) 1 M (0,58 mmol, 285 
μL). La etapa de purificación por cromatografía de exclusión por tamaño (SEC) 
se llevó a cabo con el fin de evitar el exceso de sal y el resto de productos que 
no habían reaccionado. Si una cantidad de DMAP libre se detectó por UV, una 
diálisis frente a H2O se realizó. Después de la liofilización, el rendimiento de la 
reacción fue del 60% (60 mg). 
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        2.1.c. PGA-G-AGM síntesis y purificación. 
Para realizar PGA-G-AGM, se require la síntesis previa de G-AGM. 
G-AGM: Fluorenilmetiloxicarbonilo glicina (Fmoc-G) (0,65 mmol, 193,24 mg) 
se disolvió en DMF anhidro (5 mL). La activación con DIC (0,975 mmol, 153 
μL) se realizó durante 5 min y después se añadió el 1-hidroxibenzotriazol 
(HOBt) (0,975 mmol, 132 mg). Después de 10 minutos, AGM (0,65 mmol, 147 
mg) fue finalmente añadido. El pH se controló y se ajustó a pH 8 con DIEA. La 
reacción se dejó reaccionar durante 36 h a temperatura ambiente. El DMF se 
evaporó a vacío elevado y Fmoc-G-AGM se purificó por extracción liq / liq. 
Fmoc-G-AGM se disolvió en AcOEt (10 mL) y se extrajo con NaHCO3 (3x10 
mL). A continuación la fase orgánica se lavó con ácido clorhídrico (HCl) 1 M 
(3x10 mL), se secó sobre sulfato de sodio (Na2 (SO4)) y se evaporó para 
producir 90% de un producto blanco. La etapa de desprotección se realizó con 
piperidina al 20% en AcOEt durante 1 h. La purificación del producto se realizó 
por columna C18. Las condiciones cromatografías iniciales fueron: agua (H2O) / 
acetonitrilo (ACN) (30:70). La purificación se controló por TLC (G-AGM Rf: 0, 
Fmoc Rf: 0,83 con hexano: EtOAc 1:4). El protocolo de detección utilizizado 
fue doble: UV y tinción Nihindrina. El rendimiento de la reacción fue del 70% 
(0,46 mmol, 125 mg). 
PGA-G-AGM: La síntesis de PGA-G-AGM se realizó mediante el siguiente 
protocolo. PGA (0,51 mmol, 80,3 mg) se disolvió en DMF anhidro (5 mL), DIC 
(0,808 mmol, 126,2 µL) fue añadido y después de 5 min HOBt (0,808 mmol, 
109 mg). Después de la activación de los grupos de ácido carboxílico por DIC y 
HOBt, G-AGM (0,0269 mmol, 7,8 mg) se añadió. El pH se controló y se ajustó 
a pH 8 con DIEA. La reacción se monitorizó por TLC y se dejó reaccionar 36 h 
a temperatura ambiente. El DMF se evaporó a vacío elevado y el polímero 
conjugado de fármaco se precipitó por CHCl3/Acetone 4/1 a 4 ° C con agitación 
media hora y media hora sin agitación. PGA-G-AGM sal de sodio se obtiene 
mediante la adición de NaHCO3 1 M (0,51 mmol, 250 μL). La etapa de 
purificación (Diálisis y columna G25) se llevó a cabo con el fin de evitar el 
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exceso de sal y eliminar el fármaco libre. Después de la liofilización, el 
rendimiento de la reacción fue del 60%. 
        2.1.d. PGA-GG-AGM síntesis y purificación. 
En este caso, la síntesis previa de GG-AGM también era necesaria, sin embargo 
Fmoc-GG no estaba disponible comercialmente, por lo tanto Fmoc-GG se 
sintetizó en un paso anterior. 
Fmoc-GG: GG (0,28 mmol, 37,8 mg) se disolvió en una solución de NaHCO3 
(10%) (1,6 mL), después se añadió dioxano (0,9 mL) y la reacción se enfrió en 
hielo. Una vez alcanzada  la temperatura adecuada, cloruro de 
fluorenilmetiloxicarbonilo (Fmoc-Cl) (0,28 mmol, 80 mg) fue cuidadosamente 
añadido gota a gota. La reacción se dejó reaccionar durante 4 horas en un baño 
de hielo y durante la noche a temperatura ambiente. Fmoc-GG se purificó por 
extracción liq / liq. La fase acuosa se extrajo con AcOEt (3x5 mL), a 
continuación seacidificó con HCl (1 M) hasta pH 2 y se extrajo con EtOAc (3x5 
mL). La fase orgánica se recogió, se secó sobre Na2 (SO4) y se evaporó para 
producir 81% de un producto blanco. 
La síntesis GG-AGM y PGA-GG AGM-se llevaron a cabo siguiendo el mismo 
procedimiento descrito anteriormente para G-AGM y PGA-G-AGM. 
        2.1.e. PGA-DOX síntesis y purificación. 
PGA (0,51 mmol, 80,3 mg) se disolvió en DMF anhidro (5 mL), a continuación, 
DIC (0,808 mmol, 126,2 µL) fue añadido y después de 5 min HOBt (0,808 
mmol, 109 mg) se añadió también como sólido. Después de 10 min, Dox.HCl 
(0,0269 mmol, 14 mg) se añadió. El pH se controló y se ajustó a pH 8 con 
DIEA. La reacción se controló por TLC y se dejó reaccionar durante 36 h a 
temperatura ambiente (TA). DMF se evaporó mediante vacío elevado y el 
polímero conjugado de droga se precipitó usando CHCl3/Acetone 4 / solución 
de 1 hora a 4 ° C con agitación y media hora sin agitación media. PGA-Dox sal 
de sodio se obtuvo por adición de NaHCO3 1 M (0,51 mmol, 250 μL). La 
purificación se realizó del mismo modo que los conjugados PGA-X-AGM. 
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        2.1.f. PGA-G-Dox síntesis y purificación. 
G-Dox: Bz-G (0,083 mmol, 31,8 mg) se disolvió en DMF anhidro (5 mL), a 
continuación se adicionó DIC (0,124 mmol, 20 μL) y después de 5 min HOBt 
(0,124 mmol, 22 mg) se añadió también como sólido. Después de 10 min de 
activación, Dox, HCl (0,083 mmol, 45,5 mg) fue finalmente incorporado. El pH 
se controló y se ajustó con DIEA para conseguir pH 8. La reacción se dejó 
reaccionar durante 36 h a TA. El DMF se evaporó a vacío elevado. El gránulo 
seco se disolvió en MeOH y la purificación se realizó por cromatografía RP-
(C18) con 10 mL de 2-propanol/H2O (12:88) (v / v), 10 mL de 2-propanol/H2O 
(29 : 71) (v / v) y luego 20 mL de MeOH (pH 3,2). El procedimiento de 
purificación se controló por TLC a través de un sistema de detección de doble 
fijado en λ = 254 nm y λ = 366 nm. Entonces, la desprotección se llevó a cabo 
en H2 Pd / Cact durante la noche. La solución se filtró a través de celita y con un 
filtro de 0,2 micras. Después de la eliminación de MeOH, con un rendimiento de 
50% fue alcanzada. 
PGA-G-Dox se sintetizó siguiendo el mismo procedimiento utilizado para PGA-
Dox. 
        2.1.g. PGA-GG-Dox síntesis y purificación. 
La síntesis de GG-Dox y PGA-GG-Dox se llevaron a cabo siguiendo el 
protocolo descrito para el G-Dox y PGA-Dox, respectivamente. 
        2.1.h. síntesis y purificación de los conjugados de combinación. 
PGA-AGM-Dox:PGA-OS (0,259 mmol, 85,45 mg) se disolvió en DMF anhidro 
(5 mL). Una cantidad catalítica de DMAP se añadió y el pH se ajustó a 8 con 
DIEA. A continuación se adicionó, AGM (0,027 mmol, 6.3mg). La reacción se 
controló por TLC y se dejó reaccionar durante 36 h a TA. Entonces se añadió 
DIC (0,036 mmol, 5,7 µL) y después de 5 min HOBt (0,036 mmol, 4.9 mg). 
Después de la activación de los grupos de ácido carboxílico por DIC y HOBt, se 
añadió a continuación Dox (0,024 mmol, 13,6 mg), se ajustó el pH a 8 con 
DIEA y la reacción se dejó reaccionar durante 36 h más a TA. El DMF se 
evaporó a vacío elevado y el polímero conjugado precipitó por adición de 5 mL 
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de CHCl3: acetona (1:1). PGA-AGM-Dox sal sódica se obtuvo mediante la 
adición de NaHCO3 1 M (0,51 mmol, 250 μL). La purificación se realizó del 
mismo modo que los conjugados PGA-X-AGM. 
 
PGA-X-AGM-Y-Dox: El PGA se disolvió en DMF anhidro (5 mL). DIC (1,5 eq 
de X-AGM) se añadió y, después de 5 min el HOBt (1,5 eq de X-AGM). 
Siguiendo a la activación de los grupos ácido carboxílico mediante DIC y HOBt, 
se añadió X-AGM, el pH se ajustó a 8 con DIEA y la reacción se dejó 
reaccionar durante 36 h a TA. El DMF se evaporó a vacío elevado y el polímero 
conjugado precipitó por adición de 5 mL de CHCl3: acetona (1:1). PGA-X-
AGM-Y-Dox sal sódica se obtuvo mediante la adición de NaHCO3 1 M (0,51 
mmol, 250 μL). La purificación se realizó del mismo modo que los conjugados 
PGA-X-AGM. 
    2.2. Caracterización de los conjugados 
        2.2.a. Determinación de la carga de fármaco total y el contenido de 
fármaco libre en el conjugado sintetizado. 
X-AGM y AGM fueron utilizados como un estándar para producir una curva de 
calibración. Se disolvió en MeOH grado HPLC para tener una solución stock de 
1 mg/mL. Este se diluyó entonces para producir una gama de concentración (0-
65 µg/mL para AGM y 0-65 µg/mL de X-AGM). La absorbancia UV de cada 
muestra se determinó entre 200-400 nm. 
La otra posibilidad para evaluar la cantidad total de carga de fármaco consiste en 
la cuantificación del fármaco que no ha reaccionado. El primer paso fue realizar 
la curva de calibración de HPLC utilizando las soluciones añadidas para la curva 
de calibración UV. A continuación, el precipitado de AcOEt/acetona (4/1) 
obtenido después de la precipitación del polímero conjugado de fármaco, se 
evaporó, se disolvió en 10 mL de HPLC, y se inyectó en HPLC. La carga de 
fármaco se determinó de manera indirecta usando RP18 columna (125x4mm), 
con un flujo de 1mL/min y usando un gradiente de elución [A: H2O +0,1% TFA 
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milliQ, disolvente B: ACN +0,1% TFA]. El tiempo total de análisis fue de 25 
min y con el gradiente siguiente: t = 0 A 90%, t = 4 Un 90%, t = 19 A 10%, t = 
21 A = 90%, t = 25 A = 90%, t = 40 A 0%, t = 42 A 0%. Un estándar interno 
(estradiol) se usó para la cuantificación del AGM. El tiempo de retención fue de 
2 min para GG-AGM, 6 min para G-AGM y 5 min para AGM. 
Para evaluar la carga de fármaco libre, 100 µL de una concentración conocida de 
polímero conjugado de fármaco se añadió con 100 µL de bicarbonato sódico y 
100uL de estradiol (1 µg/mL) como patrón interno. X-AGM libre y estradiol se 
extrajo a fondo con una mezcla de AcOEt / Isopropyl alcohol 4/1 (10s x 3). La 
capa orgánica superior se recuperó cuidadosamente y se secó a través de flujo de 
N2. El residuo seco se disolvió en 100 μL de grado HPLC ACN. En paralelo 
para construir una curva estándar, los mismos puntos utilizados para la 
determinación de la carga de fármaco total se utilizaron para hacer la curva 
HPLC estándar. 100 μL de cada punto se añadió a una mezcla de 100 μL de 
bicarbonato, 100μL de estradiol y 700 μL de agua MilliQ y después se extrajo 
con AcOEt / alcohol isopropílico (4/1) como se ha descrito antes. La cantidad de 
fármaco libre se determinó por HPLC usando el mismo método descrito para la 
carga de fármaco no directa. El tiempo de retención fue de 2 para GG-AGM, 6 
min para G-AGM, 5 min para AGM y 12 min para el estradiol. 
        2.2.b. Determinación de Dox total y libre por HPLC. 
Para determinar la carga de fármaco total de PGA-Y-Dox conjugado, 100 µL de 
una concentración conocida del polímero se añadió a una solución de ácido (1 
mL de HCl 2 M). 100 µL de Dau (1 μg/mL) se utilizó como estándar interno. La 
solución se dejó 30 minutos a 80 ° C. Después de enfriar hasta TA, 360uL de 
5M de NaOH se añadió para neutralizar el pH. Dox aglicona se extrajo con una 
mezcla de CHCl3/Isopropyl 4/1 (30 x 3). La capa acuosa superior se retiró 
cuidadosamente y la fase orgánica se secó usando flujo de N2. El residuo seco 
se disolvió en 100 µL de MeOH grado HPLC. En paralelo el mismo proceso se 
llevó a cabo con una mezcla de Y-Dox y daunorrubicina (DAU) para construir 
una curva estándar. Los estándares se disolvieron en 1 mL de MeOH grado 
HPLC para dar 100 µg/mL de solución madre de la que se preparó un intervalo 
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de concentración (5-100 µg/mL). La cantidad de fármaco total liberado se 
determinó por HPLC utilizando columna RP18 (125x4 mm), con un flujo de 
1mL/min y usando un gradiente de elución [A: 2-propanol/H2O 12:88 (v/v), 
disolvente B: 2-propanol/H2O 29:71 (v/v)] se ajustó a pH 3,2 con ácido 
fosfórico. Tiempo total fue de 25 min y el perfil del gradiente utilizado fue: t = 
0% A 0, t = 1 A 60%, t = 3 A 60%, t = 8 A = 0%, t = 18 A = 0%, t = 20 Un 
100%, t = 20 A 100%. Mediante detección por fluorescencia (λ excitación = 
485nm y λ emisión = 560 nm) se supervisaron los estándares internos Dox y 
Dau. El tiempo de retención (tr) fue de 15 min para aglicona Dox y 20 min para 
aglicona Dau. 
Para evaluar la carga de fármaco libre, 100 µL de una concentración conocida de 
conjugado se añadió a 100 µL de NaHCO3 y 100 µL de Dau (1 µg/mL) como 
patrón interno. La Dox libre y la Dau se extrajo con alcohol CHCl3/Isorpopyl 
4/1 (30x3). La capa acuosa superior se retiró cuidadosamente y la fase orgánica 
se seco a través de flujo de N2. El residuo seco se disolvió en 100 µL de MeOH 
grado HPLC. En paralelo el mismo proceso también se llevó a cabo con una 
mezcla de Dox y Dau para construir una curva estándar. Los estándares se 
disolvieron en 1 mL de MeOH grado HPLC para tener una solución madre de 
100 µg/mL de la cual se preparó un intervalo de concentración (0-65 µg/mL). La 
cantidad de fármaco libre se determinó por HPLC utilizando columna RP18 
(125x4 mm), con un flujo de 1mL/min y usando un gradiente de elución [A: 2-
propanol/H2O 12:88 (v/v), disolvente B: 2 -propanol/H2O 29:71 (v / v)], a 
continuación se ajustó a pH 3,2 con ácido fosfórico. El tiempo total fue de 42 
min y el perfil de gradiente utilizado fue: t = 0% A 0, t = 1% A 0, t = 26 A 
100%, t = 27 A = 50%, t = 37 A = 50%, t = 40 A = 0%, t = 42 A 0%. Para 
cuantificar la Dox y la Dau se utilizó la detección por fluorescencia El Tr fue de 
20 min para Dox y 30 min para Dau. Para evaluar la carga de fármaco de 
manera indirecta se utilizó el mismo procedimiento que el desarrollado para 
PGA X AGM. 
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      2.2.c. Peso Molecular (MW) determinación por GPC. 
Para evaluar la masa del conjugado, 100 μL de 3 mg/mL exactamente PGA-G-
Dox solución se inyectó en GPC utilizando dos columnas TSK Gel en serie 
G2500 PWXL y PWXL G3000 con Viscoteck TDA detector 302 en serie con 
una detección UV. La fase móvil usando es PBS 0,1 M. 
      2.2.d. Small angle neautron scattering (SANS). 
Los experimentos de SANS se realizaron en el reactor HFR 57 MW (High-Flux 
Reactor) en el Instituto Max Von Laue-Paul Langevin (ILL) de Grenoble, 
Francia. Los conjugados se disolvieron a 10 mg/mL en D2O y los experimentos 
de dispersión se realizaron a 37 °C, condiciones que imitan la conformación en 
el cuerpo. Todos los experimentos se realizaron en células de cuarzo de 2 mm 
con la medición de tiempos de 1 h por muestra. 
    2.3. Estabilidad en plasma de conjugado y cinética de la liberación del 
fármaco en presencia de la catepsina B. 
        2.3.a. Cinética de liberación de fármaco en presencia de catepsina B. 
PGA-X-AGM, PGA-Y-Dox y PGA-X-AGM-Y-Dox (3 mg/mL) se incubaron 
(37 ° C) en una solución de acetato sódico (20 mM, pH 6), DTT (5 mM) y 
EDTA (2 mM). Para comenzar la degradación 5 unidades de catepsina B (100 
μL) eran adicionadas. Alícuotas de los conjugados (150 μL) se tomaban de 
forma consecutiva en momentos seleccionados (0, 0,5, 1, 2, 5, 8, 24, 48, 72, 96 
h) horas hasta dos semanas, y se congelaban inmediatamente en nitrógeno 
líquido hasta realizar el ensayo de HPLC. Para los experimentos control se 
reproducía el mismo ensayo pero sin conjugados. 
Una vez recopiladas las muestras, se descongelaron y se añadieron a tubos de 
polipropileno, completando hasta 1 mL con H2O incluyendo 100μL de Dau (1 
μg/mL) como patrón interno y 100 μL de tampón de formiato de amonio (pH 
8,8), seguido por la adición de una mezcla de CHCl3: isopropanol 4 : 1 (5 mL). 
A continuación las muestras fueron extraídas a fondo con el vórtex (3x30s). La 
capa acuosa superior se retiró cuidadosamente y el disolvente se evaporó bajo 
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N2. El residuo seco se disolvió en 100 μL de metanol para análisis por HPLC. La 
cantidad de liberación de fármaco de conjugados se determinó mediante HPLC 
utilizando el método descrito para el fármaco libre, y los metabolitos liberados 
fueron identificados por MALDI-TOF. En un volumen de 30 μL las muestras sin 
ningún tipo de preparación se inyectaron en GPC para seguir el perfil de 
degradación del polímero. 
        2.3.b. Estabilidad en plasma. 
Los conjugados (3 mg/mL) se incubaron a 37°C en suero recién extraído de 
ratones Balb/c hasta 24 h. En las horas programadas se recogieron alícuotas de 
100 µL a los cuales se añadió 100 µL de MeOH con el fin de precipitar las 
proteínas del suero y recuperar el fármaco libre. Después de la centrifugación 
(12000 g, 5 min), los sobrenadantes se analizaron por HPLC como se informó 
anteriormente. 
        2.3.c. Identificación de metabolitos por MS. 
Los metabolitos X-AGM se identificaron utilizando un sistema UPLC-MS de 
Waters. El método fue optimizado masa capilar (kV) 3,50, el cono (V) 20, 
Extractor (V) 6, RF Lente (V) 0,2. La temperatura de la fuente era 120 ° C y la 
temperatura de desolvatación era de 380 ° C. Desolvatación Gas y el cono de 
gas eran respetablemente 950 y 50 L / H. El parámetro analizador y detector era 
lo normal para este tipo de masa ZQ. El método UPLC era 90/10 H2O + 0,1% de 
ácido fórmico / ACN ácido fórmico 0,1% a 10/90 H2O + 0,1 ácido fórmico / 
ACN ácido fórmico + 0,1% en 15 min. Las condiciones iniciales se recuperaron 
en 2 minutos y el sistema se equilibró en 4 min. Después de 20 µL de filtración 
de la muestra,  se inyectó. Este sistema tenía una doble detección por UV 
(DAD), λ = 268 nm se utilizó en este caso y el TIC de masa. 
Para los metabolitos Y-Dox, el Pm es mayores, en consecuencia un experimento 
de MALDI-TOF se realizó. La matriz utilizada fue α-ciano-4-hydroxucinnamic 
ácido, se extrajo con un láser pulsado a 337 nm. La adquisición se realizo en 
modo reflectron. 
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    2.4. Ensayos in vitro. 
        2.4.a. Cultivo celular. 
Para los ensayos in vitro las siguientes líneas celulares inmortalizadas fueron 
utilizadas: MCF7, MCF7 Ca, 4T1 (cáncer de mama metastásico de origen 
murino) y MDA-MB 231 (cáncer de mama humano ER-). La línea celular 
MCF7 Ca es el resultado de la transfección estable del gen de la aromatasa 
humana en MCF7 (cáncer de mama humano hormono dependiente). La línea 
MCF7 Ca fue generosamente proporcionada por la Universidad de Cardiff. Las 
células se cultivaron en placas P100 con el medio adecuado suplementado con 
suero bovino fetal (SBF) (10%) a 37 °C y 5% CO2. Para MCF7 Ca, el SBF 
utilizado fue previamente tratado con el fin de imitar las condiciones post-
menopáusicas añadiendo una alícuota de estradiol a una concentración final de 
10
-9
 M para el cultivo celular. En todos los casos, el medio celular se cambiaba 
cada dos días para inducir el crecimiento celular. Una vez alcanzada una 
confluencia celular de 70-90%, después de retirar el medio, y lavar las células 
con PBS, se añadía 1 mL de tripsina durante 5 min a 37 ºC, las células 
despegadas se recuperaban con 9 mL de medio libre y se centrifugaban durante 
5 min a 200 g a TA. El sobrenadante se retiraba cuidadosamente y a 
continuación las células se resuspendían en medio fresco. Tras el recuento 
celular utilizando una cámara de Neubauer, las células fueron sembradas en 
placas de P100 a 40.000 cels/mL o a 20.000 cels/mL para alcanzar la 
confluencia después de una o dos semanas, respectivamente. 
 
        2.4.b. Preparación de SBF empobrecido en estrógeno. 
Con el fin de cultivar MCF7 Ca imitando las condiciones hormonales de mama 
en mujeres postmenopáusicas, el SBF fue previamente tratado para eliminar la 
mayoría de los factores de crecimiento y hormonas de origen y posteriormente 
se adicionó un nivel de hormona control al medio final. Para ello, el SBF (500 
mL) se desactivó a 56°C durante 30 min. Una vez a temperatura ambiente, se 
ajustó a pH 4,2 con HCl (5 M) y se equilibró a 4 °C. A continuación una 
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suspensión de carbón (25 mL) preparada añadiendo 18 mL de H2O dd, 0,2 g de 
carbón Norit A y 0,01 g de dextrano 80.000 era añadida al SBF frío durante16 
horas a 4 °C. Posteriormente se centrifugó (40 min a 12.000 g) y por filtración 
gruesa se separó el carbón vegetal. El pH se reajustó a 7,2 con NaOH (5 M) y el 
SBF obtenido era esterilizado por filtración con filtros Millipore de 0,2 micras y 
alicuotado en recipientes universales a -20°C. Finalmente, para el cultivo de 
células MCF7 Ca, una alícuota de estradiol (concentración final 10
-9
 M) se 
adicionó al medio de cultivo conteniendo 10% de SBF pretratado. 
 
        2.4.c. Ensayo de MTS para la determinación de la viabilidad celular. 
Para poder realizar ensayos de viabilidad celular, en primer lugar se realizó una 
curva de crecimiento para todas las líneas celulares de cáncer de mama 
utilizadas. Las concentraciones de siembra celular óptimas para los ensayos de 
citotoxicidad fueron determinadas. 50 μL de las concentraciones seleccionadas 
de MCF7 Ca (4000cels/pocillo), 4T1 (2000 cels/pocillo) y MDA MB 231 
(10000 cels/pocillo) se sembraron en placas transparentes de 96 pocillos (P96). 
Transcurridas 24 h en el caso de MCF7 Ca y 4T1cells y 48 h para MDA 
MB231, se adicionaron a los cultivos celulares diluciones seriadas de los 
conjugados poliméricos o compuestos libres (50 μL) (n = 6) y se incubaron 
durante 72 h a 37ºC y 5% de CO2 con el fin de evaluar los posibles efectos 
citotóxicos. Las células control fueron tratadas idénticamente, añadiendo medio 
sin compuestos. La viabilidad celular se determinó procediendo posteriormente 
al ensayo colorimétrico del MTS [3 - (4,5-dimetiltiazol-2-il) -5 - (3-
carboximetoxifenil) -2 - (4-sulfopheyl) 2H-tetrazolio], siguiendo instrucciones 
del fabricante (Cell Titer 96
®
 AQueous Non-Radioactive Cell Proliferation Assay 
Technical Bulletin TB169, Promega Corporation). 10 ul de solución de MTS se 
añadió a cada pocillo, y las células se incubaron durante otras 2 h a 37°C, CO2 
5%. Las células vivas y metabólicamente activas son capaces de reducir el MTS 
a formazano, un producto soluble en el medio de cultivo, la absorbancia del 
formazano puede medirse a 490 nm y es directamente proporcional al número de 
células vivas en el cultivo. El efecto citotóxico se obtiene al comparar 
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directamente el resultado obtenido en las células no tratadas (control) frente a las 
células tratadas con los compuestos. 
El mismo sistema de determinación de viabilidad celular fue utilizado para el 
desarrollo de la plataforma de cribado  (HTPS). Sin embargo, en este caso las 
líneas celulares MCF7 y MDA MB 231 se cultivaron con antibiótico P/S (1%), 
con el fin de evitar cualquier posible contaminación durante la utilización del 
robot TECAN (condiciones no estériles controladas), imprescindible para la 
dispensación de los compuestos y sus combinaciones en las placas de 96 
pocillos. 
    2.5. Ensayos in vivo. 
        2.5.a. Modelo de tumor en ratones atímicos con células MCF7 Ca. 
Todos los experimentos con animales se realizaron de acuerdo con las 
directrices establecidas por el Consejo de las Comunidades Europeas 
(86/609/ECC) y por el Real Decreto Español 1201/2005. Todos los 
procedimientos experimentales fueron aprobados por el Cuidado de Animales 
institucional. Ratones atímicos hembra Balb/c de 4-6 semanas de edad se 
adquirieron de Harlan (Europa). Los animales fueron alojados en un entorno 
libre de patógenos bajo condiciones de control. La ovariectomía se realizó bajo 
sevofluorano 1 semana antes de la inoculación de células. Las células MCF7 Ca 
se resuspendieron en matrigel y 10 millones de células en una alícuota de 100 
μL se inyectaron en cada animal, en la tercera mama. Comenzando un día 
después de la inoculación de células, los animales recibían 100 μL de 
androstenodiona subcutánea (0,1 mg/ratón/día). La evolución del crecimiento 
tumoral se supervisaba dos veces a la semana midiendo el volumen del tumor 
con un calibrador para calcular el tamaño de los tumores. En el momento en que 
los tumores alcanzaban el tamaño máximo autorizado, los ratones se 
sacrificaban y el tumor era extirpado para realizar estudios histológicos y de 
vascularización. 
Posteriormente al proceso de optimización del modelo in vivo, los conjugados de 
polímero se ensayaron con el fin de evaluarse su actividad antitumoral. Por 
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tanto, 10 millones de células MCF7 Ca fueron inyectados en la tercera mama. 
Una vez que el tamaño del tumor alcanzaba 0,2 cm
3
, los conjugados se 
inyectaban por vía intravenosa 3 veces cada 3 días y el peso del animal y el 
tamaño del tumor eran evaluados dos veces a la semana. Cuando el tumor 
alcanzó el tamaño máximo autorizado, corazón, hígado, riñón y bazo se 
extrajeron, se pesaron y se fijaron para continuar con análisis histológicos. En 
paralelo, los tumores fueron congelados en hielo seco para el análisis de 
expresión de proteínas mediante western blot. 
 
    2.5.b. Modelo de tumor inducido por células 4T1. 
Ratones hembra Balb/c de 4-6 semanas fueron comprados en Harlan Inc. 
(Europa). Los animales fueron alojados en un entorno libre de patógenos bajo 
condiciones de control. Dos concentraciones diferentes  de células 4T1 (5x10
5
 y 
10
6
 células) fueron inyectadas en la tercera mama. El crecimiento del tumor se 
siguió cada día. Una vez que el tamaño límite del tumor era alcanzado (1cm
3
), 
los ratones se sacrificaban y los órganos principales y el tumor se extraían con el 
fin de realizar estudios histológicos y vascularización. 
En una segunda etapa, con el fin de testar la actividad antitumoral de los 
conjugados de polímero en el modelo murino 4T1, 5x10
5
 células fueron 
inyectadas en la tercera mama. Transcurridos 8 días el tamaño del tumor alcanzó 
0,1 cm
3
 y a continuación los conjugados se inyectaban por vía intravenosa 3 
veces cada 3 días y el peso de los animales así como el tamaño del tumor se 
evaluó cada día. Cuando el tumor alcanzó el tamaño máximo autorizado 1 cm
3
, 
corazón, hígado, riñón y bazo se extrajeron, pesaron y se fijaron para realizar 
estudios histológicos y el tumor  fue congelado para el análisis de expresión 
proteica mediante western blot. 
    2.5.c. Análisis de la vascularización del tumor. 
Los tumores desarrollados en ambos modelos in vivo se retiraron y se analizaron 
para evaluar la vascularización y el poder de penetración de nuestros 
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compuestos. Diferentes tamaños de tumor se desarrollaron en 10 ratones y 
cuando el tamaño del tumor alcanzó de 0,1 a 0,5 cm3, una solución de BSA-azul 
de Evans se inyectó por vía intravenosa. Una hora después de la inyección, los 
ratones se sacrificaron y el tumor, así como varios órganos se extrajeron. El 
tumor fue puesto en 1 mL de formamida durante 48 h a 60 °C con el fin de 
extraer el azul de Evans. La cuantificación se realizaba entonces en UV a 620 
nm. 
2.5.d. Análisis toxicológico: Evaluación hepática en sangre. 
La sangre extraída de corazón se centrifugó a 4000 g durante 10 minutos para 
obtener el plasma. El plasma fue enviado a Analitica Clínica Veterinaria Lab 
(ACVLAB) para evaluar las características de las diferentes enzimas implicadas 
en el daño hepático como transaminasa glutámico oxalacética (GOT), 
transaminasa glutámico piruvato (GPT), lactato deshidrogenasa (LDH) y 
fosfatasa alcalina (ALP). 
    2.5.e. Análisis histológico. 
El tumor fue retirado de los animales control después de la optimización de 
ambos modelos in vivo. A continuación los tumores se lavaron en PBS y se 
fijaron en paraformaldehído (PFA) durante una noche. El exceso de PFA se 
eliminó por lavado con PBS a través de una fuerte de agitación (200 rpm) 
durante 20 min 3 veces. Finalmente, las muestras se almacenaron en una 
solución de PBS con 0,05% de azida sódica. Con el fin de incluir las muestra en 
parafina, una deshidratación previa de las muestras a través de 2 min de 
incubación en baños de alcohol de concentración creciente (30%, 50%, 70%, 
96% y 2 baños de 100%) se llevó a cabo, seguido por 2 lavados en xileno de 1 
min para incluir finalmente la muestra en parafina. A continuación, el bloque de 
parafina se redujo a un grosor de 4 micras y se instaló en Superfrost Plus 
portaobjetos de vidrio para proceder a la tinción hematoxilina-eosina. 
La hematoxilina tiene un profundo color azul-morado y tiñe los ácidos nucleídos 
de las células mediante una reacción compleja. La eosina es de color rosa y tiñe 
las proteínas forma no específica. En un tejido típico, los núcleos están teñidos 
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en azul, mientras que el citoplasma y la matriz extracelular tienen diferentes 
grados de tinción de color rosa. Para la tinción de hematoxilina-eosina, en 
primer lugar los cortes de 4 micras se desparafinaron con xileno y 
posteriormente las muestras se rehidrataron con una batería de etanoles 
decreciente (100%, 95%, 70%, 50%, 30%, agua destilada). A continuación se 
sumergieron en 2 baños de agua  de 5 min seguido de baño de hematoxilina 2 
min y 2 lavados de agua de 5 min. Posteriormente los portaobjetos se incubaron 
3 min en carbonato de litio y HCl al 0,25% en etanol al 70% para eliminar el 
exceso de tinción hematoxilina. Después de 2 lavados en agua durante 5 min, los 
cortes se incubaban en un solución fresca de eosina-floxina (0,35% de eosina, 
1,1% de floxin a 2%, 83 mL de alcohol absoluto, 3,3 mL de agua destilada y 
ácido acético 450 μL) durante 6 min. Para finalizar, los cortes se lavaron hasta 
eliminar los restos de tinción y se deshidrataron de nuevo con diferentes baños 
en alcohol de graduación creciente. Tras el baño con etanol absoluto, los cortes 
se lavan con xileno y se montan con el medio de montaje no acuoso Eukitt. 
    2.5.f. Inmunodetección por Western blot. 
Las proteínas contenidas en los tumores extraídos de los ratones después de 16 
días de tratamiento en el modelo 4T1 se separaron mediante electroforesis en 
geles de poliacrilamida-SDS (dodecilsulfato sódico). De este modo las bandas 
de proteína obtenidas según su peso molecular eran posteriormente transferidas 
a membranas que permiten su inmunodetección. Para ello, los tumores extraídos 
se homogeneizaron en tampón RIPA (150 mM NaCl, 1% de NP40, 0,5% de 
desoxicolato de sodio, 0,1% SDS, 50 mM Tris PH8, 50 mM NaF, 100μM 
Na3VO4 y la tableta de cóctel inhibidor de la proteasa), seguido de 15 min en 
agitación a 4 °C, una serie de tres sonicaciónes 5 s y 1 h a 4 °C en agitación. A 
continuación, la solución obtenida se centrifugó durante 20 min a 13.500 g, 4 ºC 
y los niveles de proteína contenida en el sobrenadante se determinaron mediante 
el ensayo de Bradford. 100 µg de proteína se mezclaron con tampón de muestra 
desnaturalizante 5xSDS y se hirvió durante siete minutos a 95 °C. Dependiendo 
del peso molecular de la proteína que se requiere analizar, se seleccionaba un 
porcentaje u otro de acrilamida, en este caso las proteínas se separaron a través 
de geles de 8% a 15% SDS-PAGE. Después de la electroforesis, las proteínas se 
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transfirieron a membranas de PVDF (Amersham Pharmacia Biotech, UK). 
Posteriormente las membranas se bloquearon en 5% de leche desnatada durante 
2 h, y se incubaron durante la noche a 4 ºC con los siguientes anticuerpos 
primarios: beta-actina y α-tubulina (Sigma), bax, (Santa Cruz Biotechnology), 
caspasa 3, Beclin-1, LC3B, pAKT, Bcl2 y VEGF (Cell Signaling), iNOS 
(Cayman Chemical) y HIF1α (BD Biosciences Pharmingen). El exceso de 
anticuerpos se retiró por lavado de las membranas en PBS/0,1% de Tween 20. 
Seguidamente las membranas se incubaron durante 1 h con anticuerpos 
secundarios específicos para el primario a detectar y marcados con peroxidasa 
(cabra anti-IgG de ratón, asno anti-IgG de conejo y conejo anti IgG de cabra) 
(1:5000) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, EE.UU.). Después de 
3 lavados en PBS/0,1% de Tween 20, la inmunodetección se realizó mediante el 
sistema de detección por quimioluminiscencia intensificada ECL Western Blot 
(Amersham Pharmacia Biotech, Reino Unido), de acuerdo con las instrucciones 
del fabricante. Los niveles relativos de proteína se cuantificaron por 
densitometría con el programa Scion Image. Los resultados fueron normalizados 
utilizando β-actina como referencia. 
    2.5.g. Análisis estadístico. 
Los resultados procedentes de ensayos in vitro han sido expresados como media 
± SD (n = 3). Los resultados obtenidos de cada experiencia in vivo han sido 
expresados como media ± SEM (n = 4). 
El análisis estadístico se ha realizado mediante el programa informático 
GraphPad Prism 5. 
Los valores obtenidos de las experiencias se analizaron empleando ANOVA 
simple y el método de la t de Dunnett para comparaciones múltiples. Este 
método permite comparar los valores medios obtenidos para varios grupos 
problema respecto a un único grupo control en un mismo experimento, teniendo 
en cuenta el error asociado a las comparaciones múltiples (Dunnett, 1964). La 
significatividad respecto a la diferencia entre los grupos tratados y el control es 
(*) cuando el valor de t obtenido es mayor que el tabulado para un margen de 
confianza del 95% (p  0,05), (**) cuando es mayor del 99% (p  0,01) y (***) 
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cuando es mayor del 99,9% ( p  0,001). No empleamos símbolo indicativo 
cuando la diferencia respecto al grupo control no es significativa. 
3. Conclusión. 
- Dos modelos in vivo de cáncer de mama han sido establecidos, optimizados y 
caracterizados a partir de dos líneas celulares inmortalizadas, MCF7 Ca 
humanas y 4T1 murinas. 
- La prueba de concepto de sinergismo ha sido demostrada con HPMA 
copolímero-AGM-Dox, mostrando una diferencia significativa en la inhibición 
del crecimiento del tumor en comparación con Dox, HPMA copolímero-Dox o 
la combinación HPMA copolímero-AGM + HPMA copolímero-Dox. Ambos 
conjugados han ejercido una disminución importante del volumen tumoral en 
comparación con Dox en el modelo in vivo inducido utilizando la células 
humanas MCF7 Ca. 
- Se han establecido diferencias en el mecanismo molecular responsable del 
efecto antitumoral obtenido con ambos conjugados HPMA copolímero-AGM-
Dox y HPMA copolímero-Dox. HPMA copolímero-AGM-Dox indujo una 
inhibición significativa de las proteínas involucradas en angiogenesis (VEGF) 
desde el segundo dia después de la última inyección, en comparación con 
HPMA copolímero-Dox y el control. Por lo tanto, HPMA copolímero-AGM-
Dox presentaba un efecto inhibidor tumoral temprano en comparación con 
HPMA copolímero-Dox. Este mecanismo se completa a largo plazo con la 
inducción de autofagia por HPMA copolímero-AGM-Dox frente al efecto 
apoptótico generado por HPMA copolímero-Dox. 
- Una plataforma de combinación mas revelante para una aplicación clínica 
crónica ha sido desarollada utilizando PGA como portador. Tres familias PGA-
X-AGM, PGA-Y-Dox y PGA-X-AGM-Y-Dox han sido sintetizadas, 
caracterizadas y evaluadas en cultivo celular. 
-Una relación directa entre la conformación en solución y la actividad in vitro ha 
sido demonstrada por los conjugados PGA de combinación. 
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- El mejor candidato, PGA-(G-AGM)5mol% - (Dox)5mol%, fue seleccionado para su 
evaluación in vivo y mostró un retraso significativo en el crecimiento tumoral en 
el modelo de ratón 4T1, 10 días después de la primera inyección en comparación 
con los otros grupos. 
- Nuevos candidatos (quimioterapia + terapia endocrina 2ª generación) han sido 
evaluados in vitro a través de una plataforma de cribado con el objetivo de  
identificar una combinación de fármacos con mayor efecto sinérgico. Esto 
permitirá sintetizar conjugados de combinación con mayor eficacia en etapas 
posteriores. La mejor combinación encontrada ha sido (PTX, 4-OHT) en la 
relación (1,15:1). 
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Annexe II. Tumour Node Metastasis (TNM) nomenclature. 
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TNM  Criteria 
T1 m1c The tumour is 0.1cm across or less 
T1 a The tumour is more than 0.1 cm but not more than 0.5 cm 
T1 b The tumour is more than 0.5 cm but not more than 1 cm 
T1c The tumour is more than 1 cm but not more than 2 cm 
T2 The tumour is more than 2 cm, but no more than 5 cm across 
T3 The tumour is bigger than 5 cm across 
T4 a The tumour has spread into the chest wall 
T4 b The tumour has spread into the skin and the breast may be swollen 
T4c The tumour has spread to both the skin and the chest wall 
T4 d Inflammatory carcinoma – this is a cancer in which the overlying skin is red, 
swollen and painful to the touch 
 
TNM Criteria 
N1 Cancer cells are in the upper levels of lymph nodes in the armpit but the nodes 
are not stuck to surrounding tissues 
N2 a There are cancer cells in the lymph nodes in the armpit, which are stuck to each 
other and to other structures 
N2 b 
There are cancer cells in the lymph nodes behind the breast bone (the internal 
mammary nodes), which have either been seen on a scan or felt by the doctor. 
There is no evidence of cancer in lymph nodes in the armpit 
N3 a There are cancer cells in lymph nodes below the collarbone 
N3 b There are cancer cells in lymph nodes in the armpit and behind the breast bone 
N3 c There are cancer cells in lymph nodes above the collarbone 
 
TNM  Criteria 
cMo 
(i+) 
 
It means there is no sign of the cancer on physical examination, scans or X-rays 
but cancer cells are present in blood, bone marrow, or lymph nodes far away 
from the breast cancer – the cells are found by laboratory tests  
M1 It means the cancer has spread to another part of the body 
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Annexe III. Breast cancer stage. 
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Breast cancer 
stages 
Classification TNM 
Stage 1 T1,N0,M0 
Stage 2 A (T0,N1,M0), (T1,N1,M0), (T2,N0,M0) 
Stage 2 B (T2,N1,M0), (T3,N0,M0) 
Stage 3 A (T0,N2,M0), (T1,N2,M0), (T2,N2,M0), (T3,N1,M0), (T3,N2,M0) 
Stage 3 B (T4,N0,M0), (T4,N1,M0), (T4,N2,M0) 
Stage 3 C Any T,N3,M0 
Stage 4 Any T,any N, any M 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
